TWI358540B - A novel method for chromatographic finger printing - Google Patents

A novel method for chromatographic finger printing Download PDF

Info

Publication number
TWI358540B
TWI358540B TW90100326A TW90100326A TWI358540B TW I358540 B TWI358540 B TW I358540B TW 90100326 A TW90100326 A TW 90100326A TW 90100326 A TW90100326 A TW 90100326A TW I358540 B TWI358540 B TW I358540B
Authority
TW
Taiwan
Prior art keywords
image
software
drug
ability
page
Prior art date
Application number
TW90100326A
Other languages
Chinese (zh)
Inventor
Kumar Dadala Vijaya
Vijaya Raghavan Kondapuram
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Priority to TW90100326A priority Critical patent/TWI358540B/en
Application granted granted Critical
Publication of TWI358540B publication Critical patent/TWI358540B/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Description

五、發明說明(1) 5 ~ 1發明領域 技術範圍: 治療的標準化。特特徵鑑定的新方法可用於化學與 有機與有機金屬分子^ 士本發明的層析特徵鑑定是關於 物,動物或其他任何且;m -可見輻射吸收特性在植 。本發明有助於一 u早-或複方藥物能力的來源 條碼製作。本發明也ίΐϊ特徵鑑定訊息中的成分之 所有關於該率:發有徵資料庫的商業使用,具有 «於及樂物發展及使用企業資源計晝(erp, 11 erprise Resource P 1 ann i ng)與客戶關係管理( ’ Customer Relationship Management)電腦網絡雁 販賣機等等的資訊。 〜用如 析譜( 的實驗 物的層 本發明利用一草藥及配方的輪廓及3— D色彩層 Contour and 3- D chromatograms),發展自標準 (化學和儀器的)環境,之新方法被提議作為該藥 析特徵。 另外,本發明是關於以一運用電腦的方法來八 1刀祈這此 色彩層析譜。這種新方法對於單一藥物及配方的化學二 之可靠鑑定非常有用。 千 >V. INSTRUCTIONS (1) 5 ~ 1 Field of the Invention Technical scope: Standardization of treatment. A new method for characterization can be used for chemistry and organic and organometallic molecules. The chromatographic characterization of the present invention is related to matter, animal or any other; m-visible radiation absorption characteristics in the plant. The present invention facilitates the production of a bar code for early u- or compound drug abilities. The present invention also relates to all of the components of the characterization information regarding the rate: commercial use of the levied database, with the development and use of enterprise resources (erp, 11 erprise Resource P 1 ann i ng) Information about customer relationship management ('Customer Relationship Management') computer network geese vending machine. ~ Using a layer such as the spectrum of the experimental material (the invention utilizes a contour of an herbal and formula and 3-D color layer Contour and 3-D chromatograms), developed from a standard (chemical and instrumental) environment, a new method is proposed As the drug analysis feature. Further, the present invention relates to a color chromatogram of a computer using a method of using a computer. This new method is very useful for the reliable identification of the chemical chemistry of a single drug and formulation. Thousands >

第5頁 1358540Page 5 1358540

5-2發明背景 世界的傳統草藥史 然 古代人在多年的進化後開始思考自我並試著了解大自 =古開始生活在遮蔽物之下,穴居並群居。該思考過程鼓 代人去了解大自然與其内部活動包括生物。開始使用 …''传到的植物及動物來提供其日常所需,在其中古代 。在,^二植物與動物的材料作為其飲食及健康上的需要 也灿ΐ過長下’發現世界上不同成分的性質’如各種生物 /、植物 止、| J何枓之地質的,靈魂的及藥用的特性。該現象發 生自石器眸此+ , ^5-2 Background of the Invention History of Traditional Herbs in the World After many years of evolution, the ancients began to think about themselves and tried to understand that the self began to live under shelter, burrowing and living in groups. This thought process encourages people to understand nature and its internal activities including biology. Start using ...'' plants and animals to provide their daily needs, in ancient times. In the two plants and animal materials as their dietary and health needs are also too long to 'discover the nature of different ingredients in the world' such as various organisms /, plants, | J He Gezhi, the soul of And medicinal properties. This phenomenon occurs from the stone device + this + , ^

a ^ 守代有文字紀錄開始。古代人繼續探索’標準化 自然可得的材料用於日復一日的生活中。 _該過程發生在地球上許多地方,平行發生在世界的不 同處’並且在那些由知識份子發展出更多文明的地方有更 多的發展。因此,該藥物史與該文化史有一直接的關係。 在印度’已查出藥物有一良好組織的系統之證據在何拉帕 (Harappa)與莫翰雜德羅(M〇hanzadaro)(藥物史在印度a ^ The guardian has a written record to begin with. Ancient people continued to explore 'standardization. Naturally available materials are used in day-to-day life. The process takes place in many parts of the globe, parallel to different parts of the world, and there is more development in places where more civilizations are developed by intellectuals. Therefore, the history of the drug has a direct relationship with the history of the culture. In India, there has been evidence of a well-organized system of drugs in Harappa and M〇hanzadaro (drug history in India)

’普利亞·凡埤特.夏爾馬博士,印度國家科學研究院, 新德里)(Histry of Medicine in India, Dr. Pr i y a Vrit Sharma, Indian National Science Academy, New D e 1 h i )。在印度河流域文化中,一藥物的系統已經流行, 在其中使用蔬菜的’動物的及礦物的藥品來源。瑞格維達 (Rigveda)的歐撒得海速克塔 (0sadhisukta)是最早關'Histry of Medicine in India, Dr. Pr i y a Vrit Sharma, Indian National Science Academy, New D e 1 h i ). In the Indus culture, a system of drugs has become popular, using the 'animal and mineral sources of medicine' for vegetables. The Ossar Seak Tower (0sadhisukta) in Rigveda is the earliest

第6頁 1358540 五、發明說明(3) 於植物與草藥的知識文件。藥物在印度應歸功於阿撒爾伐 惟達(Atharvaveda )的傳統知識,其中的阿祐爾惟達 (Ayurveda)被稱作游帕惟達(Upaveda)。定義與敘述大 量的疾病併發症關係在恰拉卡(Charaka)和蘇斯盧塔( 8113 1'1^3)的論文、、山姆海塔斯//(丁116831111^七35)中。該治 療也規定在一系統化的方式並在合理的基礎上。 另一方面’可以了解的是,這種生物現象不能普遍地 以機械化的工具來解釋當其基本的組成中的每一個體變化 時’那就是當指定飲食或藥品給病人的時候必須記住普列 克盧新(Prakruthi)。這種二元性的概念如普列克理提—普 暑 魯夏(Prakriti-Purusha),陰-陽(Yin-Yang),正常-反常 在大部分的哲學中可看到。 疾病是體液不平衡的表現,必須在身體和心理的基礎 上廣泛地處理。因此健康是維持在身體的心理的與精神層 次上的平衡。因此’由蘇斯爾圖塔(Susrtuta)所提出之 健康三次元定義是一理想的定義,已經被現代的世界衛生 組織(World Health Organization,WHO)所接受並反映 在其定義中。 在古代文獻的討論後可發現,該藥物可利用其材料的 物理一化學特性來標準化》其顏色,構造,香氣及味道用 於作為任何藥物功效的判斷基準。甚至該藥物的外形也用Page 6 1358540 V. INSTRUCTIONS (3) Knowledge documents on plants and herbs. The drug in India is due to the traditional knowledge of Atharveveda, of which Ayurveda is called Upaveda. Defining and narrating a large number of disease complications in the papers of Charaka and Suslut (8113 1'1^3), Sam Haitas // (Ding 116831111^7 35). The treatment is also prescribed in a systematic manner and on a reasonable basis. On the other hand, it can be understood that this biological phenomenon cannot be universally explained by mechanized tools when each individual in its basic composition changes. That is, when specifying a diet or medicine for a patient, it must be remembered. Prakruthi. The concept of duality, such as Prakriti-Purusha, Yin-Yang, normal-abnormality can be seen in most philosophies. Disease is a manifestation of fluid imbalance and must be treated extensively on a physical and psychological basis. Therefore, health is the balance between the psychological and spiritual levels of the body. Therefore, the three-dimensional definition of health proposed by Susrtuta is an ideal definition that has been accepted by the modern World Health Organization (WHO) and reflected in its definition. After discussion in the ancient literature, it was found that the drug can be standardized by the physical-chemical properties of its materials. Its color, texture, aroma and taste are used as a basis for judging the efficacy of any drug. Even the shape of the drug is used

第7頁 1358540 五、發明說明(4) 來了解該藥物之藥性。用於治療上的不同哲學與各種要素 之總結置於出現在稍後敘述的表格1 - 6中。圖1特別提供一 詳細的資訊在印度個別的哲學與概念一阿祐爾惟達,中國 傳統藥物 (H.M.塞斯所著之’藥物在中國’及由丹尼爾·雷 伊德,西蒙與思古士特所著之’中國治療草藥的手冊 ’; Medicine in China by Η. M. Sais and A hand book of Chinese Healing Herbs by Daniel Reid, Simon & Schuster)與一般哲學上。一藥物的療效最後是依據該藥 物中所使用的化學成份而且該成份的化學性質將為生物體 内的化學組成帶來必須的變化。 許多阿祐爾惟達(一種印度的藥物系統)的學者已將藥 物依顏色與療效作定義與分類。一簡短的總結列於表格7 ,出現在稍後的敘述中。因此,該材料與人的物理一化學 性質被列入考慮了解其性質並用於治療以達到所需的治療 效果。出現在稍後敘述部分的表格8— 9提供關於其物理性 Λ 質(顏色)及化學性質(味道)如何用來理解該藥物的療效與 其在~人體生理學上的影響之資訊。本發明的工作有一部分 也使用相同的方法學,但伴隨著儀器來進行。 一般說來,存在於藥品與食物中的組成分子可廣泛地 分成三類,如極性,中極性與非極性分子。該分子的總極 性依據隨著該分子之不飽和度以共軛形式附帶於該分子之 總親電子性與親核性的部分。活著的人體,動物體與植物Page 7 1358540 V. Description of the invention (4) to understand the drug's medicinal properties. A summary of the different philosophies and various elements used in therapy is presented in Tables 1-6, which are described later. Figure 1 specifically provides a detailed information on the individual philosophy and concepts in India. Awkal, the traditional Chinese medicine (HM's "Drug in China" and by Daniel Reid, Simon and Scots The 'Handbook of Chinese Herbal Medicine'; Medicine in China by Η. M. Sais and A hand book of Chinese Healing Herbs by Daniel Reid, Simon & Schuster) and general philosophy. The efficacy of a drug is ultimately based on the chemical composition used in the drug and the chemical nature of the component will bring about the necessary changes in the chemical composition of the organism. Many scholars of Ajal Verda (an Indian drug system) have defined and classified drugs in terms of color and efficacy. A short summary is presented in Table 7 and appears in a later narrative. Therefore, the physical and chemical properties of the material and human are included in consideration of its properties and used in therapy to achieve the desired therapeutic effect. Table 8-9, which appears in the later section, provides information on how its physical properties (color) and chemical properties (taste) are used to understand the efficacy of the drug and its effects on human physiology. Some of the work of the present invention also uses the same methodology, but is carried out with the instrument. In general, the constituent molecules present in medicines and foods can be broadly classified into three categories, such as polar, medium-polar and non-polar molecules. The total polarity of the molecule is based on the portion of the molecule that is attached to the total electrophilicity and nucleophilicity of the molecule in a conjugated form with the degree of unsaturation of the molecule. Living human body, animal body and plants

第8頁 1358540 五、發明說明(5) 體也將包含同類型的分子,在其中不同極性的分子將執行 不同的功能。疾病可以用與造成疾病的化學成份相同極性 的藥物來加以治療。換句話說,產生混亂的藥可以治療相' 同的混亂,如韓尼曼博士 (Dr. Hanemann)所言。 .世界衛生組織對草藥的定義, 世界衛生組織已將草藥定義為一 ''完成的,已標·記的 藥物產品包括有效的成份氣體或植物的地下部份,或其他 的植物材料或其不管是在未加工的狀態或是作為植物調配 的組成。植物的材料包括其汁液,膠質,脂肪油,精油, 及任何其他自然的物質。草藥可能包括附加至活性成份的 輔藥(e X c i p i e n t s )。包含植物材料的藥物若結合了化學上 定義的活性物質,包括化學定義的,從植物中分離出的物 質,則不被認為是草藥。例外地,有些國家的草藥也包含 ,在傳統上,非植物來源的天然有機或無機活性成份。〃 所以,這些指導方針的目的,,是、'為草藥在品質安全 及效用的價值上定義基本的規範,如此一來有助於政府管 理當局,科學機構,及製造商來保證一..憑證/委託書/有關 檔案的評價在這類產品的關心上。〃,如在該評價中的一普 遍規則,傳統的經驗是指這些產品長期使用而且必須考慮 之藥用的,歷史的和民族學的背景。長期使用的定義可能 因國而異,但至少必須是數個世紀以上。因此,該評價需 考慮一在藥用的/製藥的文獻或類似來源中的描述,或一Page 8 1358540 V. INSTRUCTIONS (5) The body will also contain molecules of the same type in which molecules of different polarities will perform different functions. The disease can be treated with a drug of the same polarity as the chemical component that caused the disease. In other words, a messy drug can treat the same mess, as Dr. Hanemann said. The definition of herbal medicine by the World Health Organization, the World Health Organization has defined herbal medicine as a 'completed, labeled pharmaceutical product that includes an effective ingredient gas or a subterranean part of a plant, or other plant material or whatever It is in the unprocessed state or as a component of plant blending. Plant materials include their juices, gums, fatty oils, essential oils, and any other natural substances. Herbs may include adjuvants (e X c i p i e n t s ) attached to the active ingredient. Drugs containing plant material that are combined with chemically defined active substances, including chemically defined substances isolated from plants, are not considered herbal medicines. Exceptionally, herbs in some countries also contain, naturally, non-plant derived natural organic or inorganic active ingredients. 〃 Therefore, the purpose of these guidelines is to define the basic norms for the quality and safety of herbs, so that government authorities, scientific institutions, and manufacturers can guarantee a certificate. / Power of Attorney / Evaluation of relevant files in the care of such products. Well, as in the general rule of the evaluation, traditional experience refers to the long-term use of these products and the medicinal, historical and ethnographic backgrounds that must be considered. The definition of long-term use may vary from country to country, but it must be at least several centuries. Therefore, the evaluation needs to consider a description in a medicinal/pharmaceutical literature or similar source, or a

1358540 五、發明說明(6) 知識憑證在草藥的應用上沒有一時間限制的明確定義。類 似產品的銷售之授權也必須考慮。依據該報告 > 該品質的 評價需以下列的變數來進行? · 世界衛生組織之指導方針提供該完成的產品對於其功 效的評價,活性,證明必須支持其跡象與組合的產品。許 多草本的醫藥是由數種有效成份的組合所組成,而且雖然 傳統醫藥的使用經驗通常是基於組合的產品,在新舊組合 產品之間必有不同的評價。相同的需要對於新舊組合產品 ί 的評價會造成某一傳統藥物的不適當評價。在傳統使用的 組合產品之例子中,該傳統用途的憑證(例如阿祐爾惟達 的經典版本,傳統中藥,優那尼與席德哈)(Unan i and S i d d h a )與經驗可作為其功效的證明。 一關於已知物質的新組合之解釋、包括有效劑量範圍 與適合性」必須附加在每一種,單一組成成份的傳統知識文 件上。每一種有效成份都對該藥物的效用有貢獻。臨床研 究在界定一新成份的效用及其在整體組合上的正面影響是 必須的。 在該報告中」同樣須注意的是該製造過程及分子式, 包括該輔藥的量,必須詳細地描述。一完成的產品說明書 必須確認。一確認的方法以及如果可能的話,在該完成的 產品中該植物材料的定量亦應確認。如果不可能確認其活1358540 V. INSTRUCTIONS (6) There is no clear definition of knowledge voucher in the application of herbs. Authorization for the sale of similar products must also be considered. According to the report > The evaluation of this quality is carried out with the following variables? · The World Health Organization's guidelines provide an assessment of the effectiveness of the finished product, its activity, and the product that must support its signs and combinations. Many herbal medicines are made up of a combination of several active ingredients, and although the experience of traditional medicine is usually based on a combination of products, there must be different evaluations between new and old combinations. The same need for an evaluation of the old and new combination products ί will result in an inappropriate evaluation of a traditional medicine. In the case of traditionally used combination products, the credentials of the traditional use (such as the classic version of Ajalta, traditional Chinese medicine, Unani and Sidha) and experience can be used as its efficacy. prove. An explanation of the new combination of known substances, including the effective dose range and suitability, must be attached to each of the traditional components of a single component. Each active ingredient contributes to the utility of the drug. Clinical research is necessary to define the utility of a new ingredient and its positive impact on the overall portfolio. It is also important to note in this report that the manufacturing process and molecular formula, including the amount of the adjuvant, must be described in detail. A completed product manual must be confirmed. A method of confirmation and, if possible, the quantification of the plant material in the finished product should also be confirmed. If it is impossible to confirm its live

第10頁 1358540 五、發明說明(7) 性原則,則必須充分的確認一有特色的物質或混合物(例 如, ''層析特徵鑑定〃)以保證該產品之成分品質。該完 成的產品需遵守對於特別服用量形式的一般要求。 對於進口之已完成產品,必須提供在該輸出國之完整 的狀態確認。該世界衛生組織檢定計劃必須應用於進入國 際貿易之製藥產品的品質上。置入更多關於穩定性,安全 與使用的評估至上述的世界衛生組織的報告中。 該進入國際貿易之草藥品質的有效控制也需要國家的 機構間緊密的聯絡才能保持標準的檢閱所有的生產方向與 草藥的使用。同樣地,引導或發起關於該效用,毒性,安 全性,可受性,費用及相關價值之可評價研究與現在已使 用的藥物互相比較。 因此,如上所述,在該項工作中需要有一品質控制的 確實方法。需要一符合,所有明確地提到上述目的之方法。 所推薦的分析方法將針對幾乎所有上述的需要提供解答。 現有標準化之方法: 在解釋本發明的標準化方法之前,現有的標準化方法 (化學的與治療的)以及層析特徵鑑定法先敘述如下。 在化學的標準化上之現有技術:Page 10 1358540 V. INSTRUCTIONS (7) The principle of sexuality must be sufficient to identify a distinctive substance or mixture (for example, ''chromatographic characterization') to ensure the quality of the product. The finished product is subject to the general requirements for special dosage forms. For imported finished products, a complete status confirmation in the exporting country must be provided. The WHO certification program must be applied to the quality of pharmaceutical products entering international trade. Put more assessments of stability, safety and use into the above-mentioned World Health Organization report. The effective control of the quality of the herbs entering international trade also requires close liaison between national agencies to maintain a standard review of all production directions and use of herbs. Similarly, an evaluable study that directs or initiates the utility, toxicity, safety, acceptability, cost, and associated value is compared to the currently used drugs. Therefore, as mentioned above, there is a need for a reliable method of quality control in this work. A match is required, all methods that explicitly mention the above objectives. The recommended analytical method will provide answers to almost all of the above needs. Existing Standardization Methods: Prior to explaining the standardized methods of the present invention, existing standardization methods (chemical and therapeutic) and chromatographic characterization methods are described below. Existing technology in the standardization of chemistry:

第11頁 1358540 五、發明說明(8) i )傳統上: 偉大的賢人薛若卡(Charaka)在其薛若卡•山姆海塔 (Charaka Samhita)中解釋 ''實體全貌的了解不會出自一 片段的知識〃(薛若卡.山姆海塔 V 1. 4. 5 )。這使我們清 楚地知道,任何藥物的標準化與療效時,若不將其中所有 成份列入考慮則會徒勞無功。 一草藥大致上的質與量將會因許多因素而變化,例如 地質的,生態的因素,採集的時間,採集的地點,採集的 年代及採集時的天候等等。 傳統的草本學者習慣根據感官的方法來選擇一藥物, 在當時利用所能得到如顏色,構造,氣息與味道來評估該 藥物之化學與治療的功效。 這些方法包括内在的知識及在藥物與身體組成之間或 之内的治療作用以治癒疾病。這種知識會隨個體而異並端 賴個別的技巧與能力。事實上,該方法很難對任何解釋的 機構提出合理的辯解。因此,現代的科學利用儀器作各種 的假設藉以消除個別的因素並促進數據與資料的再現性。 i i )現代: 任何食物或藥品的治療特性將依據其化學與物理的狀 態而定。於是,利用其物理一化學的性質來了解該化學成Page 11 1358540 V. Description of invention (8) i) Traditionally: The great sage Charaka explained in his Charaka Samhita that 'the understanding of the whole picture will not come from one. Fragment of knowledge 〃 (Sherokka. Sam Haita V 1. 4. 5). This makes it clear to us that the standardization and efficacy of any drug will be in vain if all of its ingredients are not taken into account. The approximate quality and quantity of an herbal medicine will vary depending on many factors, such as geological, ecological factors, time of collection, location of collection, age of collection, and weather during collection. Traditional herbalists are accustomed to selecting a drug based on sensory methods, and at that time, using the color, texture, breath and taste to evaluate the chemistry and treatment of the drug. These methods include intrinsic knowledge and therapeutic effects between or within the drug and body composition to cure the disease. This knowledge varies from individual to individual and depends on individual skills and abilities. In fact, this method is difficult to justify any interpretative agency. Therefore, modern science uses instruments to make various assumptions to eliminate individual factors and promote the reproducibility of data and data. i i ) Modern: The therapeutic properties of any food or drug will depend on its chemical and physical state. Thus, using its physical-chemical properties to understand the chemical formation

第12頁 1358540 五、發明說明(9) . 份將有助於了解該藥物的療效。 該藥物的物理一化學性質在該藥物的治療活性上扮演 一重要的角色。這些分子的特性可以用兩種變數加以研究 ,極性與共軛性質。極性是電化學性質的結果,是因為不 同的提供電子(親核性,n u c 1 e 〇 p h i 1 i c)與接受電子(親電 子性,e 1 e c t r o p h i 1 i c )的性質沿著在該分子中的不飽和雙 鍵或參鍵而附加於該分子之上。該現象將影響該分子在化 學或生化反應中的活性或反應性之速率。該分子的總極性 之完全評估將提供一單一分子或一群分子表現在化學上與 治療上的功效。因此,任何用來評估上述特性的標準化都 將有助於了解其活性。 與極性相同,主要與該分子的電化學性質有關,該分 子的物理結構也在該分子的活性上扮演相當重要的角色。 愈多活性位置附加於該分子,則該分子會愈活潑。該分子 有愈多的共軛(有間隔的雙鍵或參鍵),則該分子將會在 化學上與治療上更具活性。 第二個影響該分子活性的變數是在相同分子中的原子 空間排列,該排列將因結構而異。根據該因素,該同分異 構的(幾何學的和光學的)分子在其生物活性上扮演一重 要的角色。該立體選擇的本質使得該分子在一同時進行著 大量的生化反應而不會互相影響或干擾的生物體内具有高Page 12 1358540 V. Inventive Note (9) . A copy will help to understand the efficacy of the drug. The physical-chemical nature of the drug plays an important role in the therapeutic activity of the drug. The properties of these molecules can be studied with two variables, polarity and conjugate properties. Polarity is the result of electrochemical properties because of the different properties of the electrons (nuclear, nuc 1 e 〇phi 1 ic) and accepting electrons (electrophilic, e 1 ectrophi 1 ic ) along the molecule An unsaturated double bond or a bond is attached to the molecule. This phenomenon will affect the rate of activity or reactivity of the molecule in a chemical or biochemical reaction. A full assessment of the total polarity of the molecule will provide a single molecule or group of molecules for chemical and therapeutic efficacy. Therefore, any standardization used to evaluate these characteristics will help to understand its activity. Like the polarity, it is mainly related to the electrochemical properties of the molecule, and the physical structure of the molecule also plays a very important role in the activity of the molecule. The more active sites are attached to the molecule, the more active the molecule will be. The more conjugated (double-bonded or bonded) the molecule, the more chemically and therapeutically the molecule will be. The second variable affecting the activity of the molecule is the arrangement of atoms in the same molecule, which will vary from structure to structure. According to this factor, the isomerized (geometric and optical) molecules play an important role in their biological activities. The nature of this stereoselection allows the molecule to be high in a living organism that undergoes a large number of biochemical reactions simultaneously without interfering with or interfering with each other.

第13頁 1358540 五、發明說明(ίο) 度的選擇性。因此,光學活性藥物的化學已經變得非常重 要。換言之,沒有一把鑰匙(光學分子)能打開一個不同 的鎖(受體,receptor )。 植物通常會準備許多分子的組合群組(combinatorial library),這些分子有相同基本的母結構且在附帶的官能 基上有所不同。例如,黃δί (flavones),奥酮(alirones) 及類黃酮(flavonoids)的卡銅(chalcones)當其存在於自 然中且單一植物具有這些分子的形式時將會表現得像一複 合藥物(muti drug)。 通常具有不飽和度與許多共軛的分子會吸收在紫外一 可見區(200-800 nm)的電磁幅射乂當該分子與幅射作用 時,根據其化學共軛及結構的特性該分子會吸收一特殊波 長(最大吸收)。此時稱為特性波長.(characteristic wave 1 enth)。一分子可依其結構與官能基的性質而具有一 個以上的最大吸收。當一分子由白光中吸收一特殊顏色時 ’該分子將表現出其他未被吸收顏色的合成色。所以,該 材料根據其化學成分從白光中吸收不同的顏色將表現出不 同的顏色並顯示該顏色是起因於附加在該分子上的不同官 能基(出現在稍後敘述中的表格1 0有相同的解釋)。相同 的原理被用在分光測量學(spectrophotometry)上的化學 與物理性質的測量。Page 13 1358540 V. INSTRUCTIONS (ίο) Degree selectivity. Therefore, the chemistry of optically active drugs has become very important. In other words, no key (optical molecule) can open a different lock (receptor). Plants typically prepare a combinatorial library of molecules that have the same basic parent structure and differ in the attached functional groups. For example, yellow δ ( (flavones), errones and flavonoids of chaconcones will behave like a compound when they are found in nature and a single plant has the form of these molecules. Drug). Usually with unsaturation and many conjugated molecules will absorb electromagnetic radiation in the ultraviolet-visible region (200-800 nm). When the molecule interacts with radiation, the molecule will be based on its chemical conjugate and structural properties. Absorbs a special wavelength (maximum absorption). This is called the characteristic wavelength (characteristic wave 1 enth). A molecule may have more than one maximum absorption depending on the nature of its structure and functional groups. When a molecule absorbs a particular color from white light, the molecule will exhibit other synthetic colors that are not absorbed. Therefore, the material will exhibit different colors depending on its chemical composition from different colors of white light and show that the color is caused by different functional groups attached to the molecule (the table 10 0 appearing in the later description has the same explanation of). The same principle is used for the measurement of chemical and physical properties on spectrophotometry.

第14頁 1358540 五、發明說明⑽ 現代科學是如何完成標準化。 根據報導(WWW// Shilajit,Fulvic acid etc,, html )’一種在印度藥用許拉集特的系統中非常重要的藥物, 報導成有許多成份與富瓦酸(Fulvicacid)同在,並視 為有效原則。當收集來自於在陸地儲藏許多年後的煙煤藥 物 可以視為若是在陸地中儲藏愈久則將會愈有療效。不 過’在全球’地質的變動可能不會在所有來自世界各地的 樣本中產生相同的分子。另一影響這些藥物的化學之因素 是其純化的過程,該過程同樣需要被標準化。 根據報導(WWW//Herbology. html),多數用於關鍵成 分的標準化已經完成。該項標準化憑經驗地且合乎科學地 證明對人類系統非常有幫助。如此通常地,某一超越一切 現有’已完成所發現具活性的分子之標準化。然而,該藥 物中其他成份的加成作用使得該藥物的整體概況必須列入 其功效的考慮。 根據報導(WWW// Tribulus Terrestrius puncture vine, html),漠藜(TribulusTerrestrius)果實的酒精 萃出物顯示出抗尿道結石 (a n t i u r ο 1 i t h i a t i c )的活性。 除此之外,該萃出物也顯示出一明顯的利尿活性。該生物 驗哈爾曼(Harman)據報導來自該藥草且肉葉芸驗 (Harmine)來自於其種子。該植物含有皂素(Saponins),Page 14 1358540 V. INSTRUCTIONS (10) How modern science completes standardization. According to reports (WWW//Shilajit, Fulvic acid etc, html), a drug that is very important in the Indian medicinal system, reported that many components are present with Fulvicacid, and For the principle of effectiveness. When collecting bituminous chemicals from many years after storage on land, it can be seen that the longer they are stored on land, the more effective they will be. However, changes in the 'global' geology may not produce the same molecules in all samples from around the world. Another chemical factor affecting these drugs is the process of their purification, which also needs to be standardized. According to the report (WWW//Herbology.html), most of the standardization for key components has been completed. This standardization is empirically and scientifically proven to be very helpful for human systems. So generally, a certain standardization beyond all existing molecules that have been found to be active. However, the addition of other ingredients in the drug makes the overall profile of the drug mandatory for its efficacy considerations. According to the report (WWW//Tribulus Terrestrius puncture vine, html), the alcohol extract of the fruit of the Tribulus Terrestrius showed anti-urethral stones (a n t i u r ο 1 i t h i a t i c ). In addition to this, the extract also showed a significant diuretic activity. The biochemical Harman was reported to have come from the herb and the Harmine is from its seeds. The plant contains saponins,

第16頁 1358540 五、發明說明(13) 可在水解後產生固醇類(steriodal)皂素。已報導天然類 黃酮中的許多分子在其活性原理中發現皂素。該分析報導 提供了重金屬分析及總皂素含量 (20%w/w)。 根據報導(WWW// Chra k_ com.— Quality control page-html),人類的生活是心理生理與靈魂的成份的合作 ,這關係到阿祐爾惟達的印度哲學中所提及,皮塔 ( Pi tta),卡發(Kapha),與伐塔(Vata)認為是人類整體健 康的基礎。標準化的更細節部分置於傳統方法的治療標準 化的敘述中。 根據報導(WWW//Standardized Herbal Extracts\ A Herbalists Perspective^, Dr. M i chea 1 T i erra L. Ac· 0. M. D html),由於歐洲保障權力法 (European Guaranteed Potency Law) ’草藥的標準化變成強制性的 。草本的標準化的意義定義為一活性成份或標記萃出物的 定量,如果該藥物的活性主要是歸因於這些成份。 依據解釋(Frank R Stermitz et al,PAINS/Febl5, 200/Vol 97,No4, ppl433-143?),在該植物針緣葉小薛 (Berber i s Aristata)中,該萃出物的抗菌特性是由於標 精 (5-Hydroxy Hydnocarpin)的存在,該黃連素扮演對 抗微生物的角色’沒有它不行。因此,當處理一不僅只有 一種有效成份的草藥時’其所有成份的加成作用必須考處Page 16 1358540 V. INSTRUCTIONS (13) Steroidal saponin can be produced after hydrolysis. Many molecules in natural flavonoids have been reported to find saponin in their principle of activity. This analysis provides heavy metal analysis and total saponin content (20% w/w). According to the report (WWW// Chra k_ com.—Quality control page-html), human life is a collaboration between psychophysiology and the components of the soul, which is related to the Indian philosophy mentioned in Ajul, Pita (Pi Tta), Kapha, and Vata are considered to be the basis of human health as a whole. The more detailed part of the standardization is placed in the narrative of the standardization of treatment in traditional methods. According to the report (WWW//Standardized Herbal Extracts\ A Herbalists Perspective^, Dr. M i chea 1 T i erra L. Ac. 0. M. D html), due to the European Guaranteed Potency Law Standardization becomes mandatory. The standardized meaning of herbs is defined as the quantification of an active ingredient or labeled extract if the activity of the drug is primarily attributed to these ingredients. According to the explanation (Frank R Stermitz et al, PAINS/Febl 5, 200/Vol 97, No 4, ppl 433-143?), in the plant Berber is Aristata, the antibacterial property of the extract is due to In the presence of 5-Hydroxy Hydnocarpin, this berberine plays a role in fighting microbes. 'Nothing is not enough. Therefore, when dealing with an herb that has more than one active ingredient, the addition of all its ingredients must be tested.

第17頁 1358540 五、發明說明(14) 。世界衛生組織在其局部的出版物(潤津特.羅伊.喬德 瑞博士,關於人類健康的草藥;Dr.Ranjit Roy Choudary ,Hrebal Medicine for Human Health, Searo no 20) 中清楚地提到,該藥物關於標準化是什麼以及會員國們應 如何實行的最佳作法。 酸性和驗性的角色可經由該成份從藥物的萃取過程中 所用萃取液之不同pH值而得知。這有助於了解該藥物在腸 中釋放的過程,因為藥物的消耗會因人們腸中不同的pH值 而異。在了解一藥物的療效上,仔細地研究其酸性與鹼性 扮演的角色。徹底地研究有機與無機分子的酸性和鹼性以 了解其特性如表格11所示,出現在稍後的敘述中。在酸性 和鹼性方面顯示出在健康上酸性和鹼性的角色(、、手中的 健康〃由迪凡卓·佛拉所著,那伐尼特出版物(印度)有限 的; Health in Hands by Devendra Vora, Navaneet publications (Indea) Ltd)。 根據報導 (WWW// Chewing. Html),在一研究中發 現,具酸性體質的人會比已建立適當血液鹼性岛人吸收更 多的污染物。酸驗 (p Η值)平衡對正常的細胞功能是重要 的》更詳細的部分將在文章中加以討論。因此,酸性或鹼 性(有機或無機)的討論,就’極性’而言,將提供該藥物 在療效方面的資訊。因此,當前的方法,可以勝任這個工 作,將大量使用於對該藥物療效的了解。使用所推薦的方Page 17 1358540 V. Description of invention (14). The World Health Organization clearly mentions the drug in its local publication (Dr. Runzit Roy. Jodrill, Herbs for Human Health; Dr. Ranjit Roy Choudary, Hrebal Medicine for Human Health, Searo no 20) The best practice on what is standardization and how Member States should implement it. The acidic and anatory role can be known from the different pH values of the extract used in the extraction of the drug. This helps to understand the release of the drug in the intestine because the consumption of the drug will vary depending on the pH of the intestines. In understanding the efficacy of a drug, carefully study its role in acidity and alkalinity. The acidity and alkalinity of organic and inorganic molecules have been thoroughly studied to understand their properties as shown in Table 11, which appears in later description. It shows a healthy and acidic character in terms of acidity and alkalinity (, the health of the hands is written by Divandra Fola, the Navalite publication (India) is limited; Health in Hands by Devendra Vora, Navaneet publications (Indea) Ltd). According to the report (WWW//Chewing. Html), it was found in a study that people with acidic constitutions absorbed more pollutants than those who had established appropriate blood alkaline islands. Acid testing (p Η value) balance is important for normal cellular function. A more detailed section will be discussed in the article. Therefore, the discussion of acidic or basic (organic or inorganic), in terms of 'polarity', will provide information on the efficacy of the drug. Therefore, the current method is competent for this work and will be used in large quantities to understand the efficacy of the drug. Use the recommended party

第18頁 1358540 五、發明說明(15) 法,則可以確定用在藥物的治療標準化上的酸鹼性。 上述的參考資料將解釋標準化之常見的與已報導的方 法,其中該個別的成份被分離至一預備的稱盤上並與存在 於研究中的樣本藥物之相同化合物作定性及定量上的比較 在其中的一篇報 賈等人,美國專利6, Palmetto, Khwaja, 出,巴爾麥鋸齒棕櫚 個不同的部分藉由在 試驗之半數有效濃度 亦討論到總脂肪酸在 該含有亞麻油酸乙酯 桂酸乙S旨 (1 a u r i c 出。其每一部分對男 算出來。該項分析已 其分子量與個別的脂 物活性的計算中。該 亞麻油酸與月桂酸乙 導(製藥等級的巴爾麥鋸齒棕橺,奎 039,950;Pharmaceutical grade Saw et al US Patent 6,039,950)中指 (Saw Palmetto)的酒精萃出物中各 測定在一男性荷爾蒙受體結合的抑制 (1C 50) 中用來研究其生物活性。 總萃出物及個別部分中含量的檢測。 (linoleic acid ethyl ester)與月 acid ethyl ester)的部分已經鑑定 性荷爾蒙受體結合抑制的活性可被計 被作為該樣本之總生物活性的比較。 肪酸含量已被鑑定並且被包含於該生 萃出物的.總生物活性的計算是相較於 酯部分的活性之整體百分比。 在該傳統藥物標準化中,其整體的概況必須列入該草 藥療效之考慮中。因此,在現今運用電腦儀器的方法中,Page 18 1358540 V. The invention (15) method can determine the acidity and alkalinity used in the standardization of the treatment of drugs. The above references will explain the common and reported methods of standardization in which the individual components are separated onto a prepared scale and compared qualitatively and quantitatively to the same compound present in the study sample. One of the newspapers, J. et al., US Patent 6, Palmetto, Khwaja, Out, a different part of the Balmian sawtooth palm, also discussed the total fatty acid in the test containing half of the effective concentration in the linoleic acid ethyl laurate B. (1 auric out. Each part of it is calculated for males. The analysis has been calculated for its molecular weight and individual lipid activity. The linoleic acid and lauric acid beta (pharmaceutical grade of Balmer sawtooth palm , Kui 039, 950; Pharmaceutical grade Saw et al US Patent 6, 039, 950) The alcohol extract of the middle finger (Saw Palmetto) was used to study its biological activity in the inhibition of male hormone receptor binding (1C 50). Detection of the content of the substance and individual parts. (linoleic acid ethyl ester) and part of the monthly acid ethyl ester) have been identified to inhibit the binding of hormonal receptors. Activity can be counted as the total biological activity of the comparison of the sample. The fatty acid content has been identified and included in the extract. The total biological activity is calculated as an overall percentage of the activity of the ester moiety. In the standardization of this traditional medicine, its overall profile must be included in the consideration of the efficacy of the herb. Therefore, in today’s method of using computer instruments,

第19頁 1358540 五、發明說明(16) 所有成份^以生質考慮成在傳統概念世界之丨的建議。 該藥物的特徵提議成為一看得見的工具與處理許多特殊傳 統藥物的效果之證明。在討論該發明的方法之前,現存分 析方法的钦述如下。 現存的化學標準化之分析方法. 現代的分析方法與儀器的改良與使用已明顯地導致藥 物^品質控制上的優點。在分析上的改良已導致許多上述 草藥有更精確的結果並有助於準備標準化的萃出物。 有任何一種能如同該植物的特徵提供一可靠的鑑定 雖然有許多藥用植物的 用顯微鏡的及物理的方法, 鐘定之傳統方法,如感官的, 但是就其化學的概況而言,沒 〇Page 19 1358540 V. INSTRUCTIONS (16) All ingredients ^ are considered to be the top of the traditional concept world with biomass. The characteristics of the drug are proposed to be a visible tool and proof of the effectiveness of many special traditional drugs. Prior to discussing the method of the invention, the existing analytical methods are described below. Existing analytical methods for chemical standardization. The improvement and use of modern analytical methods and instruments has clearly led to the advantages of drug quality control. Improvements in analysis have led to many of the above-mentioned herbs having more accurate results and helping to prepare standardized extracts. Any one can provide a reliable identification as the characteristics of the plant. Although there are many medicinal plants using microscopic and physical methods, the traditional methods of Zhongding, such as sensory, but in terms of their chemical profile, there is no flaw.

因此’該層析特徵鑑定法在藥用植物的品質控制上更 有用而提礅取代其他感官的及顯微鏡的研究。最後大量參 與该藥物的療效的化學成份,伴隨著該草藥的其他性質; S亥化學成份的分析資料必定可以提供該藥物可靠的功效。 一個體的特徵好像提供了其自己的特性。 直到如5》專色層分析(Thin Layer Chromatography, TLC) 向效此薄色層分析(High Performance ThinTherefore, the chromatographic characterization method is more useful in the quality control of medicinal plants to replace other sensory and microscopic studies. Finally, a large number of chemical ingredients involved in the efficacy of the drug, along with other properties of the herb; S Hai chemical composition analysis data must provide reliable efficacy of the drug. The characteristics of a body seem to provide its own characteristics. Until such as 5" Thin Layer Chromatography (TLC) to the effect of this thin layer analysis (High Performance Thin

Layer Chr*〇raat〇graphy,HPTLC),及高壓(效能)液相色層 分析(High pressure ( Performance ) LiquidLayer Chr*〇raat〇graphy, HPTLC), and high pressure (performance) liquid chromatography (High pressure (Performance) Liquid

第20頁 Γ/Ι358540 五、發明說明(17) --Page 20 Γ/Ι358540 V. Description of invention (17) --

Chromatography)是一般用於有機或有機金屬化合物及特 徵的分析之方法。但是,這些方法用在一藥物的可靠分析 時都有其優點與缺點。表格丨2出現在稍後的敘述中比較數 種現存的分析方法,並提供該方法之優點與缺點的一般見 解。 本說明書的圖4,指出如何將一由薄色層分析法發展 出的色彩層析譜以,層析特徵鑑定法,用在商業產品的標示 上。除成份的分析之外該特徵不會提供任何的資訊。 ,,察過上述表格後可發現,最適合用於混合物分析的 技術疋色層分析法’’,該方法在分離與以適當偵測器鑑定 之後可提供該混合物的概況。 、在幾種層色層分析的技術中,最適合的是高壓液相色Chromatography) is a method generally used for the analysis of organic or organometallic compounds and features. However, these methods have advantages and disadvantages when used in the reliable analysis of a drug. Table 丨2 appears in a later narrative comparing several existing analytical methods and provides a general insight into the advantages and disadvantages of the method. Figure 4 of this specification shows how a color chromatogram developed by the thin-layer analysis method, chromatographic characterization, can be used on the labeling of commercial products. This feature does not provide any information other than the analysis of the ingredients. After reviewing the above table, it was found that the technical chromatographic layer method '' is most suitable for use in mixture analysis, which provides an overview of the mixture after separation and identification by a suitable detector. Among the techniques of several layers of color analysis, the most suitable one is high pressure liquid color.

層分析(High pressure Liquid Chromatography,HPLC )。雖然薄色層分析至今仍被使用,但是進步使得高壓液 相色層分析儀器與分離管柱的出現已徹底改變了色声八 的分析領域。 β刀n 大多數的製藥分析是以一色彩層析譜的形式來報導。 該層析谱包含一些由於各分子經一報導於官方資料或藥典 上的動相(m 〇 b i 1 e p h a s e )沖提後得到之吸收峰。該成p 的为析方法是在經過高壓液相色層分析的分離管柱上沖提High pressure Liquid Chromatography (HPLC). Although the analysis of thin color layers has been used to date, advances in the field of high-pressure liquid phase chromatography and separation columns have completely changed the field of analysis of color sounds. Beta knife n Most pharmaceutical analyses are reported in the form of a color chromatogram. The chromatogram contains some of the absorption peaks obtained after the molecules have been extracted from the official data or pharmacopoeia (m 〇 b i 1 e p h a s e ). The p-forming method is performed on a separation column subjected to high-pressure liquid chromatography analysis.

第21頁 1358540 五、發明說明(18) 後再以任何適當的彳貞測器作分析。通常該色層分析法在操 作時會使用一參考標準品(内標準法或外標準法)。若缺 少一標準參考物,則該分析不具任何意義,因為該層析譜 上的吸收峰無法提供任何關於所沖提出的化合物之化學性 質。因此,該成份在定性與定量上(光譜的或化學的)的 確認會變得不清楚。 在醫藥/毒品的定性與定量分析上(單一或公式化), 主要強調的是,在分析過樣品後,所沖提出的成份之光譜 與化學的性質。該分析的完成是基於電磁幅射(稱為紫外 -可見幅射)在該分析物上的影響及該分析物的回應。在 現存的色層分析法中,該分析報告,也就是該層析譜並不 提供任何化學性質,如極性與該成份的紫外一可見吸收性 質。該層析譜不能顯示出那些在該波長不吸收或具有不同 於設定波長 (2 2 5或2 5 4 nm)的''最大吸收11。即使該樣品 是1 0 0 %的純度,即使它是一已知分子還有該分析在一可接 受的固定波長,但是在一含有大於一活性分子的藥物案例 中是非常不實際的。 圖5 -1 2中顯示許多在單一波長的例子,在這些層析譜 中有許多不同的波長。沒有任何一單一層析譜能提供關於 含有超過一活性物質的傳統藥物的成份之完整化學性質。 當這些層析譜與特徵相互比較的時候,即可了解該特徵的 用途。Page 21 1358540 V. INSTRUCTIONS (18) After analysis with any appropriate detector. Usually, the chromatography method uses a reference standard (internal standard method or external standard method) during operation. If a standard reference is missing, the analysis does not make any sense because the absorption peak on the chromatogram does not provide any chemistry about the compound being flushed. Therefore, the qualitative and quantitative confirmation of the composition (spectral or chemical) becomes unclear. In the qualitative and quantitative analysis of medicines/drugs (single or formulation), the main emphasis is on the spectral and chemical properties of the components being flushed after the samples have been analyzed. The completion of the analysis is based on the effect of electromagnetic radiation (referred to as UV-visible radiation) on the analyte and the response of the analyte. In existing chromatographic methods, the analytical report, that is, the chromatogram does not provide any chemical properties such as polarity and UV-visible absorption properties of the component. The chromatogram does not show those 'maximum absorptions 11 that do not absorb at this wavelength or have a different wavelength than the set wavelength (2 2 5 or 2 5 4 nm). Even though the sample is 100% pure, even though it is a known molecule and the analysis is at an acceptable fixed wavelength, it is highly impractical in a drug case containing more than one active molecule. A number of examples at a single wavelength are shown in Figure 5-1, where there are many different wavelengths. None of the single chromatograms provide the complete chemical properties of the ingredients of conventional drugs containing more than one active substance. When these chromatograms are compared to features, the use of the feature can be understood.

第22頁 1358540 五、發明說明(19) 因此,任何在一特殊波長的層析譜不能提供在一單一 藥物與一配方中之原料的完整化學概況。所以,該層析譜 是其報告的一部分,且令人不能接受。任何分析的方法, 若不能提出該分析完整的資訊,都不能算是合乎科學的。 在一草藥的分析中,不同種類的分子具有不同的光譜性質 (最大吸收)在一固定的單一波長之層析譜將不再是有意 義的分析報告或層析譜。 在草藥的使用上,就整體藥物來看是用於一些古代的 文獻或手稿中所規定的標準治療環境。因此,尋找一有效 原料的概念被認為是不完整的,因為完整的概況是該藥物 之藥性的原因。所以,任何分析方法,若不能說出該研究 中藥物所有成份之完整的化學性質,將不會是有用的。 態與 生, 多代 許年 於的 由集 會採 況, 概點 的地 量的 定集 與採 陡 , 。 定間等 之時等 藥的況 草集狀 1採風 ,如季 地’的 樣異分 同而部 素集 因採 已提及(法蘭克· R ·斯德爾密爾茲等人) (Frank R Stermirtz et al) 的是,伴隨著主成份由其他成份引 起的加成作用也同樣重要,因為該加成作用不能沒有其他 在萃出物中的成份存在而發揮功能,如同之前的解釋。Page 22 1358540 V. INSTRUCTIONS (19) Therefore, any chromatogram at a particular wavelength does not provide a complete chemical profile of the material in a single drug and a formulation. Therefore, this chromatogram is part of its report and is unacceptable. Any method of analysis, if it is impossible to present complete information about the analysis, is not scientific. In the analysis of an herb, different kinds of molecules with different spectral properties (maximum absorption) at a fixed single wavelength chromatogram will no longer be meaningful analytical reports or chromatograms. In the use of herbal medicines, the overall drug is used in the standard treatment environment specified in some ancient literature or manuscripts. Therefore, the concept of finding an effective ingredient is considered to be incomplete because the complete profile is the cause of the drug's medicinal properties. Therefore, any analytical method would not be useful without the complete chemical nature of all the components of the drug in the study. State and life, multi-generational years of collection, the collection of points and the steepness of the point. When the time is equal, etc., the situation of the medicine is set in the form of a collection of winds, such as the plot of the season, and the collection of the monosyllabic elements has been mentioned (Frank R. Stelmiltz et al.) (Frank R Stermirtz Et al), the additive effect associated with the main component is also important, since the addition cannot function without the presence of other components in the extract, as explained earlier.

第23頁 1358540Page 23 1358540

在治療的標準化 傳統的方法: 偉大的印度醫學 的性質,成份與體液 到在其間產生的内部 中,該基本概念包含 角色。據說人體 Saptahatus)所組成。 有三種。宇宙中任何 恰補塔斯’ pancha 結合的作用將影響其 於了解其物理與化學 界各地的哲學家皆已 上之現有技術: 地定義生物 同時也了解 有傳統哲學 上所扮演的 塔哈圖斯, ,Tridosha) 種元素(潘 同的變更與 了解將有助 其療效。世 社會的概念 聖人們已瞭解並藉由清楚 來定義印度醫藥的概念。 與之間的關係。在幾乎所 大自然與其在人類的體液 疋由七種成份(撒普 5 一般的失調(促伊都夏 材料的唯物性質是由於五 bhutas)。這些元素間不 健康。因此’這些性質的 的性質’而且可藉以了解 發展出這類適合其傳統與 在前聖海堤克與前瑟斯盧提克的古印度時代(pa Samhitlc and pre Susrutic peri〇d in India),治療者 'J用那迪撒斯特拉(Nadi sasi:ra ;研究脈搏 促伊都夏(伐塔,卡發,與皮塔)在診斷時的科二兄)Γ了ϊ 該病患的健康狀態。該特殊種類的脈搏(不是心臟的脈搏) 7來解釋該病患的疾病種類(印度的醫藥史,普利亞•發 知特•夏爾馬博士所著,印度國家科學研究院;HistoryStandardization of treatment Traditional methods: The nature of great Indian medicine, the composition and body fluids into the interior created between them, the basic concept contains roles. It is said to consist of the human body Saptahatus). There are three. The role of any tantra's pancha combination in the universe will affect its existing philosophers who understand its physics and chemistry: the definition of biology and the understanding of traditional philosophical Tahatus , ,Tridosha) elements (Pan Tong's change and understanding will help its efficacy. The concept of the world society Saints have understood and defined the concept of Indian medicine by clarity. The relationship between it and the nature In human body fluids are composed of seven components (Sarp 5 general disorders (promoting the material nature of the Idira material due to five bhutas). These elements are unhealthy. So 'the nature of these properties' and can be used to understand the development of this The class is suitable for its traditions and the ancient Indian era (pa Samhitlc and pre Susrutic peri〇d in India) in the former St. Haitick and the former Seslutik, the healer 'J with Nadis sasi: Ra; study pulse to promote Yidu Xia (cutting tower, Kafa, and Pita) at the time of diagnosis of the second brother) Γ ϊ The health status of the patient. The special kind of pulse (not the heart) Pulse) 7 to explain the types of diseases the patient (history of medicine in India, Puglia • Special • Dr. Sharma made known book, the Indian National Academy of Sciences; History

Medicine in India by Dr. Priya Vrat Sharma, I n d i a η N a t i 〇 n a 1 S c i e n c e A c a d e m y )。Medicine in India by Dr. Priya Vrat Sharma, I n d i a η N a t i 〇 n a 1 S c i e n c e A c a d e m y ).

第24頁 1358540 五、發明說明(21) 在診斷的時候用以了解該病患的主要是都夏(dosha (s))的種類以及治病時各別的都夏受損害的情形。但是這 項研究那迪 (Nadi,脈搏)的技術只批准一些具有高程度 個人技術及大量訓練所得之能力的人才能進行。因此,不 是每個傳統的從事者皆能實行該技術。 為了克服該現象,必須發展與標準化該了解藥物與人 類體液的物理一化學性質的技術。這些會影響健康的天然 性質的内部與之間的關係已研究與標準化,從而該藥理學 與藥物治療學的技術由治療者所發展。 一藥物的療效是以一能在人體(克里亞古那伐特, Kriyagunavat)中產生一(藥理學的)作用之物質的使用 來定義及由於採集工作中的幾項因素,(撒馬發亞卡拉南 ,Samavayikaranam),正如同一塊布的產生是來自於許多 成份共同演出的結果。 世界上的生物主要有兩類,動物與植物。亦有人說, 世界是由五種重要元素即地水風火空(在阿祐爾惟達中被 稱為’潘恰補塔斯’)所組成。這些物質的基本性質有兩類 ,稱為激烈的(強大的)與輕微的(柔和的)。如果我們 同意這個非常經得起批判的邏輯,則我們可以說,是世界 上所有作用皆由於上述性質不同的變動與結合之申聯,在Page 24 1358540 V. INSTRUCTIONS (21) The type of dosha (s) used to understand the patient at the time of diagnosis and the case where the disease was damaged during the treatment. But this study, Nadi's technology, only approves those who have a high level of personal skills and a large amount of training. Therefore, not every traditional practitioner can implement this technology. In order to overcome this phenomenon, it is necessary to develop and standardize the technique of understanding the physical-chemical properties of drugs and human body fluids. These internal and interrelated relationships that affect the natural properties of health have been studied and standardized so that the pharmacology and pharmacotherapeutic techniques are developed by the therapist. The efficacy of a drug is defined by the use of a substance that produces a (pharmacological) effect in the human body (Kryagnaput, Kriyagunavat) and due to several factors in the collection work (Samafa Akaranan, Samavayikaranam, just as the production of the same piece of cloth is the result of a joint performance of many ingredients. There are two main types of organisms in the world, animals and plants. It has also been said that the world is composed of five important elements, namely, the water and the wind (known as the 'Pancha Titas' in Ajulda). There are two basic properties of these substances, called intense (strong) and light (soft). If we agree with this very criticized logic, we can say that it is the combination of all the changes in the world that are due to the above-mentioned nature.

第25頁 1358540 五、發明說明(22) 其強度上提供一廣泛的性質及材料的變化 學中,並存於大自然中的 慮之中。該成分將有助於 貫性在阿祐爾惟達中稱為 。出現在稍後敘述的表格 上述的兩項因素,如何的 化。中國醫藥對人體的狀 樂如前所述。這些因素歸 。該因素的主張是隨著將 入考慮而完成。大部分的 生物能量中心有直接或間 用亦然。報導於其他哲學 點。在潘恰補提克 ( 促伊都夏的概念(皮塔, 中扮演重要角色與人體組 ,Saptadhatus)。阿祐爾 對於疾病介紹上的強調多 在大部分傳統藥物世界的哲 這五種成份已列入人體組成的考 了解病患的疾病與不適。這種連 ’普魯夏’,在中藥上稱為’陰陽 6中提出中國的系統中如何使用 分類與定義使治療和疾病能標準 態分類成陰與陽表現在悲傷與快 因於該藥物及生物中不同的性質 化學的,生理的及社會的因素列 時候該中國醫藥與人體中不同的 接的關係。該針灸治療技術的使 中的因素都與中國的醫藥有相似 panchabhautic) 的才既念後,該 卡發,與伐塔)在印度傳統藥物 成的七種成份(撒普塔德哈圖斯 惟達相信生活中全部的哲學並且 於疾病的治療。 阿祐爾惟達的所有方法是提倡靈魂,心理與身體是構 成生命的三個部分且當這些在機能的平衡與和諧時,該狀 態稱為良好的健康(阿若格亞,Arogya)。當它們處於不平 衡與不和諧的時候,該狀態稱為疾病(罰哀享亞,Page 25 1358540 V. INSTRUCTIONS (22) The strength provides a wide range of properties and changes in materials that exist in nature and are considered by nature. This ingredient will contribute to the consistency referred to in Ajal. The two factors mentioned above appear in the table described later. The Chinese medicine's taste for the human body is as described above. These factors are returned. The claim for this factor is completed as will be considered. Most bioenergy centers are directly or indirectly used. Reported on other philosophical points. In Pancha Bu Tike (promoting the concept of Idusia (Pitta, plays an important role in the human body, Saptadhatus). Ayur's emphasis on disease introduction is mostly in the five traditional ingredients of the traditional medicine world. Into the composition of the body to understand the disease and discomfort of the patient. This kind of 'Prussian', in the traditional Chinese medicine called 'Yin and Yang 6' proposed in China's system how to use classification and definition to classify treatment and disease standard state into Yin and Yang are manifested in sadness and quickness due to the different nature of the drug and the chemical, physiological and social factors of the Chinese medicine and the human body. The factors in the acupuncture treatment technology Both have similarities with Chinese medicine, panchabhautic), after learning, the card is issued, and the pagoda) is made up of seven ingredients in traditional Indian medicine (Sapta de Hatus, who believes in all the philosophy of life and The treatment of diseases. All the methods of Ajul are to promote the soul, the mind and the body are the three parts of life and when these are in the balance and harmony of function, Called good health (Ah, if Geya, Arogya). When they are in imbalance and disharmony, the state is called disease (penalty grief enjoy Asian,

第26頁 1358540 五、發明說明(23)Page 26 1358540 V. Description of invention (23)

Va i shamya )° "依據阿祐爾惟達,促伊都夏維持各種系統在機能平 ί f下的生理特徵。換言之,促伊都夏的和諧蘊含良好的 =,而促伊都夏的不和諸則會造成疾病…匕,大部: 的’候:伊都夏用於治療任何疾病的討論 的樂品選擇時必須討論促伊都夏。 疋戾病 會靖Ϊ病:定義是、'任何會將悲傷或不幸帶給這個人(普 二:的事物就是疾病"。可分成四種:;. ,ς野根塔伐哈,agantavaha) 2.身體產生的(撒理 Ϊ3.心理產生的(綿納撒,Manasah)及4.自 邱八从神卡 abhavlkah)。因為這個理由,大 4为的傳統概念在以赭妯去合 人 的方法來治療疾病。神素會依據-生命的規定與標準 疾T基本上可分成三大類。i .可治癒& (撒德亞, ahya) 2.可緩和或可控制的(亞並西 γ 、: 治癒的(阿撒拽亞,二 丄曰亞,加”)3·不可 那此身體的= * Ρ)。如上所述,主要考慮的是 伐:卡ηί發生的原因經由促伊都夏的相反,即 伐塔卡务,及皮塔與血液個別地或盥另—個原^ 但是,那此a 又兴方一個原因結合。 則β以不^ Μ疋由述原因,如心理因素,所引起的疾病 則疋以不同的方法*考 _ a . 丨'\〜佚炳 户瘆呼瘅广Μ Μ 1來處理。适疋為什麼任何傳統概念列入 Ί該疾病的精神因素之考量。都夏斯(Doshas)的= 1358540 五、發明說明(24) 個別性質解釋如下。 可廣泛簡述的是,該伐塔或伐悠都夏 (v a y u d 〇 s h a) 處理内分泌的,神經肌肉的及源自神經系統的那些造成生 命的主要或全部動力的活動,那些造成氣體產生的食物可 分在這一類。皮塔都夏 (Pitta dosha)與消化及化學作 用有關或瑞撒柯力亞 (rasa kriya)大致與卡發都夏 ( Kapha dosha) 包括提供形成穩定和結合與潤滑因素。如 同第一個都夏,’伐塔’被認為能影響另外兩個因素所以被 認為是所有疾病的主因。關於這些體液的詳盡敘述已放在 本文主體的其他地方。 伐塔的減少會造成活動上的遲鈍。因此,該種能降低 遲純的藥品,將是伐塔 赫拉 (V a t a H a r a )。這種消化能 力的降低稱為皮塔 都夏。一藥物,可增加該消化能力或 活化膽汁 (b i 1 e )機構,將是自然的皮塔 赫拉。 為了更廣泛地了解不同的傳統醫藥世界,所有這類因 素的詳細描述放在各種哲學之中。表格1與表格2 (出現在 稍後的敘述中)提供一印度阿祐爾惟達的 (Ayuvedic)哲 學及其中各種組成的詳細描述。 因此,為了解一藥物或食物的療效,必須先了解其物 理與化學的特性。在古代,人們利用感官的方法,如該材Va i shamya ) ° "According to Ajul, we promoted the physical characteristics of various systems under the function of the function. In other words, the harmony of Yiduxia implies a good =, and the disharmony of Yidu Xia will cause disease... Hey, most of the 'waiting: Yiduxia must discuss when choosing the music for the discussion of any disease. Promote Idusia.疋戾病会靖Ϊ: The definition is, 'anything will bring sorrow or misfortune to this person (Pu 2: The thing is disease " can be divided into four:;., ς野根塔瓦哈, agantavaha) 2 The body produces (Sali Ϊ 3. Psychologically produced (Minna, Manasah) and 4. Since Qiu Ba from the god card abhavlkah). For this reason, the traditional concept of the Big 4 is to treat diseases in a way that is combined with others. The gods will be divided into three categories based on the rules of life and the standard. I.curable & (Sadya, ahya) 2. Can be moderated or controllable (Asian and West γ,: Healed (Assaya, Dijon, Plus)) 3. Can not be this body = * Ρ). As mentioned above, the main consideration is that the reason for the occurrence of the card: ηί is via the opposite of the promotion of Iduh, that is, the slashing of the card, and the pita and the blood, either individually or separately. Then a is combined with a reason for the reason. Then β is not caused by the reasons, such as psychological factors, the disease is caused by different methods* test _ a. 丨 '\~ 佚 瘆 瘆 瘆 瘅广Μ Μ 1 to deal with. It is appropriate to consider why any traditional concept is included in the mental factors of the disease. Doshas = 1358540 V. Description of invention (24) The individual nature is explained as follows. Yes, the pagoda or vajud 〇sha deals with endocrine, neuromuscular and neurotransmitter-derived activities that cause vital or total motility, and those that cause gas production can be classified in this category. Pitta dosha is related to digestion and chemistry Rasa kriya is roughly associated with Kapha dosha, which provides stability and bonding and lubrication. Like the first summer, the 'vata' is considered to affect the other two factors. It is considered to be the main cause of all diseases. A detailed description of these body fluids has been placed elsewhere in the main body of this article. The reduction of the pagoda will cause slow activity. Therefore, this kind of drug that can reduce the late purity will be Huatahela. (Vata H ara). This reduction in digestive capacity is called Pita Ducha. A drug that can increase the digestive capacity or activate bile (bi 1 e ) mechanism will be natural Pita Hera. To understand the different traditional medicine worlds, a detailed description of all such factors is placed in various philosophies. Tables 1 and 2 (shown in later narratives) provide an Ayuvedic philosophy in India and its A detailed description of the various components. Therefore, in order to understand the efficacy of a drug or food, it is necessary to understand its physical and chemical properties. In ancient times, people used sensory methods, such as

第28頁 1358540 五、發明說明(25) 料之味道,氣息及顏色來了解其性質。這些基本性質可分 為1 ·味道(蕊撒,Rasa),2.品質(古納,Guna),3.效 力(維爾亞,Veerya),4.該成分帶來的同化情形與影響 (維帕卡,Vipaka )及5.特殊作用(普拉伯哈伐,.prabhava, 幾何與光學的異構分子)。 這三種稱為,都夏斯 (the Doshas,失調),丹圖斯 (the Dhatus,成份)及瑪伊艾斯 (the Maias,排泄物) 的因素主要用來治療疾病或失調。若上述該藥物的性質符 合該都夏,則該都夏將被損害或中和,所以可治癒該疾病 這種藥品依據阿祐爾惟達的藥物動力學與遺傳法則的 分類與區別因該病患都須克(doshi c)優勢的情況而異。 換言之,在該德拉維亞古納斯(d r a v y a g u n a s,藥性)與 都夏斯(失調)之間有一關連性。一或多種藥物的增減可能 被迫對該患有相同疾病且具有不同的個別的都夏斯或都夏 斯的組合之病患。因此,阿祐爾惟達的藥物療法是比較個 人主義的根據該病患的都夏優勢且不像現代醫藥的藥物治 療的例子般廣義。適合都夏的性質(蕊撒,古納,維爾亞 ,維帕卡及普拉伯哈伐)之鑑定是唯一的且可靠的在阿祐 爾惟達的藥物治療上。 i i )治療標準化的現代方法:Page 28 1358540 V. INSTRUCTIONS (25) The taste, breath and color of the material are to be understood. These basic properties can be divided into 1 · taste (Risa), 2. quality (Guna, Guna), 3. effectiveness (Veliya, Veerya), 4. Assimilation and influence brought by this component (Vipa) Card, Vipaka) and 5. Special effects (Pulaberhava, .prabhava, geometric and optical isomers). These three factors, the Doshas, the Dhatus, and the Maias, are mainly used to treat diseases or disorders. If the nature of the drug is consistent with the summer, the summer will be damaged or neutralized, so the disease can be cured. The drug is classified and distinguished according to the pharmacokinetics and genetic rules of Ajurda. The situation of doshi c's advantage varies. In other words, there is a correlation between the Drava Gunas (drug) and Duchas (disorder). The increase or decrease of one or more drugs may be forced to the patient who has the same disease and has a different combination of Duchas or Dusit. Therefore, Ajul's drug therapy is more generalized in terms of personalism based on the summer advantage of the patient and not as much as the drug treatment of modern medicine. The identification of the nature of the summer (Roussa, Guna, Vera, Vipaca and Prabhavar) is the only and reliable drug treatment in Ajal. i i ) Modern methods of treatment standardization:

第29頁 1358540 五、發明說明(26) 現存的藥物治療並沒有將上述概念列入考慮。植物化 學家只對該分離自植物並經過藥理學家之生物活性研究的 活性原理之分離,純化與結構說明有興趣。該藥理學家依 次掃瞄分子的藥理學活性,建立其作用的機構並大體上地 評估其功效與現有標準且已用於現代醫藥的藥品之比較。 這個概念將無法幫助該傳統醫藥的從事者因為該活性 原理之分離徹底地改變該藥物的全部特性與其療效。 取代化驗溶劑萃出的部分,活性原理等等,得自於個 別的植物,使用一適合人類細胞與人體細胞膜的溶劑對來 自一藥物的總萃出物之分析,將在評估這些藥物的藥理學 活性上是非常有用的。 在治療標準化所引導的現代臨床嘗試中,已經完成了 三個階段(第四在國際效用的例子中),包含大量的人們。 該與一新藥有關的資料提交給藥物管理者 (Drug Controller) 通常構成要件有: 1. 化學結構 2. 藥理學的種類 3. 配方的細節 4. 在動物上的數據包括毒性研究數據 5. 在臨床藥理學上的數據包括藥物動力學(Page 29 1358540 V. INSTRUCTIONS (26) Existing medical treatments do not take into account the above concepts. Phytochemologists are only interested in the separation, purification and structural description of the principle of activity isolated from plants and studied by pharmacologists for biological activity. The pharmacologist then scans the pharmacological activity of the molecule, establishes its role, and generally evaluates its efficacy against existing standards and drugs that have been used in modern medicine. This concept will not help the practitioner of traditional medicine to completely change the full properties of the drug and its efficacy because of the separation of this principle of activity. Substituting the solvent extraction fraction, the principle of activity, etc., from individual plants, using a solvent suitable for human cells and human cell membranes to analyze the total extract from a drug will be evaluated in the pharmacology of these drugs. It is very useful in terms of activity. In the modern clinical trials led by treatment standardization, three phases have been completed (fourth in the case of international utility), involving a large number of people. The information related to a new drug is submitted to the Drug Controller. The usual components are: 1. Chemical structure 2. Pharmacological types 3. Formulation details 4. Animal data includes toxicity study data 5. Clinical pharmacology data includes pharmacokinetics (

第30頁 1358540 五、發明說明(27) pharmacokinetics)的數據(藥品在人體内的行為) 6·藥物熱力學 (pharmacodynamics)(藥品在體内的 作用) 7. 該藥物在世界上剩餘量的特殊研究與狀態 8. 在生物平衡研究上的數據 該研究的第一階段主要關於對該藥物的安全評估以了 解該藥物在人體内如何被吸收,新陳代謝與排泄,該評估 也設想去估計該藥物的附作用與劑量。 該研究的第二階段致力於以隨機化的方式來測試該藥 物的功效。將會提供真藥給一群病患而另一群病患則是供 應安慰劑。 在該研究的第三階段,將開始從事大量的測試以研究 該藥物的效力,益處及該藥物可能有害的反作用的範圍。 在成功完成此步驟後,企業將會把該藥物上市銷售。 在最後階段II I與I V的研究中,製藥的公司將有許多 的目標。研究將有助於知道該新藥與現有藥物在功效上的 比較。將可了解該新藥對一病患生活品質的長效性及影響 。亦可知道該藥物療法與其他傳統及新的一療法間相對的成 本效益關係。 但是所有上述的研究是昂貴且耗時的。其不會考慮到Page 30 1358540 V. INSTRUCTIONS (27) Pharmacokinetics) (Pharmaceutical behavior in the human body) 6. Pharmacodynamics (the role of drugs in the body) 7. Special study of the drug's remaining amount in the world And state 8. Data on biobalance studies The first phase of the study focused on the safety assessment of the drug to understand how the drug is absorbed, metabolized and excreted in the human body, and the assessment also envisages estimating the drug's attachment. Function and dose. The second phase of the study focused on testing the efficacy of the drug in a randomized manner. The real medicine will be given to a group of patients and the other group will be a placebo. In the third phase of the study, a number of tests will begin to study the efficacy, benefits, and range of possible adverse effects of the drug. After successfully completing this step, the company will market the drug. In the final phase of II I and I V research, pharmaceutical companies will have many goals. The study will help to understand the efficacy of the new drug compared to existing drugs. The long-term effects and effects of the new drug on the quality of life of a patient will be known. It is also known that the drug therapy has a relative cost-effective relationship with other traditional and new one therapies. But all of the above studies are expensive and time consuming. It won't take into account

第31頁 1358540 五、發明說明(28) 生態因素,基因的訓練(例如在印度的家族及婚姻中熟練 的關係),精神的,社會的及其他該病患的各種的變數。 這將會使該藥物的功效只限定在一特殊的族群或人們的基 因型態。 C.條碼與企業資源計畫 (ERP)客戶關係管理應用之 先前技術 製造任何商業的貨物所有權的現代化方法就是條碼。 對於所有的商業交易而言,條碼已廣泛地應用在許多方面 。為了使該藥物可識別成專賣的貨物,在本發明中提出一 條碼製作的新方法。 根據報導(Peerne t bar-code store (Java Active X servlet e-business))有 1800 字元與 2700 位數(甚至 9,9 9 , 9 9 9個)能滿足一可買到的條碼製作軟體以產生任何 項目的條碼。當一數字的數值與/或以數字表示的數量供 應給該條碼製作軟體時,該條碼製作軟體會產生一特殊的 條碼樣式經由該邏輯操作,指定於該軟體所有權代表一使 用者。 〃看 窗器 示機 顯當 A , 的節 屬細 附的 亥己 =口=0 在標 並\ 成品 造產 將該 生有 產所 式有 方具 此料 以資 碼案 條檔 該示 顯 候關 時戶 的客 碼與 條晝 讀計 可源 之資 上業 品企 產何 售任 出由 一網 }訊 器資 測球 偵全 或過 眼透 電可 過碼 (it條 C該 見。Page 31 1358540 V. INSTRUCTIONS (28) Ecological factors, genetic training (eg, proficiency in family and marriage in India), mental, social, and other variables of the patient. This will limit the efficacy of the drug to only a specific ethnic group or human genotype. C. Barcode and Enterprise Resource Planning (ERP) Customer Relationship Management Applications Prior Art Modern methods of manufacturing ownership of any commercial goods are bar codes. Bar codes have been widely used in many ways for all commercial transactions. In order to make the drug recognizable as a monopoly product, a new method of code making is proposed in the present invention. According to the report (Peerne t bar-code store (Java Active X servlet e-business)), there are 1800 characters and 2700 digits (or 9,9 9 , 999) to satisfy a commercially available bar code creation software. Generate a bar code for any item. When a numeric value and/or a numerical representation is supplied to the barcode creation software, the barcode creation software generates a special barcode pattern via which the software ownership is assigned to represent a user. 〃 〃 窗 示 显 显 显 显 显 显 显 显 显 显 显 显 显 = = = = = = = = = = = = = = = = = = = = = = = = = = =0 = = =0 = = = Waiting for the customer's code and the reading of the account can be sourced from the source of the business, what is the product of the sale of a network of equipment, the detector of the ball, or the eye can be over-coded.

第32頁 1358540 五、發明說明(29) 係管理的應用上而讀取。 現在,目錄的數字已使用條碼識別其機器與相關產品 ,特別地是不含任何如該方法所提及產物的特性。 5 - 3發明目的及概述: 本發明之主要目的是推薦一新方法給層析的特徵鑑定 ,化學與治療的標準化,及來自於一植物,動物的或天然 可得或人工製造可用作藥物的材料之有機與有機金屬分子 的條碼製作。 本發明之另一目的是為草藥與配方提供一新的層析特 徵鑑定的方法,可排除上述複雜的缺點。 .本發明之另一目的是為研究藥物的成份提供一完整的 化學分析。該以新軟體發展出的成份之共軛性質指出如同 該藥物傳統概念的療效。 本發明之再一目的是為草藥的層析特徵鑑定提供一新 方法,有助於快速確認所使用藥物中具療效成份的化合物 的實際概況。Page 32 1358540 V. Description of the invention (29) Read from the application of the management. The number of catalogues has now been bar coded to identify its machine and related products, in particular without any of the characteristics of the products mentioned in the method. 5 - 3 OBJECTS AND SUMMARY: The main object of the present invention is to recommend a new method for the characterization of chromatography, standardization of chemistry and treatment, and from a plant, animal or naturally available or artificially manufactured drug. The material is made of organic and organic metal molecules in bar code. Another object of the present invention is to provide a new method of chromatographic identification for herbs and formulations that eliminates the aforementioned complex disadvantages. Another object of the invention is to provide a complete chemical analysis for studying the composition of a drug. The conjugate nature of the ingredients developed with the new software indicates the efficacy of the traditional concept of the drug. A further object of the present invention is to provide a new method for the chromatographic characterization of herbal medicines which facilitates the rapid identification of actual profiles of compounds having therapeutic ingredients in the drugs used.

第33頁 1358540 五、發明說明(30) 本發明之再一目的是利用,草藥與配方的輪廓圖及三 次元的(3— D )層析譜為該草藥與配方提供一新的層析特 徵鑑定方法。 丨 本發明之再一目的是為草藥提供一新的層析特徵鑑定 方法有助於確認在使用藥物中的攙雜物。 ""^ 本發明之再一目的是製作一標準的分析參 ^的乙醇溶劑作萃取,相同的沖提時間,相同的動^ “)和⑽在5. 5_7. 5的礙酸鹽緩衝、、容;T目β Γ 同的紫外-可見光波長範圍2〇〇 —8〇〇 η.食衝冷液,及相 本發明之庚 α λα θ 並評估該 的極性和共軛;一 u用來自三次元及輪廓層析譜 藥物在體液上為二:物成份作分類與定量, 用(知害)之處的療效。 本發明之再一 選擇的波峰 提供一條碼。 ' 疋為該影像中一分子被 本發明之再一目的 徵製作一條碼的資料庫是為對各種資料庫應用有幫 助的特 本發明之再一目 θ 該樣品所有細節的顯=J為所有特徵鑑定的樣品產生具有 肉’如三次元及輪廓特徵,條碼,Page 33 1358540 V. INSTRUCTIONS (30) A further object of the present invention is to provide a new chromatographic feature for the herb and formula using the contour map of the herbal and formula and the three-dimensional (3-D) chromatogram. Identification method.再 A further object of the present invention is to provide a new chromatographic characterization method for herbal medicines which helps to confirm the presence of impurities in the drug. ""^ A further object of the present invention is to prepare a standard analytical parameter of the ethanol solvent for extraction, the same extraction time, the same dynamic ^ ") and (10) at 5. 5_7.5. T, β Γ The same UV-Vis wavelength range 2〇〇-8〇〇η. Food cold liquid, and the phase of the invention Gg α λα θ and evaluate the polarity and conjugate; The three-dimensional and contour chromatographic drugs are classified on the body fluid as two components: the classification and quantification of the components, and the effect of the (intelligence). The peak of the selected one of the invention provides a code. '疋 is one of the images. The numerator is further developed by the present invention. A database of codes is a further object of the invention for the application of various databases. θ All the details of the sample are shown in the sample. Such as three-dimensional and contour features, barcodes,

第34頁 1358540 五、發明說明(31) 來源的細節(工廠或國家),製造日期,到期日,已報導 的都夏,個別使用成份,樣品的試驗,生產序號,貨物號 碼,M. R· P (最大零售價)等等。 本發明之再一目的是為顯示窗附加分別的條碼以幫助 處理顯示窗在當成數據與資料來源的時候之應用。 本發明之再一目的是,製作一顯示窗的資料庫從而產 生並附屬於各自的條碼,用於企業資源計晝與客戶關係管 理應用對於所有該藥物與樣品的商業網路交易。 本發明之再一目的是製作一條碼及顯示窗及任何資訊 的資料庫,對於控制藥物在一國家進出口的管理當局特別 需要。 本發明之再一目的是,該化合物的紫外一可見光譜將 提供該分子的共軛性質及隨著該分子極性的分子個別濃度 本發明之再一目的是輪廓及3— Of析譜將是化學成份 鑑定的基礎以限定該發明的範圍。 本發明之再一目的是為攙雜的食物與藥物樣品,代替 的及有矛盾的食物與藥物樣品,和食物與藥物樣品的商業Page 34 1358540 V. Description of invention (31) Details of source (factory or country), date of manufacture, date of expiration, reported summer, individual use component, sample test, production serial number, cargo number, M. R · P (maximum retail price) and more. A further object of the present invention is to add separate bar codes to the display window to aid in the processing of the display window as it is used as data and data sources. It is yet another object of the present invention to create a database of display windows for production and affiliated with respective bar codes for use in enterprise resource planning and customer relationship management applications for all commercial transactions of the drug and sample. A further object of the present invention is to create a database of codes and display windows and any information that is particularly desirable for regulatory authorities that control the import and export of drugs in a country. A further object of the present invention is that the ultraviolet-visible spectrum of the compound will provide the conjugated nature of the molecule and the individual concentration of the molecule with the polarity of the molecule. A further object of the invention is that the profile and 3-of spectrum will be chemistry. The basis of the ingredient identification is to define the scope of the invention. A further object of the present invention is for noisy food and drug samples, alternative and contradictory food and drug samples, and commercial food and drug samples.

第35頁 1358540 五、發明說明(32) 樣品發展一特徵鑑定的方法,並鑑定其純度與攙雜物。 本發明之再一目的是對於各種樣品中的有機與有機金 屬成份發展一特徵鑑定的方法以鑑定其中的化學成份作為 品質控制的各種目的與過程的標準化。 本發明之再一目的是對於對抗療法的 (Allopathic) ,阿祐爾惟達的,順勢療法的(Homoeo), 席得哈 ( Siddha),悠納尼 (Unani), 中國的,西藏的,坎坡 (K a m ρ 〇,日本的)藥物樣品發展一特徵鑑定的方法作為品 質控制及化學與治療的標準化。 本發明之再一目的是對於研究自然存在或合成製作的 樣品之不同化學成份發展一特徵鑑定的方法並鑑定與使其 中的化學成份標準化。 本發明之再一目的是發展一特徵鑑定的方法為了研究 自然存在或合成製作的樣品之不同化學成份並鑑定與使其 中由於地質學上的,生態學的,遺傳型的,及顯型的變化 因素引起差異的化學成份標準化。 本發明之再一目的是發展一特徵鑑定的方法為了在單 一及複方藥物樣品的草藥產物中化學成份的研究與鑑定其 中的化學成份作為化學及治療的標準化。Page 35 1358540 V. INSTRUCTIONS (32) The sample develops a method of characterization and identifies its purity and inclusions. A further object of the present invention is to develop a method of characterization of organic and organic metal components in various samples to identify chemical components therein as standardization of various purposes and processes for quality control. A further object of the invention is for the treatment of allopathic, Ajul, Homoeo, Siddha, Unani, China, Tibet, Kanpo (Kam ρ 〇, Japan) Drug sample development - a method of characterization as standardization of quality control and chemistry and treatment. A further object of the present invention is to develop a method for characterizing and characterizing the chemical constituents of different naturally occurring or synthetically produced samples. A further object of the present invention is to develop a method for characterization in order to study the different chemical compositions of naturally occurring or synthetically produced samples and to identify and modify them due to geological, ecological, genetic, and phenotypic changes. Factors that cause differences in the chemical composition of the standardization. A further object of the present invention is to develop a method for characterization in order to study and characterize chemical constituents in herbal products of single and compound drug samples as standardization of chemistry and therapy.

第36頁 1358540 五、發明說明(33) 本發明之再一目的是發展一特徵鑑定的方法為了在生 物樣品中的化學成份的差異之研究並鑑定與使其中的化學 成份標準化。 本發明之再一目的是製作一巨大的資料庫,該資料庫 將可提供一特定族群的植物之療效的許多歸納,這些植物 由於一特殊疾病或治療的分類而分成一類。 本發明之再一目的是提供一利用單一成份及藥物整體 的共軛及極性性質的方法以了解並將該藥物使用於傳統治 療方法之標準化的物理-化學性質如顏色標準化。 本發明之再一目的是提供一利用單一成份及藥物整體 的共軛及極性性質的方法以了解並將該藥物使用於治療標 準化之傳統方法的物理-化學性質如味道(蕊撒)即酸, 鹹,辣,苦,及澀(如在阿祐爾惟達中所分別提及之安拉 ,拉伐納,卡圖,提克塔及卡夏亞;Amla,Lavana,Katu, Tikta, and Kashaya)標準化。 本發明之再一目的是提供一方法,該方法能了解並將 藥物的物理一化學性質如品質,功效,代謝物在吸收或此 類的改變及特殊的性質如該分子的光學活性(如在阿祐爾 惟達中分別地提及的古納,維爾亞,維帕卡,及普拉伯哈Page 36 1358540 V. INSTRUCTION DESCRIPTION (33) A further object of the present invention is to develop a method of characterization for the purpose of studying and characterizing differences in chemical composition in biological samples. A further object of the present invention is to create a vast database that will provide a number of generalizations for the efficacy of a particular group of plants that are classified into one class by a particular disease or treatment classification. It is a further object of the present invention to provide a method for utilizing the conjugate and polar nature of a single component and the drug as a whole to understand and standardize the physico-chemical properties of the drug for use in conventional therapeutic methods such as color standardization. It is a further object of the present invention to provide a method for utilizing the conjugate and polar nature of a single component and the drug as a whole to understand and apply the drug to the physico-chemical properties of a conventional method of standardization such as taste, ie, acid. Salty, spicy, bitter, and astringent (as mentioned in Alla, Lavuna, Kathu, Ticta, and Caxia); Amla, Lavana, Katu, Tikta, and Kashaya) standardization. It is a further object of the present invention to provide a method for understanding and determining the physical properties of a drug, such as quality, efficacy, metabolites in absorption or such changes, and specific properties such as the optical activity of the molecule (eg, in Abu Dhabi’s mention of Guna, Vera, Wipaca, and Prabha

第37頁 1358540 五、發明說明(34) 伐)的標準化。 本發明之再一目的是提供一方法利用該單一成份及藥 物整體的共輛與極性的性質以了解並將該藥物使用於治療 標準化之傳統方法的物理一化學性質如重的,輕的,冷的 ,熱的,輕柔滑潤的,乾的,鈍的,尖的(分別如在阿祐 爾惟達中所述之古盧,拉古,席塔,悠虛納,斯尼戈達, 曼達,提克虛納;Guru,Laghu,Sheeta,Ushna, snigdha, Manda, Teekshna)標準化。 根據以上所述之目的,本發明係關於一方法使用層析 特徵鑑定技術作為偵測及鑑定來自植物或動物的萃出物, 天然或合成的來源,上述方法的步驟至少包括: (i )以適當的溶劑來萃取出該有機或有機金屬分子; (i i )使步驟 (i )中所得之萃出物經過分離分析,使 用高壓液相層析技術; (i i i )根據p Η值與極性沖提出的組成成分來產生輪廓 及3D層析圖譜; (i ν )將所得的3 D及輪廓層析譜轉成彩色影像,利用 表示該彩色影像的三次元性質之座標來分析該影像中個別 的顏色,藉由一内建的軟體; (ν )表示出該隨時間沖提出的不同成份之濃度; (v i )根據顏色分析而產生的層析圖譜,具有隨著該 分子的共輛性質而出現在不同滯留時間(retention time)Page 37 1358540 V. INSTRUCTIONS (34) Standardization of cutting. A further object of the present invention is to provide a method for utilizing the properties of the single component and the overall car and polarity of the drug to understand and apply the drug to the physical chemistry of the conventional method of standardization such as heavy, light, cold , hot, gentle, smooth, dry, blunt, pointed (as in the Aluer, as described in Gulu, Lagu, Xita, Youxu, Sni Gododa, Manda, Tickerna; Guru, Laghu, Sheeta, Ushna, Snigdha, Manda, Teekshna) Standardization. In accordance with the above objects, the present invention relates to a method for using chromatographic characterization techniques for detecting and identifying extracts from plants or animals, natural or synthetic sources, the steps of the above method comprising at least: (i) a suitable solvent to extract the organic or organometallic molecule; (ii) subjecting the extract obtained in step (i) to separation analysis using high pressure liquid chromatography; (iii) according to p Η value and polarity The composition is used to generate contours and 3D tomograms; (i ν ) converts the resulting 3D and contour tones into color images, and uses the coordinates representing the three-dimensional nature of the color image to analyze individual colors in the image. By means of a built-in software; (ν) indicates the concentration of the different components that are rushed over time; (vi) the chromatogram produced by color analysis, with the presence of the common properties of the molecule Different retention time

第38頁 1358540 五、發明說明(35) 的吸收峰; (v i i )以該影像中不同成份的紫外一可見吸收性質來 確認在上述組成成分中的化合物; (v i i i) 根據極性與共麵性質對沖提出的化合物加以 鑑定,裁定並分類成極性,中極性及低極性或非極性; (i X)產生一條碼以X軸為滯留時間,Y軸為波長,R是 紅映像點(p i X e 1 s ),G是綠映像點及B藍映像點來代表被選 定的吸收峰;與 (X )產生一特徵及條碼的資料庫並對該樣品中個別的 化合物加以確認。 5 - 4發明詳細說明: 於是,當前方法的新基礎是,提出該化學成份表現在 3_ D及輪廓層析譜中的光譜性質作為一特徵鑑定的新方法 。以該方法產生的層析譜提供在該具有療效的藥物中的個 別分子之共輛和極性的性質。 在一分子中,該分子的紫外一可見吸收能力端賴該分 子的結構。當該分子的雙鍵或三鍵在其結構中交替地出現 ,稱為共軛。若該分子具有愈多共軛則該分子的化學與生 物性質將愈活潑。因此,若該分子具有愈多共軛則其治療 的活性愈強。所以,共軛性質的測量將提供該藥物的療效 。因此,該共軛性質的使用作為治療標準化是本發明的新Page 38 1358540 V. The absorption peak of invention (35); (vii) confirm the compound in the above composition with the UV-visible absorption properties of the different components in the image; (viii) hedge against polarity and coplanar nature The proposed compounds are identified, categorized and classified into polarity, medium polarity and low polarity or non-polar; (i X) produces a code with the X-axis as the residence time, the Y-axis as the wavelength, and R is the red image point (pi X e 1 s), G is the green image point and the B blue image point to represent the selected absorption peak; and (X) generates a database of features and barcodes and confirms the individual compounds in the sample. 5 - 4 Detailed Description of the Invention: Thus, the new basis of the current method is to propose a new method of characterization of the chemical properties of the chemical composition in the 3D and contour chromatograms. The chromatograms produced by this method provide the common and polar nature of the individual molecules in the therapeutic drug. In one molecule, the UV-visible absorption capacity of the molecule depends on the structure of the molecule. When a double bond or a triple bond of the molecule alternates in its structure, it is called a conjugation. If the molecule has more conjugation, the chemical and biological properties of the molecule will be more active. Therefore, if the molecule has more conjugation, the therapeutic activity is stronger. Therefore, the measurement of the conjugate nature will provide the efficacy of the drug. Therefore, the use of this conjugated property as a standard of treatment is a new aspect of the present invention.

第39頁 1358540 五、發明說明(36) 賴性。 一提供草藥及配方的品質控制之新方法,有助於傳統 藥物的特徵鑑定與標準化(化學及治療的),不同於現今 使用的方法以單一波長來分析藥物的單一的活性組成成分 (還不知道存在於許多草藥中)。該方法隨著該化合物的物 理及化學性質(稱為紫外一可見吸收特性與極性)提供該 傳統藥物中化學成份的整體概況。在該方法的第一部分中 ,將會產生該藥物特徵的影像。但是,因為影像不能變成 分析數據,發展一運用電腦的方法來提供該組成成分的定 性及定量數據以一分析的層析報告的形式。同樣提出該方 法作為本發明方法的新穎性。 任何分子的活性將依賴該分子中雙鍵與三鍵的數目隨 著該分子上親電子性與親核性的位置。該提供電子與接受 電子的部分將創造出該分子在總電子價數的差異。這個現 象使該分子變成具有極性。因此分子的極性將提供關於一 分子與另一分子提供或接受電子的能力之資訊。該能力將 控制該分子的活性。所以,一分子的極性資料將傳遞該分 子的活性。在該提出的方法中,以該方法提出的層析譜將 提供一藥物中的成份在特徵鑑定中之共軛與極性的性質。 所以,該方法用於藥物的標準化以藉由使用一藥物的共軛 和極性的性質來了解該藥物的療效。這是該提出方法的新 穎性。Page 39 1358540 V. Description of invention (36) Dependence. A new method for quality control of herbs and formulas that facilitates the characterization and standardization of traditional drugs (chemical and therapeutic), unlike the methods used today to analyze a single active component of a drug at a single wavelength (not yet Know that it exists in many herbs). The method provides an overall overview of the chemical composition of the conventional drug as the physical and chemical properties of the compound (referred to as UV-visible absorption characteristics and polarity). In the first part of the method, an image of the drug signature will be produced. However, because images cannot be transformed into analytical data, a computer-based approach is developed to provide qualitative and quantitative data for the constituents in the form of an analytical chromatographic report. This method is also proposed as a novelty of the method of the present invention. The activity of any molecule will depend on the number of double and triple bonds in the molecule along with the position of electrophilic and nucleophilic on the molecule. The provision of electrons and electron accepting will create a difference in the total electron valence of the molecule. This phenomenon turns the molecule into polarity. Thus the polarity of the molecule will provide information about the ability of one molecule to provide or accept electrons with another molecule. This ability will control the activity of the molecule. Therefore, a molecule of polar data will convey the activity of the molecule. In the proposed method, the chromatogram proposed by this method will provide the properties of the conjugate and polarity of the components in a drug in the characterization. Therefore, this method is used for the standardization of drugs to understand the efficacy of the drug by using the conjugate and polarity properties of a drug. This is the novelty of the proposed method.

第40頁 1358540 五、發明說明(37) 如上所述,該化合物的紫外一可見光譜與極性將指出 該化合物的共輛和極性的性質並從而指出該藥物的化學/ 藥用的性質。在一單一圖片中所有成份的光譜概況,如同 現在所提出的"特徵鑑定π將變成該成份存在於草藥與配方 中的藍圖。該藍圖變成在草藥的鑑定及標準化上比現有更 優越的方法,因為吸收峰將表示該成份的紫外一可見光性 質或共軛和極性的性質,不同於一普通的層析譜取自一單 一波長伴隨著該成份的量化。 如傳統標準化方法所述,該藥物的顏色可用來了解並 將該藥物的療效標準化。藉由分子在紫外一可見光放射範 圍的吸收特性可了解該分子的顏色。一特殊波長的吸收是 根據該分子的結構,官能基,共軛性質及不飽和度。若該 分子的共軛性質愈多,則該分子將會吸收愈長的波長。因 此,任何分子的紫外一可見光吸收廣泛地使用在成份的定 性與定量性質上。各種藥物的顏色與療效已提供在古代文 獻中。 最後,分子的顏色是由於該分子的一特殊化學本質而 產生。當研究相同的特性時,亦可了解該化學性質。在古 代火焰的顏色用於金屬及相關產品的品質控制,包括基本 分光光度量湏J 原理(spectrophotometric principles)。 所以,研究並了解該電磁幅射的作用將有助於研究該藥物Page 40 1358540 V. INSTRUCTION DESCRIPTION (37) As noted above, the UV-visible spectrum and polarity of the compound will indicate the co- and polar nature of the compound and thereby indicate the chemical/medicinal properties of the drug. The spectral profile of all the components in a single picture, as proposed now, is characterized by a blueprint for the presence of the ingredient in herbs and recipes. This blueprint becomes a superior method to the identification and standardization of herbs, because the absorption peak will indicate the UV-visible nature or the conjugate and polarity properties of the component, unlike a common chromatogram taken from a single wavelength. Along with the quantification of this component. The color of the drug can be used to understand and standardize the efficacy of the drug as described in conventional standardized methods. The color of the molecule can be understood by the absorption characteristics of the molecule in the ultraviolet-visible radiation range. The absorption of a particular wavelength is based on the structure of the molecule, the functional group, the conjugate nature and the degree of unsaturation. If the conjugated nature of the molecule is greater, the longer the wavelength the molecule will absorb. Therefore, UV-visible absorption of any molecule is widely used in the qualitative and quantitative properties of the composition. The color and efficacy of various drugs have been provided in ancient literature. Finally, the color of the molecule is due to a particular chemical nature of the molecule. This chemistry can also be understood when studying the same characteristics. The colors of the ancient flames were used for quality control of metals and related products, including spectrophotometric principles. Therefore, studying and understanding the role of this electromagnetic radiation will help to study the drug.

第41頁 1358540 五、發明說明(38) 的化學本質與療效。相同的原理已用在現有的分光光度量 測方法之特徵鑑定與標準化。 該提出方法的主要新穎性包括該'''根據波長(共軛) 及滯留時間(極性)的大小將特徵區分成不同的治療區域 以了解一單一或配方藥物的療效(就傳統而論)〃使用一儀 器的與運用軟體的程序。 利用該已發展的運用電腦的軟體,製作出一條碼以代 表該提供影像中一分子所選定的吸收峰。其中,X是滯留 時間,Y是輪廓層析譜的波長及3— D層析譜中的吸收,R是 指出該成份最高濃度的紅色,G是指出該成份較低濃度的 綠色,以及B仍是指出該成份更低濃度的藍色由該提出的 軟體所提供,滿足任何商業上可取得之可轉售的條碼製作 軟體,附加在該現有軟體可產生一條碼給一單一成份或給 許多成份。該特徵的影像可在附加於該條碼的顯示窗上看 見。每當販賣機的電眼讀到該條碼時這些資訊將會顯示出 。該特徵已要求成為該發明的方法之另一項新穎性。 當該層析管柱的極性已固定且動相的極性不斷地以遞 增或遞減的順序來改變,在一逆向層析管柱上,該樣品中 的成分將以高極性成分最先,中極性成分次之,接著是非 極性成分的次序沖提出。需注意在該成分的沖提過程中, 極性的遞增或遞減之順序,使得沒有任何極性的成分在完Page 41 1358540 V. The chemical nature and efficacy of the invention (38). The same principle has been used for characterization and standardization of existing spectrophotometric methods. The main novelty of this proposed method involves the distinction between the characteristics of wavelengths (conjugation) and residence time (polarity) into different treatment areas to understand the efficacy of a single or formulated drug (as is conventional). Use an instrument and software application program. Using the developed software for using a computer, a code is created to represent the selected absorption peak of a molecule in the provided image. Where X is the residence time, Y is the wavelength of the contour chromatogram and the absorption in the 3-D chromatogram, R is the red indicating the highest concentration of the component, G is the green indicating the lower concentration of the component, and B is still It is pointed out that the lower concentration of the blue component of the component is provided by the proposed software to satisfy any commercially available resaleable bar code making software, and the existing software can generate a code for a single component or for many components. . An image of the feature can be viewed on a display window attached to the bar code. This information will be displayed whenever the electric eye of the vending machine reads the bar code. This feature has been required to be another novelty of the method of the invention. When the polarity of the column is fixed and the polarity of the moving phase is continuously changed in increasing or decreasing order, on a reversed-phase column, the components in the sample will be the first with the highest polarity and the middle polarity. The composition is followed by the order of the non-polar components. It should be noted that in the process of extracting the component, the order of increasing or decreasing polarity makes the component without any polarity finish.

第42頁 1358540 五、發明說明(39) 成總沖提後仍留在該層析管柱之中。該次序與極性與在正 向層析管柱中的沖提可同樣適用於逆向層析管柱,但是必 須相反。在一正向層析管柱中,該非極性的成分將最先沖 提出接著是極性的成分,根據沖提中所使用動相的極性順 序。 所以,一已發展的特徵使化學成分以遞增或遞減極性 次序排列將有助於提出關於該藥物之治療的歸納。這是所 推薦的方法之另一項新穎性。 在該分析後發展出的輪廓層析譜的影像在X與Y軸上分 成三個區域。該共軛性質(特殊波長的輻射吸收)置於Y軸 且極性置於X軸,隨著該成分的沖提以使用該動相構成的 極性來控制。現在如文獻中所報導該Y軸的單位是按照其 療效,該療效是根據波長(顏色)。全部的影像區分成六個 空間在其中該化學成分具有特殊的共軛與極性的性質。該 性質與在該空間中的成分療效依次是成比例的。亦即當鑑 定一藥物特徵時,根據該出現的顏色表示一特殊波長的吸 收及具有一特殊極性,計算該區域中全體的顏色並解釋成 該藥物中成分的療效。所以,全部療效的標準化與化學的 標準化可使用該方法來完成。 大多數該樣品沖提的完成是從高極性動相到低極性動 相。所以在該成分的特徵鑑定中出現在第一區 (Ζ ο n e - 1 )Page 42 1358540 V. INSTRUCTIONS (39) After the total flushing, it remains in the column. This order and polarity can be applied to the reverse chromatography column as well as in the forward chromatography column, but it must be reversed. In a forward chromatography column, the non-polar component will be the first to be followed by a polarity component, according to the polarity sequence of the mobile phase used in the flush. Therefore, an evolving feature that aligns chemical components in increasing or decreasing polarity order will help to generalize the treatment of the drug. This is another novelty of the proposed method. The image of the contour tomogram developed after this analysis was divided into three regions on the X and Y axes. The conjugated property (radiation absorption at a particular wavelength) is placed on the Y-axis and the polarity is placed on the X-axis, with the polarity of the composition being controlled by the polarity of the composition. The unit of the Y-axis is now reported in the literature according to its efficacy, which is based on wavelength (color). All images are divided into six spaces in which the chemical composition has a special conjugate and polarity properties. This property is in turn proportional to the therapeutic effect of the components in this space. That is, when a drug characteristic is identified, the color of the particular wavelength is expressed in accordance with the color of the appearance and has a particular polarity, and the overall color in the area is calculated and interpreted as the therapeutic effect of the component in the drug. Therefore, standardization of all therapeutic effects and chemical standardization can be accomplished using this method. Most of the sample flushing is done from a high polarity phase to a low polarity phase. So appear in the first zone (Ζ ο n e - 1 ) in the characterization of the component

第43頁 1358540 五、發明說明(40) 的成分在大自然中將是屬於高極性的。相同的模式應用至 其他區域,中極性的成分沖提至中極性區域 (Zone-2)且 低極性或非極性的成分沖提至非極性區域 (Zone-3)。當 使用正向層析管柱時,由於其沖提極性如上所述,該成分 特徵的出現模式將會相反。 大部分 當其進入消 生物系統上 並進行不同 維帕卡)由 過程中,瞬 物系統作用 體的腸部分 主要的角色 物機構中扮 性,高極性 南極性 化系統 且酵素 的變化 於該部 間該尚 並顯現 歸類於 。熱引 演一重 的分子 的分子具有 的第一部份 出現在那裡 (後來的吸 分所出現的 活性(高極 出其療效。 皮塔區》該 起的反應機 要的角色。 高的化學 嘴時,將 。接著該 收作用, 消化液及 性)的分 可相較於 高極性的 構將在疾 間接地指 與生物 立刻開 成分將 在阿祐 酵素。 子立即 在阿祐 分子在 病和與 出該分 反應活 始作用 進入胃 爾惟達 在該吸 開始與 爾惟達 那裡扮 其相關 子屬於 性。 在該 及腸 中的 收的 該生 ,人 演一 的生 高活 在該吸收後,該具有所吸收成分的血液將帶其至心臟 及與心臟相連的器官。接著該血液將送至身體的不同器官 。在阿祐爾惟達中,人體較高的部分定義成卡發區,在那 裡寒冷的機構將扮演一重要的角色。所以,該中極性的分 子在與該區域相關的機構中將扮演一重要的角色。Page 43 1358540 V. The composition of the invention (40) will be highly polar in nature. The same mode is applied to other areas, the medium polarity component is flushed to the medium polarity zone (Zone-2) and the low polarity or non-polar component is flushed to the non-polar zone (Zone-3). When a forward chromatography column is used, the appearance of the characteristic of the component will be reversed due to the polarity of the extraction as described above. Most of them enter the decontamination system and carry out different Vipaca. In the process, the main part of the intestine part of the transient system acts in the body, the highly polar southern polarization system and the enzyme changes in the part. It should be classified as follows. The first part of the molecule that thermally deduces a heavy molecule appears there (the activity that occurs later in the aspiration (highly effective. Pita area) the role of the reaction machine. High chemical mouth When, then, the fraction of the action, digestive juice and sex can be compared to the high-polarity of the structure, which will indirectly refer to the immediate opening of the component with the organism will be in the Ayou enzyme. In response to the activity of the sub-reaction, the patient enters the stomach. In the beginning of the inhalation, the relationship between the child and the child is the sex. In the intestine, the life of the person, the performance of the person’s life is absorbed. After that, the blood with the absorbed component will carry it to the heart and the organ connected to the heart. The blood will then be sent to different organs of the body. In Ajal, the higher part of the human body is defined as the card-emitting area. The cold institutions there will play an important role. Therefore, the polar molecules will play an important role in the institutions associated with the region.

第44頁 1358540 五、發明說明(41) 該低極性與非極性成分將只可以通過血液傳輸進入人 體。所以身體中只能藉由血液得到該化學成分的器官將成 為該極性的最後種類。該非極性油,脂肪及其他諸如此類 的分子與人體中的機構分類成伐塔失調及所有諸如此類的 失調可使用相同種類的材料來治療之。 該低極性與非極性成分將沖提至該特徵的最後區域。 所以,該區域(第三區)被認為是伐塔區。所以,分子的 基本性質可根據其極性來分類,有助於了解該分子將作用 在何種失調上。所以,所推薦的方法有助於藥物治療的標 準化。 所以該全體的成分出現在第一區皮塔區,第二區卡發 區,第三區伐塔區出現在一餅形圖表陳述該藥物在每一種 失調中效力的比例。所以,藥物有5 0 : 2 0 : 3 0比例的成分將 是以5 0 % : 2 0 % : 3 0 %比例的促伊都夏赫拉藥物。所以,該 療效可在數量上標準化。其他都夏的任何一或二的遞增或 遞減可完成以配方藥經由加入其它藥物以及製作一適用於 治療一特殊的個體之合適配方。 所以,一特徵具有共軛的規模,吸收和極性該3— D層 析譜將提供關於該藥物療效的資訊。使用其所謂影像的三 次元的性質來分析之,將執行該藥物3-D層析譜的量化。 例如若將該3-D層析譜考慮成一‘有頭巾的帽子capPage 44 1358540 V. INSTRUCTIONS (41) The low polarity and non-polar components will only be transported through the blood into the body. Therefore, an organ in the body that can only obtain the chemical component by blood will become the last species of the polarity. The non-polar oils, fats and other such molecules are classified as stalks in the body and all such disorders can be treated with the same type of material. The low polarity and non-polar components will be flushed to the last region of the feature. Therefore, the area (the third zone) is considered to be the pagoda zone. Therefore, the basic properties of a molecule can be classified according to its polarity, helping to understand what kind of disorder the molecule will act on. Therefore, the recommended method contributes to the standardization of drug treatment. Therefore, the entire composition appears in the Pita District of the first district, the second zone, and the third zone of the pagoda zone appears in a pie chart indicating the proportion of the drug in each of the disorders. Therefore, the drug has a ratio of 50:20:30, which will be a 50%: 20%: 30% ratio of the Iduzahira drug. Therefore, the efficacy can be standardized in quantity. The increment or decrement of any one or two of the other summers can be accomplished by formulating the drug via the addition of other drugs and making a suitable formulation suitable for treating a particular individual. Therefore, a feature with a conjugate size, absorption and polarity of the 3-D layer will provide information about the efficacy of the drug. The 3-D chromatogram of the drug is quantified using the properties of the so-called three-dimensional image of the image. For example, if the 3-D chromatogram is considered as a ‘capped hat cap

第45頁 1358540 五、發明說明(42) with a hood’),該整個帽子的三次元之配合,有另一不 同定性及定量性質的樣品,該適合的範圍將描述成一定性 及定量的分析報告。在這裡該帽子的頭巾用來與該分子在 一特殊波長的吸收峰做比較。一具有許多數字的樣品將類 似一具有許多頭巾的帽子。所以該三次元座標軸的配合將 提供一極簡單的比較與分析方法。該適合的座標軸將提供 定性數據,且其合適的範圍將提供該研究中樣品的定量數 據。藉由為了該計劃而製作的特殊軟體使得該現象變成可 能。該方法變成一品質控制的根本方法。該方法成為該發 明的方法之另一項新穎性。 該發明也與一用於3— D層析譜及組成成分的彩色輪廓 影像的數據處理機上之軟體有關,上述的數據處理機包含 估算工具並具有以下的能力: a. —分析器(摘錄顏色)關於分析該彩色輪廓影像 根據各種顏色(具有在已發表的註釋,生活週期,加工處 理中提到的標準)的選擇以表示各種隨著時間而沖提出之 成分的濃度及根據滯留時間的極性; b. —分析關於分析該藥物的3 - D層析譜使用該影像所 有的三次元性質; c. 一工具關於產生一具有許多伴隨著以一明確說明 的極性順序隨時間沖提出之分子的共軛性質而出現在不同 滯留時間之吸收峰的層析譜; d. 一識別器關於確認在該上述分子中的化合物藉由Page 45 1358540 V. Description of the invention (42) with a hood'), the three-dimensional combination of the entire hat, there is another sample of different qualitative and quantitative properties, the suitable range will be described as a certain and quantitative analysis report. Here the headscarf of the hat is used to compare the absorption peak of the molecule at a particular wavelength. A sample with many numbers would resemble a hat with many headscarves. Therefore, the cooperation of the three-dimensional coordinate axis will provide a very simple comparison and analysis method. This suitable coordinate axis will provide qualitative data and the appropriate range will provide quantitative data for the sample in the study. This phenomenon is made possible by special software made for this project. This method becomes a fundamental method of quality control. This method is another novelty of the method of the invention. The invention is also related to a software on a data processor for a 3-D chromatogram and a color contour image of a composition comprising an estimation tool and having the following capabilities: a. - analyzer (excerpt) Color) Regarding the analysis of the color contour image according to the selection of various colors (having the standards mentioned in the published notes, life cycle, processing) to indicate the concentration of various components that are rushed over time and according to the residence time Polarity; b. - analysis of the 3 -D chromatogram of the drug using all of the three-dimensional properties of the image; c. a tool for producing a molecule with a number of molecules that rush over time with a well-defined polarity order a conjugated property of a chromatogram of absorption peaks at different residence times; d. an identifier for confirming compounds in the above molecule by

第46頁 1358540 五、發明說明(43) 該影像中不同成分的紫外-可見吸收性質; e. —工具根據該分子的極性與共軛性質將特徵在X及 Y軸上劃分成療效區域來使該研究藥物中各種成分之已報 導之生物的,治療的性質相關聯; f. 一工具關於產生一條碼代表一被選定的吸收峰使 用該影像座標軸,那就是,X為滯留時間,Y為波長,R是 紅映像點的數目,G是綠映像點的數目及B是藍映像點的數 目,由該計劃的軟體所提供; g. —工具關於產生一對於該樣品之特徵的資料庫及 該樣品的條碼,促進各種功能資料庫如企業資源計晝及客 戶關係管理的應用;以及 h. —工具關於產生一’顯示窗’的資料庫給所有已用 於該企業資源計晝及客戶關係管理型式的商業應用。 在該專利文件中所用到的縮寫字 ERP:企業資源計畫(Enterprise Resource Planning) CRM:客戶關係管理( Customer Relationship Management ) UV-Visible:電磁輻射在200 nm - 800 nm範圍内。 Organic molecule:有機分子,一分子在其結構中具 有C,Η,N,0,S的基本元素。Page 46 1358540 V. INSTRUCTIONS (43) UV-visible absorption properties of different components in the image; e. - The tool divides the features into therapeutic regions on the X and Y axes according to the polarity and conjugate properties of the molecule The nature of the treatment of the various components of the study drug, the nature of the treatment; f. A tool for generating a code representing a selected absorption peak using the image coordinate axis, that is, X is the residence time, Y is the wavelength , R is the number of red pixels, G is the number of green pixels, and B is the number of blue pixels, provided by the program's software; g. - the tool is about generating a database of features for the sample and Sample barcodes, facilitating the application of various functional databases such as enterprise resource planning and customer relationship management; and h. — tools for generating a 'display window' database for all of the enterprise resource planning and customer relationship management Type of commercial application. The acronym ERP used in this patent document: Enterprise Resource Planning CRM: Customer Relationship Management UV-Visible: Electromagnetic radiation in the range of 200 nm - 800 nm. Organic molecule: An organic molecule, a molecule having the basic elements of C, Η, N, 0, S in its structure.

第47頁 1358540Page 47 1358540

有機金屬分子,一分子 H’ N,〇,s的基本元素 0rgano-Me ta 11i c molecule 在其結構中具有一金屬伴隨著C, 輪廟層析譜,一種層析譜顯 、車歹4谓測器 (P h o t 〇 D i o d e # 1以範圍在2 0 0 nm - 800Organometallic molecule, a basic element of H'N, 〇, s, 0rgano-Me ta 11i c molecule has a metal in its structure accompanied by C, rimography, a chromatographic spectrum, ruthenium 4 Detector (P hot 〇D iode # 1 to range from 2 0 0 nm - 800

Contour Chromatogram: 示在該數據產生自一光學偶極 Array Detector,PDA),該偵 nm内的電磁輕射來掃描該樣品。由此產生的層析譜將會提Contour Chromatogram: The data is generated from an optical dipole Array Detector (PDA), which is used to scan the sample. The resulting chromatogram will be mentioned

供滞留時間在X轴’吸收(⑽)範圍在γ軸。不同的顏色將 用來表示該個別成分的不同濃度。 3-D chromatogram:三次元層析譜,使用與上述相同 設備而產生。具有更多關於由一混合物分離出的每一成分 之紫外一可見光譜的資訊。有助於使用該光譜來鑑定其組 成0The residence time for the absorption in the X-axis '(10) range is on the γ-axis. Different colors will be used to indicate different concentrations of the individual ingredients. 3-D chromatogram: A three-dimensional chromatogram, generated using the same equipment as above. There is more information about the UV-visible spectrum of each component separated from a mixture. Helps to use the spectrum to identify its composition

Ayurveda : 一種由印度賢人所寫的印度哲學,解釋醫 藥及健康訓練的系統化科學。Ayurveda: An Indian philosophy written by Indian sages that explains the systematic science of medicine and health training.

Oshadisukta:在瑞格維達中的一章,提供已用作醫藥 的藥物的詳細性質。Oshadisukta: A chapter in Regal Vida that provides the detailed nature of drugs that have been used as medicine.

Rasa, Guna, Veerya, Vipaka, and Prabhava:該藥Rasa, Guna, Veerya, Vipaka, and Prabhava: the drug

第48頁 1358540 五、發明說明(45) 物及材料的不同物理一化學性質可用來了解在印度醫藥系 統的藥物之效力。Page 48 1358540 V. INSTRUCTIONS (45) The different physical-chemical properties of materials and materials can be used to understand the efficacy of drugs in Indian medical systems.

LokapurushaSamanya:自然中的一致原貝1JLokapurushaSamanya: Consistent original shell 1J in nature

Tri dosha:三種體液用以研究人體亦即用於印度醫藥 系統的皮塔,卡發及伐塔。Tri dosha: Three body fluids used to study the human body, namely the pita, the hairpin and the pagoda used in the Indian medical system.

Prakriti-Purusha:第一個字被比喻成’大自然’(女人 )而第二個字是比喻’人’(男人),用於印度的醫藥系統。Prakriti-Purusha: The first word is likened to 'nature' (woman) and the second word is the metaphor of 'person' (man) for the medical system of India.

Pi tta :—被用於印度的醫藥系統的名稱,在印度的醫 藥系統中代表人體中的一種體液以表示其性格或疾病表現 出該消化及化學的功能或人體中一般的瑞撒柯力亞。Pi tta: - the name of the medical system used in India, which represents a body fluid in the body of a medical system in India to indicate that its character or disease exhibits the function of the digestive and chemical or general Reesalia in the human body. .

Kapha:—用於印度的醫藥系統的名稱,在印度的醫藥 系統中代表人體中的一種體液以表示其性格或疾病表現出 該因素提供人體中的形狀,穩定性,及凝聚與潤滑。Kapha: The name of the medical system used in India, which represents a body fluid in the human body in India to indicate its character or disease. This factor provides shape, stability, and cohesion and lubrication in the human body.

Vata: 一用於印度的醫藥系統的名稱,在印度的醫藥 系統中代表人體中的一種體液以表示其性格或疾病表現出 在人體中該神經學的,内分泌學的及神經的活動。Vata: The name of a medical system used in India that represents a body fluid in the human body in India to indicate that its character or disease exhibits this neurological, endocrinological and neurological activity in the human body.

第49頁 1358540 五、發明說明(46)Page 49 1358540 V. Description of invention (46)

Geological factors :全球的差異性在土壤本質及地 下水組成等等關於地球的構成要素。Geological factors: Global differences in the nature of the soil and the composition of the groundwater, etc. on the composition of the Earth.

Ecological factors:.全球的差異性在熱帶的地區, 印度的季風環境及氣溫。 »Ecological factors: Global differences in tropical regions, Indian monsoon environments and temperatures. »

Organoleptic methods :藥物性質的鑑定方法如1.味 道(如酸(安拉),鹹(拉伐納),辣(卡圖),苦(提克 塔),澀(卡夏亞))2.顏色,3.香氣及4.質地等等,使 用人類感覺的器官。 性 學-ο I 匕的66 τ到關 理覺is 物感田 撒與兹 蕊卜 C寸β 尺哲 覺* Μ 味色眷 顏冰 質 看及。 地質學 顯性化 明理的 可物分 ,有成 質所別 性與個 }中 丨地物 該藥物的標準化是利用其性質如味道(蕊撒),品質 (古納)效力(維爾亞),同化後的狀態及該成分的影響 (維帕卡)及特殊作用(普拉伯哈伐)。Organoleptic methods: Identification of the nature of the drug such as 1. taste (such as acid (Allah), salty (Lavalna), spicy (Catu), bitter (Ticka), 涩 (Cascia) 2. Color , 3. Aroma and 4. Texture, etc., using organs that humans feel. Sexology - ο I 匕 66 τ to Guan Lie sense is the sense of field 撒 撒 兹 卜 卜 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 C C C C C C C C C C 味Geologically explicit and identifiable, the quality of the substance, and the neutralization of the drug. The standardization of the drug is to use its properties such as taste (Rui Sa), quality (Guna) effectiveness (Veliya), The state after assimilation and the influence of this component (Vipaka) and special effects (Pulaberhaval).

Saptadha tus :七種元素如蕊撒(身體的分泌液),雷 克塔(Rakta,血液)’曼撒(Mamsa,肌肉),瑪甲(Majja, 骨髓),艾斯汐(Asthi,骨骼系統),梅達斯(Medas,脂肪 )及修克拉 (Shukra,生殖的)成分在人體中已用於印度 的醫藥系統。 ;Saptadha tus: seven elements such as Russell (body's secretion), Rakta (blood) 'Mansa (Mamsa), Muscle (Majja, bone marrow), Aspir (Asthology) Medas (fat) and Shukra (reproductive) ingredients have been used in the human body in India. ;

第50頁 1358540 五、發明說明(47)Page 50 1358540 V. Description of invention (47)

Panchbhutas:五種天然的元素如普利石夕彌( Prithivi,地),艾普(Ap,水),鐵加(Teja,火),伐 悠 (Vayu,風),及艾卡夏 (Akasha,空)存在於地球上 已用於印度的醫藥系統。Panchbhutas: Five natural elements such as Prithivi (Earth), Epp (Ap, Water), Iron (Teja, Fire), Vayu (Vayu), and Akasha (Akasha, Empty) exists in the medical system that has been used in India on Earth.

Nadisastra: 一科學,用以解釋人體的健康狀態,已 用於印度的醫藥系統藉以研究人們的脈搏。 在印度的醫藥系統中,產生疾病的因素可解釋成艾根 塔伐哈 (Agantavaha,意外的),沙里拉 (Sarirah,身體 產生的),曼納撒 (M a n a s a h,心理產生的)及斯瓦伯哈維 卡(Swabhavikah,自然的)。 .疾病被可分成三類作為每一印度的醫藥系統。分別是 可醫治的(珊得希亞,Sadhya),可缓和的或可控制的 ( 亞皮亞,Yapya)與不可醫治的(艾珊得希亞,Asadhya)。Nadisastra: A science that explains the health of the human body and has been used in India's medical systems to study people's pulse. In India's medical system, the factors that cause disease can be explained by Agantavaha (unexpected), Sharirah (Sarirah, body-generated), Manassa (Manaasah, psychologically produced) and Swah. Bobhavikah (natural). Diseases can be divided into three categories as each Indian medical system. They are treatable (Shandhi, Sadhya), moderate or controllable (Yapia, Yapya) and incurable (Ashandhya, Asadhya).

Conjugative property:共軛性質,若一分子具有交 錯的單鍵和雙鍵與電子提供和接受的性質則該現象稱為共 輛。可在一分子的紫外一可見光譜中看出該現象。根據一 分子中西格瑪 (S i gma )與派 (P i )電子從該電磁輻射激 發時吸收的能量,該分子將吸收一特殊的輻射波長。該分 子的最大吸收將因此指出該研究分子的共軛性質。Conjugative property: A phenomenon in which a molecule has a single bond and a double bond with the error and the nature of electron supply and acceptance. This phenomenon is called a common vehicle. This phenomenon can be seen in the ultraviolet-visible spectrum of one molecule. According to the energy absorbed by a molecule of sigma and pi electrons from the excitation of this electromagnetic radiation, the molecule will absorb a particular wavelength of radiation. The maximum absorption of this molecule will therefore indicate the conjugate nature of the study molecule.

第51頁 1358540 五、發明說明(48)Page 51 1358540 V. Description of invention (48)

Polar i ty property :極性,若一分子在其電化學性質 中有所不同,稱為具極性的。其依據該原子屬於該分子具 有提供電子(親核性)或接受電子(親電子性)的部分或 g旎基,該分子在其分子軌域上有電子價數的不同。這會 造成該分子具有一正的端點與一負的端點。這類的分子稱 為極性分子。該電子價數的範圍及種類將造成該分子的本 質為極性,中極性或非極性。Polarity property: Polarity, if a molecule differs in its electrochemical properties, it is called polar. It depends on the atom belonging to the molecule having a moiety (electrophilic) or accepting an electron (electrophilic) or a g-group having a difference in the number of electron valences in its molecular orbital domain. This causes the molecule to have a positive endpoint and a negative endpoint. Such molecules are called polar molecules. The range and type of the electronic valence will cause the molecule to be polar, medium-polar or non-polar.

Gradient or ternary system of HPLC: — HPLC儀器 具有二或三個液相幫浦以改變該水溶液或非水溶液的比例 。這將會有助於控制經該儀器之動相的總極性。 一些軟體中的縮寫: J D K . J a v a發展元件(java development kit)Gradient or ternary system of HPLC: - HPLC instrument having two or three liquid phase pumps to vary the ratio of the aqueous or non-aqueous solution. This will help control the overall polarity of the phase through the instrument. Abbreviations in some software: J D K . J a v a development kit (java development kit)

Con:輪廓層析譜(c〇nt〇ur Chromatogram) 3 — D:二-欠元層析譜(3_j)imenti〇nal Chromatogram) WOS: /又有單位(Without Scale) X :表示該層析譜的滯留時間 Y :表示在該3-D層析譜中的吸收及在輪廓層析譜中的 波長範圍 R :在一特殊映像點位置的紅色強度 G:在一特殊映像點位置的綠色強度 B :在一特殊映像點位置的藍色強度Con: contour chromatogram (c〇nt〇ur Chromatogram) 3 — D: di-unary chromatogram (3_j) imenti〇nal Chromatogram) WOS: /With units (Without Scale) X : indicates the chromatogram Retention time Y: indicates the absorption in the 3-D chromatogram and the wavelength range in the contour chromatogram R: the red intensity G at a particular image point: the green intensity B at a particular image point : Blue intensity at a special image point location

1358540 五、發明說明(49) 實施例 本發明所提出之一實施例是關於一方法可用在特徵的 層析鑑定,化學與治療的標準化與來自一植物,動物或一 天然可得的或一人工製造的材料之有機及有機金屬分子的 條碼製作上之。 本發明所提出之另一實施例是關於一新方法用在草藥 及配方之特徵的層析鑑定,本方法可排除之前複雜的缺點 本發明所提出之再一實施例是關於一方法用在一研究 藥物的成分之完整分析且該成分的共軛性質指出當該藥物 的傳統成分以新軟體來開發時的療效。 本發明所提出之再一實施例,是關於一藥物特徵的層 析鑑定的新方法用於一藥物的成分之實際概況及隨之而來 的,該成分療效之快速鑑定。 本發明所提出之再一實施例,是關於使用該草藥及配 方所提出的輪廓及3— D層析譜來進行該草藥及配方之特徵 的層析鑑定的新概念。這些層析譜是在一高壓液相層析儀 的光學偶極陣列偵測器上所發展出。該層析譜是描述在根 據實驗的分析條件下所沖提出的該草藥成分之光譜性質。1358540 V. INSTRUCTIONS (49) EXAMPLES One embodiment of the present invention relates to a method for chromatographic identification of features, chemical and therapeutic standardization from a plant, animal or a naturally available or artificial The bar code of the organic and organometallic molecules of the manufactured materials is made. Another embodiment of the present invention relates to chromatographic identification of a novel method for use in the characteristics of herbs and formulations. The method can eliminate the disadvantages of the prior invention. A further embodiment of the present invention relates to a method for A complete analysis of the composition of the study drug and the conjugate nature of the component indicate the efficacy when the traditional component of the drug is developed with new software. Still another embodiment of the present invention is directed to a practical method for the characterization of a drug characteristic for the actual profile of a drug component and the consequent rapid identification of the component's therapeutic effect. Still another embodiment of the present invention relates to a new concept of chromatographic identification of the characteristics of the herb and the formulation using the profile and 3-D chromatogram proposed by the herb and the formulation. These chromatograms were developed on an optical dipole array detector of a high pressure liquid chromatography. The chromatogram is a description of the spectral properties of the herbal component that was formulated under the analytical conditions of the experiment.

第53頁 1358540 五、發明說明(50) 本發明所提出之再一實施例是關於使用從一藥物萃出 物的層析特徵鑑定。該藥物含有任何可吸收紫外與可見光 範圍 (200-800 nm)的輻射或任何範圍的電磁輻射的分子 在本發明之另一實施例中,該化合物的紫外一可見光 光譜提供了該分子的共輥性質及該分子的個別濃度。 在本發明之另一實施例中,一相同藥物在不同pH值下 萃取所發展出的特徵有助於了解該藥物在一個體之不同pH 值的腸系統中釋放的情形。 在本發明之再一實施例中,所有該成分的紫外一可見 光光譜已顯示在一單一的影像π層析特徵鑑定"中。 在本發明之再一實施例中,該特徵變成了一草藥或配 方的成分的藍圖作為該研究藥物的試驗及快速鑑定。 在本發明之再一實施例中,該使用輪廓及3_ D層析譜 的特徵是鑑定已存在及/或新形成的化學成分的基礎。 在本發明之再一實施例中,該成分的紫外一可見光光 譜和極性指出該化合物的共輥和極性性質也從而指出該藥Page 53 1358540 V. INSTRUCTION DESCRIPTION (50) A further embodiment of the present invention is directed to the use of chromatographic characterization from a drug extract. The drug contains any molecule that absorbs radiation in the ultraviolet and visible range (200-800 nm) or any range of electromagnetic radiation. In another embodiment of the invention, the ultraviolet-visible spectrum of the compound provides a co-roll of the molecule. Nature and individual concentrations of the molecule. In another embodiment of the invention, the development of a feature of the same drug at different pH values facilitates understanding of the release of the drug in the intestinal system of a different pH value of the body. In still another embodiment of the invention, the ultraviolet-visible light spectrum of all of the components has been shown in a single image π-chromatographic feature ". In still another embodiment of the invention, the feature becomes a blueprint of the composition of the herbal or formula as a test and rapid identification of the study drug. In still another embodiment of the invention, the use profile and the 3_D chromatogram are characterized by the identification of existing and/or newly formed chemical constituents. In still another embodiment of the invention, the ultraviolet-visible light spectrum and polarity of the component indicate the co-roller and polar nature of the compound thereby indicating the drug

第54頁 1358540 五、發明說明(51) 物的化學一藥用的性質。所有成分的光譜概況在一單一圖 片中,"特徵鑑定"現在變成了 一草藥或配方的成分之藍圖 。這變成一比現有草藥的鑑定及標準化的方法更好的方法 ,當該吸收峰表現出該紫外一可見光性質或該成分的特性 或共輛和極性性質,並不像一普通的層析譜採用一單一波 長將該成分量化。 在本發明之再一實施例中,該 ''根據波長(共耗)及滯 留時間(極性)的大小將特徵區分成不同的治療區域以了 解一單一或配方藥物的療效(就傳統而論)〃藉由使用一儀 器的與運用軟體的程式來完成。 在本發明之再一實施例中,從一使用該方法來準備之 大資料庫,提供一特殊族群的植物的療效之許多歸納,有 療效地分類成為了 一特殊疾病的群組。 在本發明之再一實施例中,使舴X,Y,R,G,B作為 在該特徵中所選定的一吸收峰之座標軸,藉由使用一條碼 製作軟體產生一條碼,該條碼使該藥物所有權屬於一企業 在本發明之再一實施例中,該藥物的3— D層析譜被使 用該影像的所有三次元性質。假如該3— D層析譜可考慮成 一有頭巾的帽子,該整個帽子的三次元之配合,有另一不Page 54 1358540 V. INSTRUCTIONS (51) The chemical-medicinal properties of matter. The spectral profile of all components in a single image, "characterization" is now a blueprint for the composition of a herbal or formula. This becomes a better method than the identification and standardization of existing herbal medicines. When the absorption peak exhibits the ultraviolet-visible nature or the characteristics of the composition or the co-vehicle and polar properties, it is not like an ordinary chromatographic spectrum. This component is quantified by a single wavelength. In still another embodiment of the invention, the feature is differentiated into different treatment regions based on the wavelength (co-consumption) and residence time (polarity) to understand the efficacy of a single or formulated drug (as is conventional)完成 It is done by using an instrument and a software-using program. In still another embodiment of the present invention, a large database of plants prepared using the method provides a number of generalized effects of a particular group of plants, and is effectively classified into a group of specific diseases. In still another embodiment of the present invention, 舴X, Y, R, G, B is taken as a coordinate axis of an absorption peak selected in the feature, and a code is generated by using a code making software, the barcode making the drug Ownership belongs to a business In yet another embodiment of the invention, the 3-D chromatogram of the drug is used for all three-dimensional properties of the image. If the 3-D chromatogram can be considered as a hat with a headscarf, the three-dimensional fit of the entire hat has another one.

第55頁 1358540 五、發明說明(52) 同定性及定量性質的樣品,該適合的範圍可描述成一定性 及定量的分析報告。在這裡該帽子的頭巾用來與該分子在 一特殊波長的吸收峰做比較。一具有許多數字的樣品將類 似於一具有許多頭巾的帽子。所以該三次元座標軸的配合 將提供一極簡單的比較與分析方法。該適合的座標軸將提 供定性的且適合的範圍將提供該研究中樣品的定量數據。 藉由為了該計劃而製作的特殊軟體使得該現象變成可能。 該方法變成一品質控制的根本方法。 在本發明之再一實施例中,是關於一新方法可提供一 使用草藥及配方所提出的輪廓及3— D層析譜來進行該草藥 及配方之特徵的層析鑑定。這些層析譜是在一高壓液相層 析儀的光學偶極陣列偵測器上所發展出。該層析譜是描述 根據在實驗的分析條件下以一特殊的極性沖提出的草藥成 分之光譜性質的數據。 在本發明之再一實施例中,是關於該化合物的紫外一 可見光光譜之使用,可提供該分子的共軛和極性性質及隨 著該分子的極性而提供該分子的個別濃度。 在本發明之再一實施例中,是關於一方法可提供所有 顯示在一單一的影像"層析特徵"中之成分的紫外一可見光 光譜。該特徵因而變成一草藥或配方的成分之藍圖以作為 該研究藥物的試驗及快速確認。Page 55 1358540 V. INSTRUCTIONS (52) For samples of qualitative and quantitative nature, the appropriate range can be described as a qualitative and quantitative analysis report. Here the headscarf of the hat is used to compare the absorption peak of the molecule at a particular wavelength. A sample with many numbers would be similar to a hat with many headscarves. Therefore, the cooperation of the three-dimensional coordinate axis will provide a very simple comparison and analysis method. This suitable coordinate axis will provide a qualitative and suitable range that will provide quantitative data for the samples in this study. This phenomenon was made possible by the special software made for the plan. This method becomes a fundamental method of quality control. In still another embodiment of the present invention, a novel method provides a chromatographic identification of the characteristics of the herb and the formulation using a profile and a 3-D chromatogram of the herb and the formulation. These chromatograms were developed on an optical dipole array detector of a high pressure liquid phase analyzer. The chromatogram is a data describing the spectral properties of the herbal ingredients that were formulated with a particular polarity under the analytical conditions of the experiment. In still another embodiment of the invention, the use of the ultraviolet-visible spectrum of the compound provides conjugate and polar nature of the molecule and provides individual concentrations of the molecule with the polarity of the molecule. In still another embodiment of the present invention, a method is provided for providing an ultraviolet-visible light spectrum of all components displayed in a single image "chromatographic feature". This feature thus becomes a blueprint for the ingredients of a herbal or formula as a test and rapid confirmation of the study drug.

第56頁 1358540 五、發明說明(53) 在本發明之再一實施例中,是關於輪廓及3— D層析譜 的特徵作為該化學成分的鑑定基礎以限定該發明的範圍。 在本發明之再一實施例中,是關於一方法具有標準的 分析參數例如以乙醇溶劑作萃取,保持相同的沖提時間0 -6 0分鐘,使用相同的動相乙晴(acetonitrile)和pH在5.5 —7. 5的磷酸鹽緩衝溶液,及相同的紫外-可見光波長範圍 200-800 nm。 在本發明之再一實施例中,一方法使用標準的分析參 數例如以乙醇溶劑來萃取所有樣品作為該樣品之一特殊治 療族群的特徵鑑定以建造治療的標準化。 在本發明之再一實施例中,是關於一已攙雜的食物, 藥品和化學樣品的特徵之鑑定方法並確認該純物質與攙雜 物。 在本發明之再一實施例中,是關於一已取代的食物, 藥品和化學樣品的特徵之鑑定方法並確認該純物質與代替 物。 在本發明之再一實施例中,是關於一食物,藥品的商 業樣品的特徵之鑑定方法並確認該純物質與代替物。Page 56 1358540 V. INSTRUCTION DESCRIPTION (53) In still another embodiment of the present invention, the features of the contour and the 3-D chromatogram are used as the basis for the identification of the chemical composition to define the scope of the invention. In still another embodiment of the present invention, a method has standard analytical parameters such as extraction with an ethanol solvent, maintaining the same extraction time of 0 -6 0 minutes, using the same mobile phase acetonitrile and pH. The phosphate buffer solution at 5.5 - 7.5, and the same UV-Vis wavelength range of 200-800 nm. In still another embodiment of the invention, a method uses standard analytical parameters such as ethanol solvent to extract all samples as a characteristic treatment of a particular treatment population of the sample to establish a standardized treatment. In still another embodiment of the present invention, a method for identifying characteristics of a noisy food, drug, and chemical sample is confirmed and the pure substance and impurities are confirmed. In still another embodiment of the present invention, a method for identifying characteristics of a substituted food, drug, and chemical sample is identified and the pure substance and the substitute are confirmed. In still another embodiment of the present invention, it is a method for identifying characteristics of a commercial sample of a food, a drug, and confirming the pure substance and the substitute.

第57頁 1358540 五、發明說明(54) 在本發明之再一實施例中,是關於一在各種樣品中的 有機及有機金屬成分的特徵之鑑定方法以確認其中的化學 成分以達到各種品質控制的目的與過程標準化。 在本發明之再一實施例中,是關於一特徵鑑定的方法 用於對抗療法,阿祐爾惟達的,同種療法,席得哈,悠納 尼,中國的,西藏的,坎坡(曰本的)藥物樣品作為其品 質控制及化學與治療的標準化。 在本發明之再一實施例中,是關於一特徵鑑定的方法 用於研究自然存在的各種化學成份並鑑定之與使其中的化 學成份標準化。 在本發明之再一實施例中,是關於一特徵鑑定的方法 用於研究自然存在的各種化學成份並確認與使其化學成份 由於地質學上的及生態學的變化因素所引起的差異標準化 在本發明之再一實施例中,是關於一特徵鑑定的方法 用於研究自然存在的各種化學成份並鑑定與使其化學成份 由於遺傳型的及顯型的變化因素所引起的差異標準化。 在本發明之再一實施例中,是關於一特徵鑑定的方法Page 57 1358540 V. INSTRUCTION DESCRIPTION (54) In still another embodiment of the present invention, a method for identifying characteristics of organic and organometallic components in various samples to confirm chemical composition therein for various quality control The purpose and process are standardized. In still another embodiment of the present invention, a method for characterization is used for anti-therapeutic therapy, Ayur's, homeopathic, Seadha, Younani, China, Tibet, Kanpo (曰本Drug samples as standardization for their quality control and chemistry and treatment. In still another embodiment of the present invention, a method for characterization is used to study and identify various naturally occurring chemical components and to normalize chemical components therein. In still another embodiment of the present invention, a method for characterization is used to study various naturally occurring chemical components and to confirm that the differences caused by their chemical composition due to geological and ecological changes are standardized. In still another embodiment of the present invention, a method for characterization is used to study various naturally occurring chemical components and to identify and normalize differences in their chemical composition due to genetic and phenotypic variation factors. In still another embodiment of the present invention, a method for identifying a feature

第58頁 1358540 五、發明說明(55) 用·於研究合成的樣品之化學成份並鑑定與使其化學成份在 化學及治療的標準化上曾經適用的部分加以標準化。 在本發明之再一實施例中,是關於一特徵鑑定的方法 用於在單一及複合藥物配方的草藥中,化學成份的研究與 鑑定其中的化學成份作為化學及治療的標準化。 在本發明之再一實施例中,是關於一特徵鑑定的方法 用於在生物樣品中的化學成份的差異之研究並鑑定與使其 中的化學成份標準化。 在本發明之再一實施例中,是關於一特徵鑑定的方法 用於在不同商標的單一及配方食物與藥物樣品中化學成份 的差異之研究並鑑定其中的化學成份作為化學及治療的標 準化。 在本發明之再一實施例中,是關於一製作資料庫的方 法提供一特定群組的植物的療效之許多歸納,分成一類作 為一特殊疾病或治療的分類法。 在本發明之再一實施例中,是關於一方法用於發展特 徵鑑定並將其分類與一藥物成分的量化,根據極性和來自 3 - D及輪扉層析譜的共輛。Page 58 1358540 V. INSTRUCTIONS (55) Use to study the chemical composition of the synthesized samples and to identify the parts that have been applied to the chemical and therapeutic standardization of their chemical components. In still another embodiment of the present invention, a method for characterization is used for the study and identification of chemical constituents in single and multi-drug formulated herbal medicines as standardization of chemistry and treatment. In still another embodiment of the present invention, a method for characterization is used for the study of the difference in chemical composition in a biological sample and to identify and normalize the chemical components therein. In still another embodiment of the present invention, a method for characterization is used to study the differences in chemical composition between single and formulated food and drug samples of different trademarks and to identify chemical components therein as standardization of chemistry and treatment. In still another embodiment of the present invention, a method for making a database provides a plurality of generalizations of the efficacy of a particular group of plants, and is classified into a classification as a particular disease or treatment. In still another embodiment of the present invention, a method for developing a feature identification and classifying it with a drug component is quantified based on polarity and a total of from a 3-D and rim chromatogram.

第59頁 1358540 五、發明說明(56) 在本發明之再一實施例中是關於一方法,提供一條碼 給該影像中一分子所選定之吸收峰,其中X-滯留時間,γ_ 波長,卜紅色映像點的數目,G-綠色映像點的數目及β_藍 色映像點的數目是座標轴以當前的電腦 (Microchip, Dongle switch,hardware and software locked)軟體所 提供,並滿足任何商業上可得到的可轉售的條碼製作軟體 存在於所提出的軟體中,產生一條碼。一些影像的例子顯 示一特殊吸收峰的座標轴X-滯留時間,Υ—波長,R_紅色映 像點的數目’ G -綠色映像點的數目及B -藍色映像點的數目 ’是該產品特有的且該由此產生的條碼是封閉的。 在本發明之再一實施例中是關於一方法,製作一條碼 的資料庫使得該特徵的發展有助於各種資料庫的應用。 在本發明之再一實施例 所有已開發出特徵的樣品。 所有細節如3 - D及輪廓特徵 國家),製造曰期’到期曰 份,其試驗,生產序號,貨 籤上的資訊。當該標籤上的 顯示在該附加的顯示窗。該 應用上有助於了解該買賣藥 在本發明之再一實施例中是 方法,有助於在所有已當成 τ ,文關於一產生顯示窗對於 在該"顯示窗"中顯示該樣品的 ’條碼,來源的細節(工廠或 ’已報導的都夏’個別使用成 物號碼,M.R.P及任何在該標 條碼陳列在販賣機前時,將會 顯不窗在各種的管理與 的 物的化學及治療的可信 關於一將條碼附加於顯示窗的 數據及資料來源的應用中處理Page 59 1358540 V. INSTRUCTION DESCRIPTION (56) In still another embodiment of the present invention, a method is provided for providing a code to a selected absorption peak of a molecule in the image, wherein X-residence time, γ_wavelength, The number of red image points, the number of G-green image points, and the number of β_blue image points are provided by the current computer (Microchip, Dongle switch, hardware and software locked) software, and satisfy any commercially available The resulting resaleable barcode making software is present in the proposed software to produce a single code. Some examples of images show the coordinate axis X-residence time of a particular absorption peak, Υ-wavelength, the number of R_red image points 'G - the number of green image points and the number of B-blue image points' are unique to the product And the resulting barcode is closed. In yet another embodiment of the present invention, a method is described for making a database of one code such that the development of the feature facilitates the application of various databases. In still another embodiment of the invention, all of the characterized samples have been developed. All details such as 3-D and contour features of the country), manufacturing period 'expiration', its test, production serial number, and information on the label. When the label is displayed on the additional display window. The application helps to understand that the drug is a method in a further embodiment of the invention, which helps to display the sample in the "display window" The 'bar code, the source of the details (factory or 'reported Du Xia' individual use of the object number, MRP and any of the bar code displayed in front of the vending machine, will not show up in various management and things The conviction of chemistry and treatment is addressed in an application that attaches barcodes to the data and sources of the display window.

1358540 五、發明說明(57) 顯示窗。 在本發明之再一實施例中是關於一製作顯示窗的資料 庫的方法從而產生並附加至各自的條碼,以使用於企業資 源計畫與客戶關係管理應用對於所有該資料庫為其所製備 的藥物與樣品的商業網路交易。 在本發明之再一實施例中是關於一製作一條碼及顯示 窗及任何資訊的資料庫的方法,特別是對於該藥物在該國 家進出口控制所必須的管理當局。 在本發明之再一實施例中是關於一方法用於特徵的鑑 定可了解並將該藥物的物理一化學性質如顏色標準化作為 藥物與體液的化學及治療的標準化。 在本發明之再一實施例中是關於一特徵鑑定的方法用 於了解並將該藥物的物理-化學性質如味道(蕊撒)如酸 (安拉),鹹(拉伐納),辣(卡圖),苦(提克塔),及澀 (卡夏亞)標準化,以作為藥物與體液的化學及治療的標 準化。 在本發明之再一實施例中是關於一特徵鑑定的方法用 於了解並將該藥物的物理一化學性質如冷的,熱的,作用 缓慢的,作用強烈的,重的,輕的,軟的,滑潤的,柔順1358540 V. Description of the invention (57) Display window. In still another embodiment of the present invention, a method of creating a database of display windows is generated and attached to respective barcodes for use in enterprise resource planning and customer relationship management applications for all of the databases. Commercial online transactions of drugs and samples. In still another embodiment of the present invention, a method of making a database of codes and display windows and any information, particularly the management authority necessary for the import and export control of the drug in the country. In yet another embodiment of the invention, a method for identifying features can be used to understand and standardize the physical chemical properties of the drug, such as color, as a standard for chemistry and treatment of drugs and body fluids. In still another embodiment of the present invention, a method for characterization is used to understand and physico-chemical properties of the drug such as taste (Rousse) such as acid (Allah), salty (Lavaline), spicy ( Kathu), Bitter (Ticka), and 涩 (Kashaya) are standardized for the standardization of chemistry and treatment of drugs and body fluids. In still another embodiment of the present invention, a method for characterization is used to understand and physical chemistry of the drug such as cold, hot, slow, strong, heavy, light, soft Smooth, supple

第61頁 1358540 五、發明說明(58) 的,乾的(古納的諸如席塔,悠虛納,曼達,提克虛納, 古盧,拉古,斯尼戈達,及盧克夏(Rooksha)如在阿祐爾 惟達中所述)標準化,以作為該藥物治療的標準化。 在本發明之再一實施例中是關於一特徵鑑定的方法用 於了解並將該藥物的物理一化學性質如效力,吸收後的新 陳代謝,特殊性質如該分子的夏洛特 (C h a r 1 〇 11 e,解釋 成維爾亞,維帕卡及普拉伯哈伐)以作為藥物與體液的化 學及治療的標準化。 在本發明之再一實施例中提供一軟體基於一組成成分 的輪廓影像及3-D層析譜的數據處理機。 該發明的方法依次描述在隨後的表格,圖形,流程圖 及範例中。以上所述僅為本發明之較佳實施例而已.,並非 用以限定本發明之申請專利範圍;凡其他未脫離本發明所 揭示之精神下所完成之等效改變或修飾,均應包含在下述 之申請專利範圍内。 該發明被詳細描述參照如下所附之圖形,流程圖及範 例,可用來說明該發明的實施例,且同樣不應將在此所具 體化之該發明概念解釋為該發明之限制範圍。 化學標準化之方法:Page 61 1358540 V. Description of the invention (58), dry (Guna's such as Xita, Youxu, Manda, Ticker, Gulu, Lagu, Sni Goddah, and Luksha (Rooksha ) as standardized in Ajal, as standardization of the drug treatment. In still another embodiment of the present invention, a method for characterization is used to understand and analyze the physical chemistry of the drug, such as potency, absorption metabolism, and special properties such as Charlotte of the molecule (C har 1 〇 11 e, explained as Vera, Vipaca and Prabhavar as a standard for the chemistry and treatment of drugs and body fluids. In still another embodiment of the present invention, a data processor for providing a soft contour image and a 3-D chromatogram based on a composition is provided. The method of the invention is described in turn in the subsequent tables, figures, flowcharts and examples. The above is only the preferred embodiment of the present invention, and is not intended to limit the scope of the present invention; all other equivalent changes or modifications which are not departing from the spirit of the present invention should be included. Within the scope of the patent application. The invention is described in detail with reference to the accompanying drawings, the drawings, and the accompanying drawings, and the description of the invention. Method of chemical standardization:

第62頁 13!)854〇 、發明說明(59) 此,不像目前所使用的方法,其中一層析譜只提供 條 物 況 條 :二波長,一新的化學標準化之方法,提供特徵鏗定及 =,使用3— D及輪廓影像。該方法可提供複雜的藥 卓藥及配方或任何藥物中的化學成分之完整的化學概 碼|如&極性^與*共軛性質)。再者,該特徵鑑定從而產生的 理Λ田將在处理此類使用於企業資源計畫及客戶關係管 理應用的藥物上提供許多商業特色。 關係6 只可展 學性質 出一層 在其 各種不 質譜儀 因此, 助之情 $貴技 於一特 :m 一層析化特徵tlc#徵鑑定方法,如圖4, ' 一種成分的檢驗。該方法不能提供任何& ,共耗或極性。另-特徵鑑定的方法,以HP= 2瑨在一早一波長可描述成該藥物的"層 二,-選定的吸收夸經由化學上確認匕特徵 同:分析技術如核磁共振光譜儀(闕,液相:: (LC-MS)及遠外線光譜儀(IR)作為其結二 該單一層析譜無法在沒有其他更貴分^ 釋。 況下只藉由其自己來說明該藥:二m 雜的草藥及由各種有機及無機藥::: 疋> 口療用途的配方上將是非常不切實際的、勿I對 〇 任何配製藥物的品質將依據其製 將會因各藥房或藥劑師而異。對於 3:、。該過程 ,實際上需要的是一可提供在一單—:物或配二:質控制 (定量及定性的)數量,與該研究荦. 中的成分 T樂物的療致的簡單分Page 62 13!) 854〇, invention description (59) Therefore, unlike the current method, one chromatogram provides only strip conditions: two wavelengths, a new method of chemical standardization, providing features铿Set and =, use 3-D and contour image. This method provides a complete chemical profile of the complex drug and the chemical composition of the formulation or any drug | such as & polarity ^ and * conjugate properties. Furthermore, the characterization will result in a number of commercial features in dealing with such drugs used in enterprise resource planning and customer relationship management applications. Relationship 6 can only be used to develop a layer in its various mass spectrometers. Therefore, the help of $ expensive technology in a special: m a chromatographic feature tlc # levy identification method, as shown in Figure 4, 'inspection of a component. This method does not provide any & co-consumption or polarity. Another-characteristic method, with HP = 2 瑨 at one wavelength in the morning can be described as the "layer 2" of the drug, - the selected absorption is chemically confirmed by the same : characteristics: analytical techniques such as nuclear magnetic resonance spectroscopy (阙, liquid Phase:: (LC-MS) and far-outline spectrometer (IR) as its knot 2 The single chromatogram cannot be explained in other no more expensive conditions. In this case, the drug is only explained by itself: two m miscellaneous Herbs and a variety of organic and inorganic drugs::: 疋> The formulation for oral use will be very impractical, and the quality of any formulated drug will be based on the pharmacy or pharmacist. For the 3:, the process, what is actually needed is a quantity that can be provided in a single:: or two: quality control (quantitative and qualitative), and the composition of the study T. Simple treatment

1358540 五、發明說明(60) 析方法。因此,任何不能提供上述資訊的方法都是不徹底 的。 在本發明的化學標準化方法中,首先將該成分萃取至 一適當的溶劑中。該萃出物以一高壓液相層析儀在標準化 的分析狀況下分離成個別的成分。再經由該儀器所提供之 3— D及輪廓層析譜轉換成層析特徵影像。該影像利用為了 該影像的分析而特別製作之影像分析軟體來分析。該輸出 數據可用來說明上述的標準化。該方法的詳細描述已呈交 於該方法的實驗敘述。 治療標準化的方法: 該傳統治療的標準化,按照該醫生的能力及準備,是 高度個人主義的。此類方法的普遍可利用性實際上將是困 難的。但是該現存的科學方案強調任何方法或機構需要標 準化,且具再現性的。因此,在如今化學及治療的標準化 的方法中,提出一使用儀器的方法以降低人為的因素。藉 由一使用儀器的分析方法使這一切變成可能,可以一簡單 的方式來解釋所研究藥物之化學及治療的效用。在大多數 現代科學的科學上及組織化的社會中,評估該藥物療效的 知識必須以合理的-辯護而不是個別的技術和能力來解釋, 因為其因個體而異且不具再現性。本發明方法的設想同樣 沒有脫離傳統的概念。1358540 V. Description of invention (60) Analysis method. Therefore, any method that does not provide the above information is incomplete. In the chemical standardization method of the present invention, the component is first extracted into a suitable solvent. The extract was separated into individual components by a high pressure liquid chromatograph under standardized analytical conditions. It is then converted into a tomographic image by the 3-D and contour chromatograms provided by the instrument. The image is analyzed using image analysis software specially created for the analysis of the image. This output data can be used to illustrate the above standardization. A detailed description of the method has been presented to the experimental description of the method. Standardization of treatment: The standardization of this traditional treatment, according to the doctor's ability and preparation, is highly individualistic. The general availability of such methods will actually be difficult. But the existing scientific scheme emphasizes that any method or institution needs to be standardized and reproducible. Therefore, in today's standardized methods of chemistry and treatment, an instrumentation method is proposed to reduce human factors. This is made possible by an instrumental analysis that explains the chemistry and therapeutic utility of the drug being studied in a simple way. In most modern scientific scientific and organized societies, knowledge of the efficacy of the drug must be interpreted in a reasonable-defense rather than individual techniques and abilities, as it varies from individual to individual and is not reproducible. The idea of the method of the invention is likewise not divorced from the conventional concept.

第64頁 1358540 五、發明說明(61) 如上述的解避 j. 來評估該藥物的I分务能由物理-化學性質(極性與共耗: 該治療的標準化:::可了解該藥物的活性,從而達到 質可考慮用來d::方法中,該共軛及極性的性 τ估—樂物的療效。 在古代的 物理一化學本 ,結構,氣味 完成。表格8 顏色是如何使 土壤種類及藥 植物功效上的 學成分是根據 針可放在該採 所採集植物的 文獻 質及 及物 中, 用於 物作 影響 其地 集地 年代 中, 其療 理現 不同 該目 用的 也同 質學 點, ,為 一土 效而 象, 顏色 的0 多樣 樣清 的及 採集 了一 壤及植物的清楚分類已根據其 提出。根據該指導方針如顏色 對於一特殊疾病的藥物選擇已 在不同身體部位的影響顯示出 在選擇一藥物的同時也提及其 性。而氣候的影響及其在藥用 楚地提及。因為該植物中的化 生態學的變因而異,其指導方 的時間(季節性的和每日的)及 特殊治療功能的需要。 、 據般已用於常見的疾病型態的植物,該植物可分 成3 7類(撒斯盧珊的財富,κ · Η.克里須那摩錫,印度的阿 祐爾,達研究學會’孔巴托,印度-最初來自蘇斯盧塔山 姆海塔撒特拉斯山那38) (Wealth of Susrutha, Κ. Η. Krishnamurthy, Indian Institute of Ayurveda, Coimbatore, India— originally from Susruta Samhita suhasthana 3 8)。因此,此類植物必須包含在該已報導 的疾病上具有相似療效的化學成分。Page 64 1358540 V. INSTRUCTIONS (61) As described above, the evaluation of the drug can be performed by physico-chemical properties (polarity and co-consumption: standardization of the treatment::: The activity, thus achieving the quality can be considered in the d:: method, the conjugate and the polarity of the τ estimate - the effect of the music. In ancient physics, a chemical, structure, odor is completed. Table 8 how the color makes the soil The composition of the species and the efficacy of the medicinal plant is based on the quality of the literature and the plants in which the needles can be collected, and used in the age of the land to be affected by the objects. The homology point, for a soil effect, the color of the 0 diverse and clear and collected a clear classification of the soil and plants has been proposed according to the guidelines. According to the guidelines, color selection for a particular disease has been different The influence of the body part shows that the sex is also mentioned when selecting a drug. The influence of the climate is mentioned in the medicinal use. Because the chemical ecology in the plant is different, it refers to The time of the guide (seasonal and daily) and the need for special treatment functions. According to the plants that have been used for common disease types, the plants can be divided into 3 categories (Sas Lushan's wealth, κ · Η. Krishna Moss, India's Ayur, the Institute of Research's Coimbatore, India - originally from the Susluta Samhaita Tatras 38 () Wealth of Susrutha, Κ. Η Krishnamurthy, Indian Institute of Ayurveda, Coimbatore, India—originally from Susruta Samhita suhasthana 3 8). Therefore, such plants must contain chemical components with similar therapeutic effects on the reported disease.

第65頁 1358540 五、發明說明(62) 當研究不同種類的特徵時,可發現一些關於該植物療 效的共同特色。該相同的效用也報導於傳統文獻中。換言 之’即該實驗的與已報導的結果是相同的。因此,研究不 同的藥物’有不同的療效可證實該方法。Page 65 1358540 V. INSTRUCTIONS (62) When studying different types of features, some common features about the efficacy of the plant can be found. This same utility is also reported in the traditional literature. In other words, the results of this experiment are the same as those reported. Therefore, the study of different drugs has different effects to confirm the method.

、 圖1 3陳述所有黃顏色的藥物。在阿祐爾惟達的古代文 獻t所有這些藥物被分類成薑黃(Haridra)類,所有這 二κ色的藥物在顏色上類似薑黃。當該特徵被研究時,可 發現的是這些藥物已報導成作為卡發赫拉,失調的損害 有關於身體的黏膜(mucogeneous)組成的要素。因此, 可理解的是該藥物的顏色與其療效有直接的關係。就合理 性而言’該顏色與該藥物的療效是由於其化學成分及其物 理~化學性質的說法是真的。 β亥單一藥物如茜草,無憂樹 (Saraca Indica),胡黃 連’斐朗瑟斯尼魯利(P h y 1 1 a n t h u s N i r u r i )及配方如 &羅格亞凡爾德海尼(A r o g y a V a r d h i n i )和艾墨帕塔卡 拉1雀爾那 (Avipattakara Churna)已顯示於圖14中。該 β提至第一區的分子根據所設定分析條件的沖提模式指出 ψ, 其極性成分的存在。該藥物的沖提模式之一普遍趨向已報 f成皮塔 赫拉,其證實該高極性成分的作用主要類似皮 塔 赫拉。Figure 13 presents all yellow color drugs. All of these drugs are classified into the genus Haridra in the ancient literature of Ajal, and all these two-kappa drugs are similar in color to turmeric. When this feature was studied, it was found that these drugs have been reported to act as Kahera, a disorder of damage related to the body's mucogeneous composition. Therefore, it is understandable that the color of the drug is directly related to its therapeutic effect. In terms of rationality, the effect of this color and the drug is due to its chemical composition and its physical-chemical properties. β Hai single drug such as valerian, Saraca Indica, Hu Huanglian 'P hy 1 1 anthus N iruri and formula such as & Roggia Verde Hauni (A rogya V ardhini ) and Avipattakara Churna have been shown in FIG. The molecule raised to the first region by the β indicates the presence of a polar component in accordance with the elution pattern of the set analytical conditions. One of the general trends in the drug's extraction pattern has been reported to be Pitta Hera, which confirms that the action of this highly polar component is mainly similar to Pitta Hera.

第66頁 1358540 五、發明說明(63) 該單一藥物的特徵如金集柏爾 歐非新那理斯( Zinziber of f icinal is)(已加工的),茵奴拉瑞西莫撒 (innula racimosa),騷瑟理亞拉帕(Sausserea Lappa) 聖羅勒’格里瑟欣亞格拉伯拉(Glycerzia glabra) 及許拉集特被報導成卡發赫拉。該沖提至第二區的分子 $出中極性成分的存在。該已報導成卡發赫拉藥物之沖 提模式的一普遍趨向確認了中極性成分的作用主要類似卡 發赫拉如圖1 5所示。 該單一藥物如高良薑,蓖麻’及配方如瑟伐爾那優 格拉佳咕古盧(Survarna yogara ja Guggulu),柏理哈 特伐塔琴塔曼尼(Brihatvata chintamani )具有斯瓦爾那 馬克須勘(swarnamakshkam)’湖珊撒那(Huthasana)與馬 哈優格拉佳咕古盧(Mahayogaraja Guggulu)已展示在該 ,中。該沖提至第三區的分子根據所設定分析條件的沖提 換式指出非常低或非極性成分的存在,在本質上大多是油 狀。可觀察到的是任何藥物用於該失調包含或混合了油脂 、° 7著該成分的含油類型,該草本的礦物的有機金屬分子 1提至該區域也已發現伐塔赫拉,該可報導成伐塔赫拉 藥物之沖提模式的一普遍趨向確認了低或非極性成分的作 用主要類似伐塔赫拉如圖丨6所示。Page 66 1358540 V. INSTRUCTIONS (63) The characteristics of this single drug, such as Zinziber of f icinal is (processed), innula racimosa ), Sausserea Lappa St. Basil's Glycerzia glabra and Xu Lajit were reported as Kahra. The elution to the second region of the molecule $ out of the presence of polar components. A general trend that has been reported as a mode of extraction for Kapela drugs confirms that the role of the medium polarity component is similar to that of Kapela as shown in Figure 15. The single drug such as galangal, ramie and formula such as Survarna yogara ja Guggulu, Brihatvata chintamani has Svalnamark Exploration (swarnamakshkam) 'Huthasana and Mahayogaraja Guggulu have been shown in this. The molecules eluted to the third zone indicate the presence of very low or non-polar components based on the scoping of the set analytical conditions, which are mostly oily in nature. It can be observed that any drug used in the disorder contains or is mixed with oil, and the type of oil of the component, the organometallic molecule 1 of the herb's mineral has been extracted into the region and has also been found in Huata, which can be reported. A general trend in the extraction mode of the felled Tahra drug confirms that the action of low or non-polar components is mainly similar to that shown in Fig. 6.

該單一藥物如印度楝樹’鬱金(Curcuma i〇nga),侯 拉爾喜那安提帶森特里卡(HollarrheanaThe single drug, such as the Indian elm, Curcuma i〇nga, Holarrheaana

第67頁 1358540Page 67 1358540

五、發明說明(64)V. Description of invention (64)

Antidyssentrica),針緣葉小薛,索拉理亞扣爾迪佛理 亞 (Psoralia Cordifolia) 及西挫勒斯卡羅幸瑟斯 ( Citrullus Colosynthis)已展示在該圖中。該沖提至第 一區及第二區的分子可指出高極性或中極性成分的存在。 因此,這些具有中極性的成分已發現是皮塔-卡發赫拉。 這個現象確認該藥物的功效可藉由其中的成分之極性而了 解,如圖1 7所示。 該單一藥物的特徵鑑定如蒺蔡,辣木,筠醬及配方如 特里卡圖指出在第二區及第三區的存在的成分之效用在本 質上類似卡發-伐塔赫拉,圖丨8有相同的解釋。 止該單一藥物的特徵鑑定如假馬齒莧,木蝴蝶及配方如 月哈納拉咕古盧(KanchanaraGuggulu)指出在第一區 及第三區的存在的成分之效用在本質上類似皮塔伐塔赫 妆在一稱為k納德伯海拉維(A n a d a b h a i r a v i )的配方 中’雖然已報導的效用是皮塔伐塔赫拉可是卻經由特徵 ^疋可發現卡發伐塔赫拉。這個現象指出該藥物的人工 製作沒有成功製備出所需功效的藥物。因此,之前所提及 =方法在複雜配方的製作之流程標準化上是有用的。圖19 指出相同的結論。 〇 該單一藥物的特徵鑑定如艾里安席帕(A1丨iuin Cepa) 維星尼亞普必斯聖斯(Withinia Pubiscence)(紅色的Antidyssentrica), Psoralia Cordifolia and Citrullus Colosynthis have been shown in this figure. The molecules eluted to the first and second zones may indicate the presence of highly polar or medium polar components. Therefore, these components with medium polarity have been found to be Pita-Kafahra. This phenomenon confirms that the efficacy of the drug can be understood by the polarity of the components therein, as shown in Fig. 17. Characterization of the single drug, such as 蒺Cai, Moringa, Dipping Sauce and formula such as Trikatu, indicates that the effects of the ingredients present in the second and third zones are essentially similar to those of Kafka-Vatahra,丨8 has the same explanation. Characterization of the single drug, such as Pseudomonas, wood butterfly and formula, such as Kanchanara Guggulu, indicates that the effects of the components present in the first and third zones are essentially similar to Pita Tatta In a formula called Knadabhairavi, 'Herweed' has been reported to have the effect of Pitavatta Hera but it can be found through the characteristics of the card. This phenomenon indicates that the artificial production of the drug did not successfully produce the drug with the desired efficacy. Therefore, the previously mentioned = method is useful in standardizing the process of making complex recipes. Figure 19 points out the same conclusion.特征 Characterization of the single drug, such as A1丨iuin Cepa, Withinia Pubiscence (red

第68頁 1358540 五、發明說明(65) 種子),茵柏利卡 歐菲欣納里斯及配方如馬哈拉須米維 拉斯瑞斯(Mahalakshmi vilas ras)指出該成分存在於 所有該三個區域1,2及3所存在的分子之極性的全部範圍 。這個現象指出經由功效其將屬於促伊都夏赫拉。在馬 哈拉須米維拉斯瑞斯的特徵鑑定中該分子的兩種相似型 態的存在可視為本質上的同分異構。當這類的同分異構 ( 幾何的及光學的)成分存在的時候’該普拉伯哈伐效應以 該藥物的型式來理解。圖2 0展示出促伊都夏赫拉的所有 藥物之特徵。 Φ 克里姆撒里 (Kalimusali)(克庫里構歐其歐迪斯) (Curculig0 〇rchi〇idis)及塞菲德慕撒里(Safedmusali) (艾斯帕拉古斯艾德森登斯)(Asparagus Adescendens) 的特徵指出不同科的兩種植物可分在相同治療群組中。該 特徵顯示在所有該三個區域以些許差異的相同成分在化驗 上指出該促伊-都夏赫拉性質,如圖2 1中所指出。 兩種不同來源的一單一藥物之特徵如西挫勒斯 卡羅 幸瑟斯 (Citrullus Colosynthis)用於所提供的阿祐爾 惟達及順勢療法。在該特徵的觀察上,可發現包含三種極 性的成分’但是通常高極性分子佔多數。在該特徵仔細的 觀察上’可發現該分子在1 2分鐘時的出現與消失是這些影 像間唯一的差異。當與其他兩種作比較時,第一種藥物的 味道非常苦。所以也有人提議使用其味道作為該藥物功效Page 68 1358540 V. INSTRUCTIONS (65) Seed), Intralika Offiinaris and formulas such as Mahalakshmi vilas ras indicate that the ingredient is present in all three The full range of the polarities of the molecules present in regions 1, 2 and 3. This phenomenon indicates that it will belong to the promotion of Iduah Hera by efficacy. The presence of two similar forms of the molecule in the characterization of Mahaphra Verras is considered to be essentially isomeric. When such isomeric (geometric and optical) components are present, the Prabhavar effect is understood by the type of drug. Figure 20 shows the characteristics of all drugs that promote Idusha. Φ Kalimusali (Curculig0 〇rchi〇idis) and Safedmusali (Espargus Edelence) The characteristics of (Asparagus Adescendens) indicate that the two plants of different families can be divided into the same treatment group. This feature shows that the Yi-Du Chagha property is experimentally indicated in all three of the three regions with a slight difference in the same composition, as indicated in Figure 21. A single drug from two different sources is characterized by Citrulus Colosynthis for the provided Azur and homeopathic remedies. In the observation of this feature, a component containing three polarities can be found 'but usually a high polarity molecule is dominant. In the careful observation of this feature, it was found that the appearance and disappearance of the molecule at 12 minutes is the only difference between these images. The first drug tastes very bitter when compared to the other two. So some people have suggested using its taste as the efficacy of the drug.

第69頁 1358540 五、發明說明(66) 的一種權衡 2 2所示。 這曾是在# 代文獻中 主要使用的方法,如圖 侯拉里納安提帶森特 4 丄·」 .、 w 里卡(HollarrenaPage 69 1358540 V. A trade-off of the invention description (66) is shown in 2 2 . This was the main method used in the #代文文, as shown in the figure, Lalina Antin took the Center 4 丄·"., w Rika (Hollarrena

Antidyssentrica), — μ ^ ^ α s 集自一國家中兩個不同地點的藥 A , ^ 1L ^ ^ , 凤况上表現出許多不同點。這個現 ! ^ ^ t ’生態學的,顯型的及其他的變因在該 樂,化千成刀上之影響,該現象已解釋於圖23。Antidyssentrica), — μ ^ ^ α s is a collection of two different sites in a country, A , ^ 1L ^ ^ , which shows many different points. This is now! ^ ^ t 'Ecological, phenotypic and other causes of influence on the music, the influence of the thousands of knives, this phenomenon has been explained in Figure 23.

一巨大的不同點可由兩種分別來自安德拉普拉得須 / Andhra Pradesh)及印度加爾各答市(Calcutta)的荖 葉(beet le leaves)中看出,如圖24所示。該現象確認 了其地質學的,生態學的,顯型的及其他的變因在該植物 部分的化學成分之角色。 在圖25中展示了印度的生態區域,降雨量,氣溫及氣 候’以了解季節在植物群及動物群的生態學上的角色。季 節上的變化將在該草藥的化學成分上造成衝擊且藥物因此 而產生。這個現象適用於全球,每當一草藥植物採自地球 的不同地方時。 兩種用於化妝品的配方如草本洗髮粉的特徵已提供於 此。該純草本材料的特徵完全不同於摻雜物的特徵。人造 清潔劑及起泡劑在2 5至4 0分鐘沖提出,在該摻雜的樣品中A huge difference can be seen in two beet le leaves from Andhra Pradesh and Calcutta, as shown in Figure 24. This phenomenon confirms the role of its geological, ecological, phenotypic and other variables in the chemical composition of the plant part. In Figure 25, India's ecological regions, rainfall, temperature and climate are shown to understand the ecological role of the seasons in flora and fauna. Changes in the season will cause an impact on the chemical composition of the herb and the drug will be produced. This phenomenon applies globally, whenever a herbal plant is harvested from different parts of the globe. Two formulations for cosmetics such as herbal shampoos are provided here. The characteristics of this pure herbal material are completely different from the characteristics of the dopant. Artificial detergents and foaming agents are applied at 25 to 40 minutes in the doped sample

11

第70頁 1358540 五、發明說明(67) 可清楚地發現,其在本質上是非常鹼且肥皂質的。這個現 象支持了本發明的方法有助於管理當局檢驗含摻雜物和代 替物的傳統藥物之贓物,如圖26中的解釋。 兩種不同商標之一名為’特里卡圖’的配方之特徵在其 化驗上表現出不同點。該現象可能是由於單一藥物的處理 可用於從不同來源製備該配方。該現存的方法表現出其定 量與定性差異之範圍,有助於製備標準化的藥物與草藥的 萃出物,如圖2 7所示。 相同食物材料的三種不同商標之一配方,如薑黃的特 徵已顯示在圖2 8。在該天然薑黃的特徵鑑定中可發現該黃 色克爾扣銘 (curcumin)分子在2 0分鐘被沖提出。該相同 分子在所有商標中可普遍地發現。在該概況中的不同點是 因為該商業樣品是製備自已加工(煮熟的)的薑黃地下莖 而該天然物是來自未加工(未煮熟的)的地下莖。 圖2 9至9 2提供發展自不同藥物的特徵且該影像參數( 高度及旋轉)已用於表格1 3中的藥物之3— D及輪廓層析譜 。在表格1 4中,該分析藥物已依據其療效加以分類。而使 用所建議軟體作分析之個別藥物的特徵分析將支持本發明 在治療標準化上的專利請求項之效用。該現象確認了本方 法有助於在處理傳統藥物中的許多用途。對於現代藥物也 有助於了解其在傳統上的療效。Page 70 1358540 V. INSTRUCTIONS (67) It is clearly found that it is very alkaline and soapy in nature. This phenomenon supports the method of the present invention to assist the regulatory authority in testing the drug of traditional drugs containing dopants and substitutes, as explained in Figure 26. The characteristics of one of the two different trademarks, called 'Trichatu', differed in their assays. This phenomenon may be due to the fact that the treatment of a single drug can be used to prepare the formulation from different sources. This existing method exhibits a range of quantitative and qualitative differences that facilitate the preparation of standardized drug and herbal extracts, as shown in Figure 27. Formulations of one of three different trademarks of the same food material, such as turmeric, have been shown in Figure 28. In the characterization of the natural turmeric, the yellow curcumin molecule was found to be flushed at 20 minutes. This same molecule is commonly found in all trademarks. The difference in this profile is because the commercial sample is prepared from processed (cooked) turmeric underground stems from unprocessed (uncooked) underground stems. Figures 2-9 to 9 provide features developed from different drugs and the image parameters (height and rotation) have been used for the 3-D and contour chromatograms of the drugs in Table 13. In Table 14, the analytical drugs have been classified according to their efficacy. The analysis of the characteristics of individual drugs using the proposed software for analysis will support the utility of the patent claims in the treatment standardization of the present invention. This phenomenon confirms that this method contributes to many uses in the treatment of traditional medicines. For modern medicines, it is also helpful to understand its traditional efficacy.

第Π頁 1358540 條碼製作’企業資源 在現在的方法中該軟體分 為滯留時間,Y為波長, 點的數目及B是藍映像點 譜而運用電腦的軟體 ( hardware and software 特定的吸收峰。當該數據 再販售的條碼製作軟體中 的一隨意之映像點數值, 研究產物之所有細節的條 6十畫與客戶關係管理應用的方法 析該影像並可顯示出其座標軸X R是紅映像點的數目,G是綠映像 的數目藉由現在為了一輪廓層析 Microchip, Dongle switch, locked),對於該產物特有之一 已轉換/供應至一原有内建之可 ,自動地從在該影像中一吸收蜂Page 1358540 Barcode Production 'Enterprise Resources In the current method, the software is divided into residence time, Y is the wavelength, the number of points, and B is the blue image point spectrum and uses the software of the computer (hardware and software specific absorption peak. When The data is resold by a random image point value in the bar code making software, and all the details of the product are studied. The method of the customer relationship management application analyzes the image and can show that the coordinate axis XR is the number of red image points. , G is the number of green maps. Now for a contour tomography Microchip, Dongle switch, locked), one of the unique features of the product has been converted/supplied to an original built-in, automatically from the image. Absorption bee

產生一具有附加’顯示窗’帶著該 碼。 β玄發明之方法有助於將在一草藥的層析化特徵中成分 之所有數據條碼化’使用X為滯留時間,Υ為波長,R是红 映像點的數目,G是綠映像點的數目及B是藍映像點的數目 作為座標軸,藉由現在的電腦(Microchip, Dongle ^witch,hardware and software locked)軟體所提供且 每一成分的數值是由現在的軟體所提供。這些因素將呈現 該成分的化學及治療的功效。從而代替目前所使用只有目 錄數字的條碼製作,一新的條碼製作方法提出於此,該成 分的座標數值將隨著其他細節而顯示出來。所以,該條碼〇 及座標將可描述該產物的化學及治療性質。 該方法變成管理當局如藥品管理人,政府的分析師,An additional 'display window' is generated with the code. The method of the β-the invention helps to barcode all the data of the components in the chromatographic features of an herb. 'Use X as the retention time, Υ as the wavelength, R is the number of red pixels, and G is the number of green pixels. And B is the number of blue pixels as the coordinate axis, which is provided by the software of the current computer (Microchip, Dongle ^witch, hardware and software locked) and the value of each component is provided by the current software. These factors will present the chemical and therapeutic benefits of the ingredient. Thus, instead of the bar code production that currently uses only the number of records, a new bar code making method is proposed here, and the coordinate values of the components will be displayed along with other details. Therefore, the bar code and coordinates will describe the chemical and therapeutic properties of the product. The method becomes a management authority such as a drug manager, a government analyst,

1358540 五、發明說明(69) 食物摻雜物執 行當局,法 項工具。該 且當其接受檢查時應加以 控一不同標示的相同藥物 部門中心的 庭及 藥物 標記 至一 如何提供該影像的一特定吸收 值以製作一條 展現出一顯示 碼。圖9 5,9 6是 窗將如何顯示一 出該顯示窗 碼將可以表現 的條碼上時。當一大量的 上網,則任何 電腦網絡使用 企業資源計 於任何需要 何工作於一企業資源計晝 ,當 資料 畫與 的用 與客 海關草藥產物 的特徵可列印 。該方法也有 螢幕。圖93至 峰之座標。其 由此產生的條 草藥的所有標 該顯示窗附加 庫為該產物而 客戶關係管理 途。圖9 9表現 戶關係管理的 管理的 在一標 助於一 9 4陳述 將提供 碼。圖 籤細節 於該個 準備且 的應用 出電腦 網路應 貨物稅 籤上並 工廠監 該軟體 這些數 97,98 。該條 別產物 可使其 可藉由 網絡如 用。 本發明的各種步驟 在現在的分析方法中使用——有效的高壓液相層析,配 備一二進位的梯度系統之幫浦,一光學偶極陣列偵測器 ( PDA) 及一運用軟體的數據處理機為了該層析譜的呈現。 在所有成分完全沖提出之後,該3_ D及輪廓層析譜(具有 該紫外_可見光光譜的資訊,在一單一藥物或配方中所有 成分的吸收及滯留時間)可轉換成一提議作為一特徵鍵定 之影像。該方法可享受在對於一藥物中所有成分之可靠的 定性及定量分析時,不需任何内部或外部的標準品的優點 ,不像現在藥物的分析方法。1358540 V. INSTRUCTIONS (69) Food Doping Executive, legal tool. And when it is inspected, it should be controlled by a differently labeled department and drug label of the same drug department center to how to provide a specific absorption value of the image to create a display code. Figure 9 5, 9 6 is how the window will display the bar code that the display window code will be able to represent. When a large amount of Internet access is available, any computer network uses enterprise resources to calculate what is needed for any enterprise resource planning, and when the data is drawn and used, the characteristics of the customer's herbal products can be printed. This method also has a screen. Figure 93 to the coordinates of the peak. The resulting strips of herbs are all marked by the display window add-on library for this product and customer relationship management. Figure 9 9 shows the management of the household relationship management in a standard to help a 9 4 statement will provide the code. The details of the logo are in the prepared application. The computer network should be on the goods tax and the factory monitors the software. These numbers are 97,98. This separate product allows it to be used by the network. The various steps of the present invention are used in current analytical methods - efficient high pressure liquid chromatography, a pump with a binary gradient system, an optical dipole array detector (PDA) and a software-using data. The processor is for the presentation of the chromatogram. After all the components have been completely flushed, the 3_D and contour chromatograms (with information on the UV-visible spectrum, absorption and retention time of all components in a single drug or formulation) can be converted into a proposal as a feature bond. image. This method enjoys the advantages of no internal or external standards for reliable qualitative and quantitative analysis of all ingredients in a drug, unlike current drug analysis methods.

第73頁 1358540 五、發明說明(70) 該方法的實驗描述: 所推薦的方法可描述成四個步驟,參照所附之圖形, 流程圖及範例,用來說明該發明的實施例,且同樣不應將 在此具體化之本發明概念解釋為本發明之限制範圍。 該全部的方法可描述成如下所提及的步驟: 步驟1:藥物的選擇及成分的萃取 步驟2 :將該成分分離成個別的成分以及產生並轉換該 3-D及輪廓層析譜成為特徵鑑定 步驟3 :使用該已發展出的軟體來分析該特徵 步驟4 :數據的解釋 現在的分析方法之描述: 步驟1 樣品製備: 使用乙醇將成分從藥物中萃出,基於該樣品的化學本 質(極性)來選擇溶劑。當該含水的乙醇萃取液之pH值改 變時,該成分的萃出物也隨之而異。該驗性pH值的萃取液 可以比酸性pH值的萃取液萃取出更多的成分。選擇適當的 pH值以萃取不同的藥物並使用緩衝溶液以維持pH值的恆定 。酸性及驗性的角色在選擇萃取的pH值時必須列入考慮。 步驟2 在儀器上完成實驗工作:Page 73 1358540 V. INSTRUCTIONS (70) Experimental Description of the Method: The recommended method can be described in four steps, with reference to the accompanying figures, flowcharts and examples, to illustrate embodiments of the invention, and The concept of the invention as embodied herein is not to be construed as limiting the scope of the invention. The entire method can be described as the steps mentioned below: Step 1: Drug selection and component extraction step 2: Separating the component into individual components and generating and converting the 3-D and contour chromatograms into features Identification Step 3: Analyze the feature using the developed software Step 4: Interpretation of the data Description of the current analytical method: Step 1 Sample preparation: Extract the ingredients from the drug using ethanol, based on the chemical nature of the sample ( Polarity) to select the solvent. When the pH of the aqueous ethanol extract changes, the extract of the component will also vary. The pH-acquisitive extract extracts more components than the acidic pH extract. Choose the appropriate pH to extract the different drugs and use a buffer solution to maintain a constant pH. Acidic and anatory roles must be considered when selecting the pH of the extraction. Step 2 Complete the experimental work on the instrument:

第74頁 1358540 五、發明說明(71) 該萃出物經歷過分離分析,使用一高壓液相層析儀。 在現在的分析方法中使用一有效的高壓液相層析,配備一 二進位的梯度系統之幫浦,一光學偶極陣列偵測器 (PD A ) 及一運用軟體的數據處理機為了該層析譜的呈現。將該萃 出物已知數量的樣品(約莫2 0 m 1 )注入一注射器(適合 於一 2 0 m 1的樣品圈,1 ο ο p )。該樣品的沖提在適當動相的 時間程式化梯度系統,在一固定的流速 (1 m 1 /m i η) 下 進行。應注意的是沒有未沖提出的樣品殘留在該管柱中。 該流動的分析條件是為了該分析而設定。 使用一逆向層析管柱隨著一時間程式化的梯度沖提一 磷酸鹽緩衝溶液(pH範圍在5 . 5 - 7. 5 )且根據該分析樣品的 化學本質而以一非水的溶劑(乙晴或曱醇)作為沖提液。 一波長範圍2 0 0至8 0 0 nm用於該PDA债測器中且該分析 時間已固定成和該時間程式相同。 該時間程式,用於改變該非水溶劑如乙晴0 - 1 0 0 %的有 機溶劑比例,已用在該儀器的儀器參數中。 該儀器在該樣品注入該注射器後立即啟動以分析該樣 品。該程式在該分析完成的時候停止或是在該全部的時間 程式完成時該儀器將自動停止。Page 74 1358540 V. INSTRUCTIONS (71) The extract was subjected to separation analysis using a high pressure liquid chromatography. In the current analytical method, an effective high pressure liquid chromatography is used, a pump equipped with a binary gradient system, an optical dipole array detector (PD A) and a software processor using software for this layer. The presentation of the spectrum. A sample of this extract (approximately 20 m 1 ) was injected into a syringe (suitable for a sample loop of 20 μm, 1 ο ο p ). The sample is eluted in a time-programmed gradient system of the appropriate phase, at a fixed flow rate (1 m 1 /m i η). It should be noted that no unexposed samples remain in the column. The analysis conditions of this flow are set for this analysis. Using a reversed-phase column, a phosphate buffer solution (pH range of 5.9 - 7.5) was eluted with a time-stylized gradient and a non-aqueous solvent was used according to the chemical nature of the sample ( Ethyl or sterol) as a rinse. A wavelength range of 2 0 0 to 800 nm is used in the PDA debt detector and the analysis time is fixed to be the same as the time program. This time program is used to change the proportion of organic solvents such as 0-100% of the non-aqueous solvent, which has been used in the instrument parameters of the instrument. The instrument was started immediately after the sample was injected into the syringe to analyze the sample. The program stops when the analysis is complete or the instrument will automatically stop when the entire time program is completed.

第75頁 1358540 五、發明說明(72) 在三種數據的顯示方式中,該層析譜,一視窗顯示在 一特定波長的層析譜,在另一顯示方式中該輪廓層析譜顯 示出該分析物的滯留時間(分析時間)在X軸上及波長範 圍在Y轴上。在另一視窗中,顯示出該樣品的3 D層析譜其 中將該分析物的滯留時間(分析時間)顯示在X軸上,濃 度範圍顯示在Y軸上及波長範圍顯示在Z軸上。由該系統所 發展出的該3-D及輪廓層析譜可轉換成一影像。 該從而產生的影像經由所推薦的軟體來分析,該軟體 提供一新的層析譜及該藥物的要素之定性及定量的分析數 據。該映像點數值以不同的顏色來代表,從紫色,靛色, 藍色,綠色,黃色,撥色及紅色,歸因於該成分的濃度之 定量測定和該顏色成比例。萃取出上述的各個顏色並以不 同的視窗來表現每一顏色。該方法是化學標準化的基礎。 一些由此產生的層析譜已表現於圖1 0 0— 1 0 2。該由此產生 的層析譜同時藉由該軟體來提供各成分的共軛(藉由該紫 外-可見光吸收來表現)與極性的資訊。該影像可分成三 個區域來陳述,第一區(高極性區),第二區(中極性區) 及第三區(低或非極性區),依照該沖提模式的滯留時間來 定其規模,根據所使用的管柱及其動相。若反轉該分析條 件則可反轉該沖提模式。 該藥物的3— D層析譜將使用該上述影像的三次元性質 來作分析。若該3 - D層析譜可考慮成一‘有頭巾的帽子’,Page 75 1358540 V. Description of the Invention (72) In the three data display modes, the chromatogram, one window shows the chromatogram at a specific wavelength, and in another display the contour chromatogram shows The analyte retention time (analysis time) is on the X-axis and the wavelength range is on the Y-axis. In another window, the 3D chromatogram of the sample is displayed, wherein the retention time (analysis time) of the analyte is displayed on the X-axis, the concentration range is displayed on the Y-axis, and the wavelength range is displayed on the Z-axis. The 3-D and contour chromatogram developed by the system can be converted into an image. The resulting image is analyzed via a recommended software that provides a new chromatogram and qualitative and quantitative analytical data for the elements of the drug. The image point values are represented by different colors, from purple, ochre, blue, green, yellow, plucked and red, due to the quantitative determination of the concentration of the component proportional to the color. Each of the above colors is extracted and each color is represented by a different window. This method is the basis of chemical standardization. Some of the resulting chromatograms have been shown in Figure 1 0 0 - 1 0 2 . The resulting chromatogram also provides information on the conjugation of each component (expressed by the ultraviolet-visible absorption) and polarity by the software. The image can be divided into three regions, the first region (high polarity region), the second region (middle polarity region) and the third region (low or non-polar region), which are determined according to the retention time of the extraction mode. Scale, depending on the column used and its phase. If the analysis condition is reversed, the brewing mode can be reversed. The 3-D chromatogram of the drug will be analyzed using the three-dimensional nature of the above image. If the 3-D chromatogram can be considered as a 'headed hat',

第76頁 1358540 五、發明說明(73) 該帽子整個三次元的配合,有另一不同定性及定量性質的 樣品,該適合的範圍將可描述成一定性及定量的分析報告 。在這裡該帽子的頭巾用來與該分子在一特殊波長的吸收 峰做比較。一具有許多數字的樣品將類似於一具有許多頭 巾的帽子。所以該三次元座標軸的配合將提供一極簡單的 比較與分析方法。該適合的座標軸將提供定性的數據,且 其合適的範圍將提供該研究中樣品的定量數據。藉由為了 該目的而製作的特殊軟體使其變成可能。該方法變成一品 質控制的根本方法。 該方法可分開該分子的極性互動作用,所使用的靜相 極性及所使用的動相極性對於該樣品的沖提控制了該分子 的沖提模式。所有該三個及其他相關的參數如氣溫等等的 内部組合的作用,依據其極性來決定該沖提模式及該成分 的沖提次序。所以,在一藥物中所有極性分子將首先沖提 至’第一區’(該影像的極性區域),所有中極性分子將沖 提至’第二區’(該影像的中極性區域)以及所有低或非極 性分子將沖提至’第三區’(該影像的非極性區域)。當該 分子沖提至這三個具許多特徵的區域時,可製作許多重視 該藥物的化學及治療效用之歸納。這是另一治療標準化的 基礎。這些區域已顯著地表現於圖1 0 3- 1 0 5。 所以,該層析譜提供該資訊,該層析譜將如何發揮化 學及治療的作用。當個別成分存在於每一區域並生動地描Page 76 1358540 V. INSTRUCTIONS (73) The entire three-dimensional fit of the hat has a different qualitative and quantitative nature of the sample, and the appropriate range can be described as a qualitative and quantitative analysis report. Here the headscarf of the hat is used to compare the absorption peak of the molecule at a particular wavelength. A sample with many numbers would resemble a hat with many headscarves. Therefore, the cooperation of the three-dimensional coordinate axis will provide a very simple comparison and analysis method. This suitable coordinate axis will provide qualitative data and the appropriate range will provide quantitative data for the sample in the study. It is made possible by special software made for this purpose. This method becomes the fundamental method of quality control. This method separates the polar interaction of the molecule, and the polarity of the static phase used and the polarity of the phase used control the extraction of the sample to control the elution mode of the molecule. The effect of the internal combination of all three and other relevant parameters, such as temperature, determines the mode of extraction and the order in which the component is extracted based on its polarity. Therefore, all polar molecules in a drug will first be flushed to the 'first zone' (the polar region of the image), and all the polar molecules will be flushed to the 'second zone' (the middle polarity region of the image) and all Low or non-polar molecules will be eluted to the 'third zone' (the non-polar region of the image). When the molecule is extracted into these three areas with many characteristics, a number of generalizations that focus on the chemistry and therapeutic utility of the drug can be made. This is the basis for another standard of treatment. These areas have been significantly represented in Figure 10 3- 1 0 5 . Therefore, the chromatogram provides this information on how the chromatogram will function as a chemical and therapeutic. When individual ingredients are present in each area and vividly

第77頁 1358540 五、發明說明(74) 繪或藉由任何數據呈現的工具,該各自的區域的總成分提 供該百分比將作用在該特殊的都夏上。所以該數據解釋藥 物將如何發揮治療的作用在每一都夏的損害上共同地依據 該藥物中的成分之定量及定性的性質。例如若該藥物有3 0 %的成分在高極性區域(該映像點許多不同的顏色如一特 定區域的綠色,黃色,橙色及紅色作為數量)70 %在中極 性區域可表現成一藥物作用3 0祕皮塔上及7 0 °/在卡發上, 隨著該顏色作為在該特徵中的不同濃度的代表。因此一藥 物可評估成屬於皮塔-卡發赫拉 (3 0 - 7 0 %)。所以,該都 夏的損害已量化。這有助於醫生去了解該藥物的效用及決 定其劑量。一些餅形圖的例子已放在圖1 〇 6 - 1 0 8。 該已報導的草藥之3— D及輪廓層析譜可發展成用於該 分析條件的報導。該藥物的略圖觀點表現出該特徵鑑定如 何經由一軟體來控制因為用於處理人類特徵的軟體已完成 。所有該特徵適用於搜尋相似物及比較其相似的特徵等等 ,可藉由插入所需要的軟體特徵來完成。在圖109— 11 4中 提供不同藥物的特徵之略圖。以該特徵表示的藥物清單已 陳述於表格1 5。 步驟3 使用影像分析軟體來分析該影像: 在完成所有成分的沖提後,該3— D及輪廓層析譜可轉 成影像並提議作為其特徵。該方法可享受在對於一藥物中Page 77 1358540 V. INSTRUCTIONS (74) Painted or represented by any data, the total composition of the respective area provides the percentage that will be applied to the particular summer. So the data explains how the drug will play a therapeutic role in the damage of each summer based on the quantitative and qualitative nature of the ingredients in the drug. For example, if the drug has 30% of the components in the high polarity region (the image points many different colors such as a specific region of green, yellow, orange and red as the amount) 70% in the middle polarity region can be expressed as a drug effect 3 0 secret Pita and 7 0 ° / on the card, as the color is represented as a different concentration in the feature. Therefore, a drug can be assessed as belonging to Pita-Kafahra (30-70%). Therefore, the damage of the summer has been quantified. This helps the doctor understand the effectiveness of the drug and determine its dosage. Some examples of pie charts have been placed in Figure 1 〇 6 - 1 0 8 . The reported 3-D and contour chromatograms of the herbs can be developed into reports for the analytical conditions. The thumbnail view of the drug shows how the characterization is controlled via a software because the software used to process the human features has been completed. All of this feature is suitable for searching for similar objects and comparing similar features, etc., by inserting the required software features. A sketch of the characteristics of the different drugs is provided in Figures 109-11. A list of drugs represented by this feature is set forth in Table 15. Step 3 Analyze the image using image analysis software: After completing the flushing of all components, the 3-D and contour chromatograms can be converted into images and proposed as features. The method can be enjoyed in a drug

第78頁 1358540 五、發明說明(75) 所有成分之可靠的定性及定量分析時,不需任何内部或外 部的標準品的優點,不像現在藥物的分析方法。 在發展出該研究藥物的3— D及輪廓層析譜之影像後, (從此之後稱為層析化特徵鑑定)該影像可藉由所推薦的 軟體對於不同顏色的分析代表其中成分的定性及定量的性 質來分析。 .合乎科學地,一影像不能變成一分析數據,因此一運 用電腦的影像分析軟體(受保護的軟體及硬體)所發展出 以分析該軟體,並根據該成分的顏色出現在不同的滯留時 間及該影像的映像點數值來提供該研究藥物的成分之濃度 比例。 現在該特徵的影像已提供至如上所述的影像分析軟體 。該不同顏色的分析藉由該成分將表示成該層析譜的吸收 峰以完成並從而提供該層析譜一新的,以一彩色條狀圖形 式的呈現。該圖形顯示出該化合物的數量及其共軛性質, 所有沖提出的成分之紫外一可見光吸收性質。該過程的詳 細描述包含於該影像的分析内已討論於該軟體的技術特色 中 〇Page 78 1358540 V. INSTRUCTIONS (75) The reliable qualitative and quantitative analysis of all components does not require the advantages of any internal or external standards, unlike current analytical methods. After developing the image of the 3-D and contour chromatograms of the study drug (hereinafter referred to as chromatographic characterization), the image can be characterized by different software for the analysis of the components by the recommended software. Quantitative properties to analyze. Scientifically, an image cannot be transformed into an analytical data, so a computerized image analysis software (protected software and hardware) is developed to analyze the software and appear in different residence times depending on the color of the component. And the image point value of the image to provide the concentration ratio of the components of the study drug. An image of this feature is now provided to the image analysis software as described above. The analysis of the different colors is represented by the absorption peak of the chromatogram to complete and thereby provide the chromatogram as a new one, presented in a colored strip pattern. The graph shows the amount of the compound and its conjugating properties, the UV-visible absorption properties of all of the proposed components. A detailed description of the process is included in the analysis of the image and has been discussed in the technical features of the software.

由此發展出的該層析譜之條狀圖形式提供一具有滯留 時間 (0 - 6 0 )的刻度在X轴上及波長範圍在2 0 0 - 8 0 0 nm於YThe strip pattern of the chromatogram thus developed provides a scale with a residence time (0 - 60) on the X-axis and a wavelength range of 2 0 0 - 800 nm at Y.

第79頁 1358540 五、發明說明(76) 轴上之層析譜。該層析譜提供該映像點的數目由該影像中 每一在圖表中的每一顏色所擔任,有助於其中個別成分的 定性及定量分析。所以,該產生的層析譜正呈現一藥物中 的成分數量及其紫外光吸收範圍,具有與該分子濃度成比 例的映像點數目。 該影像依據該分子的沖提模式及其動袓極性之改變可 分成三個區域。當所用的管柱是一逆相管柱時,第一區是 極性區域,第二區是中極性區域,中極性分子沖提至本區 域,及最後第三區是低或非極性區域,因為非極性或非常 低極性的分子將沖提至該區域。所以,沖提至第一區的分 子將是極性的,該分子沖提至第二區在本質上將是屬於中 極性的以及沖提至第三區的分子在本質上將是屬於非常低 或非極.性的。因此該影像的三個區域將提供所有沖提出的 成分之極性。 依據所沖提出的分子之極性,該藥物可按照療效的傳 統系統來分類,其中該極性分子已發現是皮塔 赫拉,該 中極性分子是卡發 赫拉以及該非常低或非極性的分子是 伐塔 赫拉。這是該藥物的療效標準化之基礎。該成分的 極性可比喻成一連續的輻射光譜,在其中都夏可分類成劇 烈的至慢性的每一都夏。開始的區域是劇烈的而最後的區 域是慢性的。所以,在上述的區域出現的化合物將可作用 在上述的疾病強度之上。Page 79 1358540 V. INSTRUCTIONS (76) Chromatography on the axis. The chromatogram provides the number of pixels to be used for each color in the image in each of the images, aiding in the qualitative and quantitative analysis of individual components. Therefore, the resulting chromatogram is showing the number of components in a drug and its ultraviolet absorption range, and has a number of spots proportional to the concentration of the molecule. The image can be divided into three regions depending on the elution mode of the molecule and the change in its polarity. When the column used is a reverse phase column, the first zone is the polar zone, the second zone is the medium polarity zone, the medium polar molecules are extracted to the zone, and the last zone is the low or non-polar zone because Non-polar or very low polarity molecules will be eluted into this region. Therefore, the molecules that are flushed to the first zone will be polar, and the molecules that are eluted to the second zone will essentially be of medium polarity and the molecules that are flushed to the third zone will be very low in nature or Non-polar. Thus the three regions of the image will provide the polarity of all of the proposed components. Depending on the polarity of the molecule being clarified, the drug can be classified according to the traditional system of efficacy, which has been found to be Pita Hera, the medium polar molecule is Kahera and the very low or non-polar molecule It is Huata Hera. This is the basis for the standardization of the efficacy of the drug. The polarity of this component can be compared to a continuous spectrum of radiation, in which summer can be classified into a dramatic to chronic summer. The starting area is intense and the last area is chronic. Therefore, the compound appearing in the above region will act on the above disease strength.

第80頁 1358540 五、發明說明(77) 表格1 6表現出該特徵區分成不同的治療區域依據吸收 的顏色及極.性。X轴上的刻度依據該動相的極性顯示出該 分子的極性大小,且Y軸顯示吸收的波長範圍 ( 2 0 0— 8 0 0 nm )。依據文獻中所報導,不同藥物的療效依據該物理-化 學性質(顏色及化學性質)的療效與實驗而標準化。一些 誤差已發現可能是由於不同環境因素的作用而影響該藥物 的化學成分。 所以,該方法將有助於了解研究藥物的療效。因此, 該提議之方法將變成一新穎可見的簡單方法以了解已報導 或新的或單一或配方的藥物之療效。 該影像的分析使用為了該分析目的而發展的軟體來完 成。該軟體的細節已提供於該發表的注釋及圖1 1 5中。 步驟4 數據的解釋: 分析該產生的特徵是為了理解其化學及治療的性質。 一特徵中的基本特色可發現是, 1 )該成分已沖提到達的該極性區域;及 2)該個別成分所呈現的共軛性質。 該管柱的極性是固定的。其靜相為正相或逆相。在正Page 80 1358540 V. INSTRUCTIONS (77) Table 1 6 shows that the feature is differentiated into different treatment areas depending on the color and polarity of the absorption. The scale on the X-axis shows the polarity of the molecule according to the polarity of the phase, and the Y-axis shows the wavelength range of absorption (200-800 nm). According to the literature, the efficacy of different drugs is standardized based on the efficacy and experimentation of the physico-chemical properties (color and chemical properties). Some errors have been found to be due to the effects of different environmental factors affecting the chemical composition of the drug. Therefore, this method will help to understand the efficacy of the study drug. Therefore, the proposed method will become a novel and simple method to understand the efficacy of a reported or new or single or formulated drug. The analysis of this image was done using software developed for this purpose of analysis. Details of the software have been provided in the published notes and in Figure 115. Step 4 Interpretation of the data: The characteristics produced are analyzed to understand the nature of their chemistry and treatment. A basic feature of a feature can be found to be: 1) the polar region to which the component has been addressed; and 2) the conjugate nature exhibited by the individual component. The polarity of the column is fixed. Its static phase is normal or reverse phase. In positive

第81頁 1358540 五、發明說明(78) 相層析管柱中 相將是非極性 靜相的極性範 使用該動相的 該動相在一逆 次序改 就是, 動相將 低極性 的極性 任何極 到完整 的極性 需沖提 變時, 面極性 沖提出 的動相 ,不是 性的成 的沖提 至在該 次序的 ,靜相 的。即 圍也會 極性, 向層析 該樣品 的成分 中極性 沖提出 遞增就 分會未 。所以 成分的 分離。 將是極 使在相 因品牌 添加物 管柱上 中的成 將以南 的成分 。大部 是遞減 自該管 藉由控 極I生上 性的而在 同種類的 而異。該 如緩衝溶 的極性不 分將在相 極性的動 及非極性 分所喜好 的極性次 柱中沖提 制該靜相 ,產生一 逆相 逆相 靜相 液與 斷地 同次 相沖 的成 的模 層析管 或正相 的極性 pH值來 以遞增 序中沖 提出, 分將以 式是改 序,如此一 出而留下, 的極性,控 需要的作用 柱中,靜 管柱中該 將可藉由 控制。當 或遞減的 提出,那 中極性的 非極性或 變該動相 來就沒有 因此可得 制該動相 以得到所 將在正相管柱的例子中的極性次序和性質用於逆相管 柱中是適當的,只是需反轉成逆相管柱。非極性分子將最 先沖提出,接著是極性的分子,依據沖提時所用動相的極 性次序。 所以在現在的沖提中同樣控制該成分的沖提並以所需 的模式操作,藉由控制該動相的極性及以一按順序地方式 改變其次序。Page 81 1358540 V. INSTRUCTIONS (78) The phase of the phase chromatography column will be the polarity of the non-polar phase. The phase of the phase using the phase of the phase is changed, the phase of the phase will be any polarity of the polarity of the polarity. When the complete polarity needs to be changed, the surface polarity is proposed to be flushed to the static phase in the order. That is, the polarity will also be polar, and the polarity will be increased in the composition of the sample. So the separation of ingredients. It will be the component of the south of the column of the additive brand. Most of it is decremented from the same type of tube that is controlled by the governor I. The buffer-dissolving polarity will be flushed into the polar phase in the polarity-selective polar and non-polar sub-columns, resulting in a reverse phase reverse phase static phase liquid and the same phase. The polarity of the chromatographic tube or the positive phase of the positive phase is raised in an ascending order, the fraction will be in the order of reordering, so that the polarity is left, the control needs to be in the column, in the static column Will be controlled by. When or decreasing, the polarity is non-polar or the phase is changed so that the phase is not available to obtain the polarity order and properties to be used in the example of the normal phase column for the reverse phase column. Medium is appropriate, but only needs to be reversed into a reverse phase column. The non-polar molecules will be rushed first, followed by the polar molecules, depending on the polar order of the mobile phase used during the flushing. Therefore, in the current flushing, the flushing of the component is also controlled and operated in the desired mode by controlling the polarity of the phase and changing its order in a sequential manner.

第82頁 1358540 五、發明說明(79) 大部分樣品的沖提的完成是從高極性動相至低極性動 相。所以在該特徵鑑定中出現在該第一區的成分將是在本 質上屬於高極性的。相同模式應用至其他區域,該中極性 成分沖提至該中極性區域(第二區)及該低極性或非極性 成分沖提至該非極性區域(第三區)。當使用一正相管柱 時由於其沖提性質如上所述該模式將會反轉。 大多數高極性的分子在化學上,從而在生物活性上將 是高反應性的。當其進入消化系統的第一部份嘴時,其將 立即開始作用在生物系統上且酵素出現在那裡。接著該成 分將進入胃與腸並進行不同的變化(後來的吸收作用,在 阿祐爾惟達中的維帕卡)由於該部分所出現的消化液及酵 素。在該吸收的過程中具高活性(高極性)的分子將立刻 開始與生物系統作用並表現出其療效。相較於在阿祐爾惟 達中,人體的腸部分可分類成皮塔區,在其中高極性分子 扮演一主要的角色。熱所引起的機構將在與疾病及生物機 構相關的部分扮演一重要的角色。其間接指出該分子是屬 於高活性,高極性的分子。 在該吸收之後,具有所有已吸收該成分的血液將帶其 至心臟及與心臟相連接的部分。接著該血液將被至身體的 不同部分。在阿祐爾惟達中,人體較高的部分定義為卡發 區,在其中寒冷的機構將扮演一重要的角色。所以該中極 性的分子將在與該區相關的機構中扮演一重要的角色。Page 82 1358540 V. INSTRUCTIONS (79) The flushing of most samples is done from a high polarity phase to a low polarity phase. Therefore, the components present in the first zone in this characterization will be inherently highly polar. The same mode is applied to other regions, the medium polarity component is flushed to the medium polarity region (second region) and the low polarity or non-polar component is extracted to the non-polar region (third region). When a positive phase column is used, the pattern will be reversed due to its eluting properties as described above. Most highly polar molecules are chemically and thus will be highly reactive in biological activity. When it enters the first part of the digestive system, it will immediately begin to act on the biological system and the enzyme will appear there. The component then enters the stomach and intestines and undergoes different changes (later absorption, Vipaca in Ajal) due to the digestive juices and enzymes that appear in this part. Molecules with high activity (high polarity) during this absorption will immediately begin to interact with the biological system and demonstrate its efficacy. Compared to the Ayurveda, the intestine part of the human body can be classified into a pita area in which high-polarity molecules play a major role. The institutions caused by heat will play an important role in the parts related to diseases and biological institutions. It indirectly indicates that the molecule is a highly active, highly polar molecule. After this absorption, all of the blood that has absorbed the component will carry it to the heart and the portion that is connected to the heart. The blood will then be delivered to different parts of the body. In Ajal, the higher part of the human body is defined as the card-issuing area, in which cold institutions will play an important role. So the medium-polarity molecule will play an important role in the institutions associated with the area.

第83頁 1358540 五、發明說明(80) 該低極性或非極性成分將只能經由血液傳輸進入人體 。所以人體中只能藉由血液得到該化學成分的器官將成為 該極性的最後種類。該非極性油,脂肪及其他諸如此類的 分子及在人體中的機構可分類成伐塔失調,並且其他該類 的失調可使用相同種類的材料來治療之。 該低極性或非極性成分將沖提至該特徵的最後區域。 所以該區域(第三區)可視為伐塔區。因此該分子的基本 體液可定義成經由其極性有助於了解其將作用於什麼失調 (都夏)上。所以,所推薦的·的方法有助於藥物治療的標 準化。. 該影像可在X及Y軸上區分成三個區域。該共軛性質 ( -特殊波長的輻射之吸收)已呈現在Y轴且極性可呈現在X 軸,當使用該動相構成的極性來控制該成分的沖提。現在 如文獻中所報導該Y軸已按照療效依據波長(顏色)來等 分。該全部的影像可分成六個空間,在其中該化學成分具 有特殊共軛和極性的性質。該性質與在該空間中的成分療 效依次是成比例的。因此,當鑑定一藥物的特徵時,根據 所出現的顏色來表示一特殊波長的吸收及具有一特殊極性 ,估算在該區域的所有顏色並解釋成該藥物中成分的療效 。所以,全部療效的標準化及化學標準化可使用該方法來 完成。一概要的敘述已提供於表格1 5中,表示一藥物中不Page 83 1358540 V. INSTRUCTIONS (80) The low polarity or non-polar component will only be transported into the body via blood. Therefore, an organ in the human body that can only obtain the chemical component by blood will become the last species of the polarity. The non-polar oils, fats and other such molecules and mechanisms in the human body can be classified as pagoda disorders, and other such disorders can be treated with the same type of material. This low polarity or non-polar component will be flushed to the last region of the feature. Therefore, the area (the third zone) can be regarded as the pagoda zone. Thus the basic body fluid of the molecule can be defined to help to understand what disorder it will act on (in summer) via its polarity. Therefore, the recommended method contributes to the standardization of drug treatment. The image can be divided into three regions on the X and Y axes. The conjugated property (the absorption of radiation of a particular wavelength) has been presented on the Y-axis and the polarity can be present on the X-axis, using the polarity of the mobile phase to control the elution of the component. Now, as reported in the literature, the Y-axis has been equated according to the wavelength (color) according to the effect. The entire image can be divided into six spaces in which the chemical has special conjugate and polar properties. This property is in turn proportional to the component therapy in that space. Therefore, when the characteristics of a drug are identified, the absorption of a particular wavelength and the presence of a particular polarity based on the color appearing, the estimation of all colors in the region and interpretation of the efficacy of the components of the drug. Therefore, standardization of all therapeutic effects and chemical standardization can be accomplished using this method. A summary narrative has been provided in Table 15 to indicate that a drug does not

第84頁 1358540 五、發明說明(81) 同成分之療效與共耗和極性間的關係。 該藥物的3_ D層析譜將利用該上述影像的所有三次元 性質來分析。若該3— D層析譜可考慮成一‘有頭巾的帽子 ’,該帽子整個三次元的配合,有另一不同定性及定量性 質的樣品,該適合的範圍將可描述成一定性及定量的分析 報告。在這裡該帽子的頭巾用來與該分子在一特殊波長的 吸收峰做比較。一具有許多數字的樣品將類似於一具有許 多頭巾的帽子。所以該三次元座標軸的配合將提供一極簡 單的比較與分析方法。該適合的座標軸將提供定性的數據 ,且其合適的範圍將提供該研究中樣品的定量數據。藉由 為了該計劃而製作的特殊軟體使其變成可能。該方法變成 一品質控制的根本方法。 但是任何缺乏定量的方法將不能使用。因此,一特定 區域的影像中之成分的所有顏色可考慮成該藥物中的極性 成分之數量的呈現。所以該全部出現在該第一區皮塔區, 第二區卡發區,第三區伐塔區的成分以一餅形圖的形式來 呈現,該餅形圖表示該藥物療效在每一種失調上的療效之 比例。所以,具有5 0 : 2 0 : 3 0次序的成分之藥物將成為次序 為5 0 % : 2 0 % : 3 〇 %的促伊都夏之藥物。這可使用該已發展出 的軟體來完成。因此,該療效可定量地標準化。增加或減 少任何一或兩種其他的都夏可藉由配製藥物來完成,以增 加其他藥物並準備一合適的配方以治療一特殊的個體。Page 84 1358540 V. INSTRUCTIONS (81) The relationship between the efficacy of the same component and the coexistence and polarity. The 3_D chromatogram of the drug will be analyzed using all of the three-dimensional properties of the above images. If the 3-D chromatogram can be considered as a 'heads with a headscarf', the entire three-dimensional fit of the hat, there is another sample of different qualitative and quantitative properties, the suitable range will be described as certain and quantitative analysis report. Here the headscarf of the hat is used to compare the absorption peak of the molecule at a particular wavelength. A sample with many numbers would resemble a hat with many headscarves. Therefore, the cooperation of the three-dimensional coordinate axis will provide a very simple comparison and analysis method. This suitable coordinate axis will provide qualitative data and the appropriate range will provide quantitative data for the sample in the study. It is made possible by special software made for the plan. This method becomes a fundamental method of quality control. But any method that lacks quantification will not work. Thus, all colors of the components in the image of a particular region can be considered as a representation of the number of polar components in the drug. Therefore, all of the components appear in the Pita area of the first zone, the second zone of the card-issuing zone, and the components of the third zone of the pagoda zone are presented in the form of a pie chart indicating the efficacy of the drug in each disorder. The proportion of the effect on the. Therefore, a drug having a composition of 5 0 : 2 0 : 30 order will be a drug of the order of 50%: 20%: 3 〇 %. This can be done using the developed software. Therefore, the therapeutic effect can be quantitatively standardized. Increasing or reducing any one or two other summers can be accomplished by formulating the drug to add other drugs and prepare a suitable formula to treat a particular individual.

第85頁 1358540 五、發明說明(82) 該化學的標準化可藉使用該軟體經由依據其顏色代表 的該成分濃度而量化該個別成分來完成。一分子吸收的波 長範圍代表其共軛性質。 如同在傳統標準化方法中所描述,該藥物之顏色是根 據其顏色及療效來分類。甚至可應用於任何分子的例子中 。該表格8的顏色及其功效將解釋顏色如何用於一藥物功 效的標準化。該分子的顏色可藉由其紫外一可見光輻射吸 收範圍的性質來了解。在表格1 0的顏色及其與波長的關係 中,已提供該藥物的顏色及其特有的波長。根據結構,官 能基,共軛,及不飽和度將影響該分子的吸收波長(最大 吸收)。若該分子的共軛愈多則其吸收波長將會愈長。因 此,任何分子的紫外一可見光吸收可廣泛地使用於該成分 的定性及定量性質。 不同藥物的顏色及其靈驗的療效已提供於古代的文獻 中。該分子的顏色是由於該分子的特殊化學本質。該火焰 的顏色已用於金屬及相關產物的定性檢驗,包含該基本的 分光光度原理。因此,該電磁輻射的互動之研究及了解將 有助於該藥物的化學本質及療效之研究。相同原理已用於 現在的特徵鑑定及標準化之分光光度計的方法。在其他方 面,一現有的觀念已經以一新穎的分析方法之形式來呈現 ,以移除人為因素的誤差。所有置於該藥物療效的表格中Page 85 1358540 V. INSTRUCTIONS (82) The standardization of the chemistry can be accomplished by quantifying the individual components by using the software based on the concentration of the component represented by its color. The range of wavelengths absorbed by a molecule represents its conjugate nature. As described in traditional standardized methods, the color of the drug is classified according to its color and efficacy. It can even be applied to any molecule example. The color of Table 8 and its efficacy will explain how color is used for the standardization of a drug's efficacy. The color of the molecule can be understood by the nature of its ultraviolet-visible radiation absorption range. In the color of Table 10 and its relationship to wavelength, the color of the drug and its characteristic wavelength have been provided. Depending on the structure, the functional group, conjugate, and unsaturation will affect the absorption wavelength (maximum absorption) of the molecule. If the conjugate of the molecule is more, the absorption wavelength will be longer. Therefore, the ultraviolet-visible absorption of any molecule can be widely used for the qualitative and quantitative properties of the component. The color of different drugs and their efficacy have been provided in ancient literature. The color of the molecule is due to the special chemical nature of the molecule. The color of the flame has been used for qualitative testing of metals and related products, including the basic spectrophotometric principle. Therefore, the study and understanding of the interaction of electromagnetic radiation will contribute to the study of the chemical nature and efficacy of the drug. The same principle has been applied to the current method of characterization and standardization of spectrophotometers. In other respects, an existing concept has been presented in the form of a novel analytical method to remove artifacts. All in the form of the drug's efficacy

第86頁 1358540 五、發明說明(83) 已發展出鑑定特徵的藥物已提供於表格1 4中。該軟體技術 上的細節已提供於該軟體所發表的註釋中。 所推薦軟體的發表註釋 1 )系統需求(最低限度) 信息處理機:Pent ium II或更高 操作系統:Window 95,Window 98,Win NT 4.0及 Linux 隨機存取記憶體:64 MB或更高 螢幕:14"彩色螢幕(1024 X 768)或更高 軟體:Java發展工具(jdk 1.2. X) I I )該軟體的操作機構 各種操作機構可描述如下:操作上的順序具有不同功 月匕已表現於圖1 1 5。 八紅ί軟體的標題:彩虹(一針對層析的特徵鑑定之影像 分析軟體) 該軟體的發風θ * π ρ , 展疋為了層析的特徵鑑定及精微的影像Page 86 1358540 V. INSTRUCTIONS (83) Drugs that have developed identification features are provided in Table 14. Details of the software technology have been provided in the comments posted by the software. Notes on recommended software 1) System requirements (minimum) Information processor: Pentium II II or higher Operating system: Window 95, Window 98, Win NT 4.0 and Linux Random access memory: 64 MB or higher :14"Color Screen (1024 X 768) or higher: Java Development Tool (jdk 1.2. X) II) The operating mechanism of the software can be described as follows: The sequence of operations has different powers. Figure 1 1 5. The title of the eight red ί soft body: rainbow (an image analysis software for the identification of tomography) The wind θ * π ρ of the software, for the identification of the chromatogram and the subtle image

User Interface,圖解 殊的影像對於該層析的User Interface, a special image for the tomography

的# ‘ί軟體疋以GUI(Graphi 的使^者界面)為基礎的軟體 特朽a ·將设計該軟體成分析各考 特徵鑑定之分析。 ^# ί 软 软 疋 GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI GUI ^

3.該報告以圖表的方式來S3. The report is in the form of a chart S

1358540 五、發明說明(84) 4.生命週期 a. 輸入:影像 b. 處理: 分析包括 萃取的顏色(標準的7顏色與其一些不同色度) 重新按一定尺寸製作,在20分鐘的距離區分成三個區 域 用圖表來表示(條狀圖及餅形圖) 條碼製作 選用顏色的標準依據: 該軟體選用八種顏色,那就是紅色,綠色,藍色,黃 色,青綠色,洋紅色及撥色。 任何顏色不是絕對的。而是下列顏色在混合前後的濃 淡呈現,其在一數值範圍内變化。該顏色的範圍用以 定義成該顏色所提供上述各自的數值已取自該國際標準化 的2 5 6色階。該數值用於當前的軟體是: 對於紅色 紅 藍 綠 20 0 - 2 5 5 0-64 0-64及 192-200 0-64 0-321358540 V. INSTRUCTIONS (84) 4. Life cycle a. Input: Image b. Processing: Analysis includes the extracted color (standard 7 colors and some different chromaticities) Re-made according to a certain size, divided into 20 minutes The three areas are represented by graphs (bar graph and pie chart). The standard basis for bar code selection is: The software uses eight colors, namely red, green, blue, yellow, cyan, magenta and color. . Any color is not absolute. Rather, the shades of the following colors appear before and after mixing, which vary within a range of values. The range of colors used to define the respective values provided by the color has been taken from the internationally standardized 256 gradation. The value used for the current software is: For Red Red Blue Green 20 0 - 2 5 5 0-64 0-64 and 192-200 0-64 0-32

第88頁 1358540 五、發明說明(85) 對於綠色 紅 藍 綠 0-64 0-48 200-255 0-65 0-64 65-191 對於綠色 活藍綠 0-96 200-255 0-191 同樣地,其他顏色可當作顏色選取的標準。(這些顏 色是專用於該當前的軟體需求並可依需要而修改) "^ 點存 像儲 映其 個將 逐並 像 , 影色 該顏 取其 賣艮 t 写 體選。 軟準圖 該標狀 ,色條 時顏如 同的示 的定顯 析指的 分該步 像據一 影依進 在及成 取換 讀轉 出 輸 域值 區數 個點 三像 成映 分的 劃像 像影 影該 該或 將間 表時 圖留 像滯 影, X 如, 據的 數示 表存顯 圖儲所 由由由 告藉藉藉 報1 2 3 長 波 收 吸 的 譜 析 色 轉 由 鲁 4 生 產 以 。體 標軟 IV·-181 座作 層 D 製 1 3色碼 及藍條 廓{的 輪B建 的t内 及 別 一 \ly 個 > 至 -色 值 影C數 該,該 或1換Page 88 1358540 V. Description of invention (85) For green red blue green 0-64 0-48 200-255 0-65 0-64 65-191 For green live blue green 0-96 200-255 0-191 Other colors can be used as a standard for color selection. (These colors are specific to the current software requirements and can be modified as needed.) "^ The point storage image will be merged and imaged, and the color will be sold. The soft quasi-figure is the standard shape, and the color strip is as if the sub-analytic index of the sub-paragraph is in accordance with the image, and the image is converted into a trans-field value area. If the image is like a shadow, the image will be left like a stagnation, X. If the data is stored in the digital display, the data will be transferred from the long-wave data. Produced by Lu 4. The body standard soft IV·-181 seat layer D system 1 3 color code and blue bar profile { wheel B built t and other \ly > to - color value shadow C number, the or 1 change

第89頁 1358540 五、發明說明(86) 條碼。 d.使用者互動:允許使用者與該產品以各種方式產生 互動。 1. 輸入所需影像(一或多個) 2. 重新製作該影像的尺寸至所需尺寸並分析之。 3. 儲存該影像,重制尺寸的影像,及用圖表表示。 4. 列印該影像,重制尺寸的影像,及用圖表表示。 I I I )該軟體之技術特色 1. 該軟.體名為’彩虹’ (Rainbow) 2. —軟體具有自其檔案夾開啟不同格式(範圍)如BMP ,JPEG,T I F,G I F之層析特徵影像的能力並以出現在該影 像中具單一映相點靈敏度的不同顏色來分析。 3. —軟體具有顯示該映相點資訊的能力以形式1 . 一具 有X (0- (min.時間單位)和Y(200-800 nm)座標的圖表 及2. —餅形圖具有每一吸收峰自動或手動的個別數值在該 圖旁的兩單獨的欄中。 4. 一軟體具有列印所有分析後所產生的數據的能力藉 由使用一列印圖像 (P R I N T I c ο η )。Page 89 1358540 V. Invention Description (86) Barcode. d. User interaction: Allows the user to interact with the product in a variety of ways. 1. Enter the desired image (one or more) 2. Re-create the image size to the desired size and analyze it. 3. Save the image, resize the image, and graph it. 4. Print the image, resize the image, and graph it. III) Technical Features of the Software 1. The soft body name is 'Rainbow' 2. The software has chromatographic feature images of different formats (range) such as BMP, JPEG, TIF, GIF from its folder. The ability is analyzed in different colors that appear in the image with a single point of view sensitivity. 3. The software has the ability to display the information of the phase point in the form 1. A chart with X (0- (min. time unit) and Y (200-800 nm) coordinates and a pie chart with each The individual values of the absorption peaks automatically or manually are in two separate columns next to the figure. 4. A software has the ability to print data generated after all analyses by using a printed image (PRINTI c ο η ).

第90頁 1358540 五、發明說明(87) 5. —軟體具有改變列印的頁面設定的能力藉由使用一 頁面設定圖像 (PAGE SETUP Icon)。 6. —軟體具有選擇部分影像並分析之的能力藉由使用 一重新估量圖像 (RESIZE Icon)。 7. —軟體具有為不同影像而開啟任何數量的影像分析 視窗及狀態顯示於視窗圖像(WINDOW Icon)0 8. —軟體具有將該影像區分成三個區域在2 〇分鐘的距 離之能力,使用區域圖像(Z0NE Ic〇n)。 9. 一軟體具有使所選影像倒轉的能力藉由使用倒轉圖 像(INVERT IC0n)。 1〇.一軟體具有將該影像轉換成Notepad,Word pad及 MS W〇rd的能力’藉由使用編輯圖像(EDITOR Icon)。 料一,體具有關於該軟體操作上各種操作資訊的特 徵之能力,藉由使用輔助圖像(HELp ic〇n)。 傻^ f具有儲存該產生的數據,使用另存新檔圖 像(SAVE AS Ic〇n)’成*.jpEG檔案格式的能力。Page 90 1358540 V. INSTRUCTIONS (87) 5. The software has the ability to change the page settings of the print by using a PAGE SETUP Icon. 6. The software has the ability to select a partial image and analyze it by using a RESIZE Icon. 7. The software has any number of image analysis windows open for different images and the status is displayed in the WINDOW Icon. 0 8. The software has the ability to distinguish the image into three areas at a distance of 2 minutes. Use the area image (Z0NE Ic〇n). 9. A software has the ability to invert the selected image by using an inverted image (INVERT IC0n). 1. A software has the ability to convert the image into Notepad, Word pad and MS W〇rd by using an EDITOR Icon. In the first place, the body has the ability to characterize various operational information of the software by using an auxiliary image (HELp ic〇n). Silly ^ f has the ability to store the generated data, using the save new image (SAVE AS Ic〇n)' into the *.jpEG file format.

1358540 五、發明說明(88) IV)該軟體之安裝操作指南: a. J a v a 1. 2 . X軟體平台(該當前的軟體工作處)的安 裝程序 探測該 J a v a C D - R Ο Μ 在該 jdkl_2.0/jdkl.2.1/jdkl.2.2 setup icoη上連 按兩下 該設定將會解開該檔案並自使用者確認是否負載該軟 體於該系統中 在’是’上按一下進入其所要求安裝該檔案的路徑 經由隱含值,將出現路徑c : \ j d k 1. 2 若希望安裝於"d"槽,改變該路徑並安裝該軟體 一旦該安裝完成,回到c:並開啟該名為‘autoexec, bat’的檔案 提供接著的途徑在該autoexec.bat槽案 打開a u t 〇 e X e . B a t並如下列寫下, set path = d:\jdkl.2\bin:% path% setup class path = d:\jdkl.2\lib\classes. jar;% classpath% 重新啟動ii使用之 b _所推薦的影像分析軟體之安裝 1.從該系統上的CD複製該影像分析軟體的檔案夾至所 要求的路徑。1358540 V. INSTRUCTIONS (88) IV) Installation instructions for the software: a. J ava 1. 2. The installation program of the X software platform (the current software work) detects the Java CD - R Ο Μ Jdkl_2.0/jdkl.2.1/jdkl.2.2 setup icoη double-click this setting will unlock the file and confirm from the user whether to load the software in the system, click on 'Yes' to enter its requirements The path to install the file will be via the implied value. The path c:\ jdk 1. 2 If you want to install it in the "d" slot, change the path and install the software. Once the installation is complete, go back to c: and open the name. Provide the next path for the 'autoexec, bat' file to open aut 〇e X e . B at the autoexec.bat slot and write it down as follows, set path = d:\jdkl.2\bin:% path% setup Class path = d:\jdkl.2\lib\classes. jar;% classpath% restart ii using b _ recommended image analysis software installation 1. copy the image analysis software folder from the CD on the system To the required path.

第92頁 1358540 五、發明說明(89) 2 .探索已複製的影像分析軟體中所形成該軟體檔案夾 之該批檀案。 3. 在其上按右鍵並點選’送至桌面當作捷徑’ 4. 一 ’MS dos’捷徑按鍵出現在桌面。在該按鍵上按右 鍵並進入屬性,選擇程式標籤並檢查該‘接近離開檢查方 塊’ (close on exit check box),轉換視窗狀態’最小化 〇 5. 應用及關閉。 6. 現在該影像分析軟體已備妥可用。在該影像分析按 鍵上按兩下然後該軟體開始工作。 7. 在所打開的視窗中,將打開一具有’ CSIR’的方框, 其中該密碼’ dvk’需被鍵入。 8. 點選該打開視窗的右下角箭狀符號以啟動該軟體。 9. 開啟該沒有規格之輪廓影像的路徑並選擇分析該影 像。該影像將顯示在該影像視窗上。 1 0.點選該以紅色作記號之紅色分析視窗。一餅形圖 將隨著一具有滯留時間在X軸以及顯示十億分之一公尺( nanometer)在Y轴的層析譜。 1 1.對於較低濃度的成分點選綠色,黃色及橙色。其 他顏色幾乎是在基準線或是更低,因此可忽略。 1 2.該軟體使用上其他特徵的細節已提供於該軟體的 輔助項目單包含各種特徵及該軟體的應用。Page 92 1358540 V. INSTRUCTIONS (89) 2. Exploring the batch of files in the software folder formed in the copied image analysis software. 3. Right click on it and click 'Send to Desktop as a shortcut' 4. A 'MS dos' shortcut button appears on the desktop. Press the right button on the button and enter the properties, select the program tab and check the 'close on exit check box', and convert the window state to minimize 〇 5. Apply and Close. 6. The image analysis software is now ready for use. Press twice on the image analysis button and the software will start working. 7. In the window that opens, a box with 'CSIR' will be opened, where the password 'dvk' needs to be typed. 8. Click the arrow symbol in the lower right corner of the open window to launch the software. 9. Turn on the path for the unconstrained contour image and choose to analyze the image. The image will be displayed on the image window. 1 0. Click on the red analysis window marked with red. A pie chart will follow a chromatogram with a residence time on the X-axis and a nanometer on the Y-axis. 1 1. Select green, yellow and orange for lower concentration components. Other colors are almost at the baseline or lower and can therefore be ignored. 1 2. The details of the other features used in the software have been provided in the software. The auxiliary project list contains various features and applications of the software.

第93頁 1358540 五、發明說明(90) V )已知的程式錯誤: 未發現 v I)縮寫的使用: J D K : J a v a發展工具 C ο η :輪廝層析譜 3 - D :三次元層析譜 W0S:沒有單位 X :表示該層析譜的滯留時間 Υ :表示在該3 - D層析譜中的吸收及在輪廢層析譜中的 波長範圍 R:在一特殊映像點位置的紅色強度 G:在一特殊映像點位置的綠色強度 Β:在一特殊映像點位置的藍色強度 VII)各種圖像 (icon)及功能的含義 a. 列印圖像將有助於列印所有分析後所產生的數據。 b. 頁面設定圖像將有助於改變列印頁面的設定。 c. 重新估量圖像將有助於選擇部分影像並分析該影像 之選擇部分。 d. 視窗圖像將有助於為不同影像開啟任何數量的影像 分析視窗及狀態顯示。 e. 區域圖像將有助於將該影像區分成二個區域在2 0分 鐘的距離。Page 93 1358540 V. INSTRUCTIONS (90) V) Known program errors: No use of v I) abbreviations: JDK: Java development tools C ο η: rim chromatography 3 - D: three-dimensional layer Spectrum W0S: no unit X: indicates the retention time of the chromatogram Υ: indicates the absorption in the 3-D spectrum and the wavelength range R in the wheel waste chromatogram: at a particular image point Red intensity G: Green intensity at a particular image point Β: Blue intensity at a particular image point VII) Meaning of various images (icons) and functions a. Printing images will help print all The data generated after the analysis. b. The page setup image will help to change the settings of the print page. c. Re-evaluating the image will help select a portion of the image and analyze the selected portion of the image. d. The window image will help open any number of image analysis windows and status displays for different images. e. The area image will help to separate the image into two areas at a distance of 20 minutes.

第94頁 1358540 五、發明說明(91) f .倒轉圖像將有助於倒轉所選影像。 g. 編輯圖像將有助於轉換成Notepad, Word padA MS Word ° h. 辅助圖像將有助於關於該軟體操作上各種特徵的才桑 作資訊。 i. 另存新棺圖像將有助於將該產生的數據儲存成 JPEG檔案格式。 VIII)限制(Constraint): a )該當前的軟體只作用於沒有單位的輪廓層析譜。 b ) X軸上的單位是1 -(屬於"分鐘")以呈現該輪廓層 析譜的滯留時間 c) Y軸上的單位是200-800 n m呈現引導該分析的波長 範圍。 d) 所得的影像必須經由影像軟體重定尺寸以符合其在 X及Y軸上之分析時間與波長範圍。 e) 該分析後之影像將只可儲存成沒有單位的JPEG格式 〇 f )該影像應該儲在士 4 崎伟成S玄座標的延伸即X 1及Y 2。 本發明的主要優點是: 1 _藥物的輪廓層杯^•並嫩u μ i A \ η 析4變成該藥物的一特徵。因為該層 析譜包含具有§亥成分濃择沾取 77展度的紫外一可見光光譜帶,伴隨著Page 94 1358540 V. INSTRUCTIONS (91) f. Reversing the image will help reverse the selected image. g. Editing the image will help to convert to Notepad, Word padA MS Word ° h. The auxiliary image will help you to learn about the various features of the software operation. i. Saving a new image will help to store the resulting data in a JPEG file format. VIII) Constraint: a) The current software only acts on contour profiles without units. b) The unit on the X-axis is 1 - (belongs to "minute") to represent the residence time of the profile spectrum c) The unit on the Y-axis is 200-800 nm to present the wavelength range that guides the analysis. d) The resulting image must be sized via the image soft weight to match its analysis time and wavelength range on the X and Y axes. e) The image after the analysis will only be stored in JPEG format without unit 〇 f) The image should be stored in the extension of X 4 and the Y 2 and Y 2 of the S. The main advantages of the present invention are: 1 _ drug contour layer cup ^ • and tender u μ i A \ η analysis 4 becomes a feature of the drug. Because the spectrum contains an ultraviolet-visible spectral band with a thickness of 77, which is accompanied by

1358540 五、發明說明(92) 該分子的極性。對於一相同藥物在不同p Η值下萃取而發展 的特徵鑑定有助於了解該藥物在不同pH值的腸道系統中之 釋放從而促進該研究藥物之藥物熱力學。 2.所有成分的光譜帶可提供至一單一圖片中以評估該 藥物關於其療效及本質,非常容易。 有S 所彳 的學 分化 成的 一子 每分 中出 片提 圖沖 一已 單出 一指 在可 成, 變片 譜照 析的。 g譜質 -D光性 3 有 } 該所性 3之極 長與 波軛 有心 r& ηβ 料所 資眾 徵民 特理 的管 藥來 草門 之部 到的 得關 可海 家與 國庭 一法。 在及用 多以誤 許,與 於制用 屬控使 一質之 4·品藥 於草 助的 5 .該資料庫也提供關於該國家中各種藥用植物區域( 依療效分類)的醫療評價資訊及該生態因素在可得自該國 家各種熱帶地區之相同植物的化學成分上之角色。其可促 進一醫藥專家或一草藥商針對適用於該治療處理之草藥的 採集來選擇一植物。 6 .使用該軟體之特徵分析可提供在可得自該國家的.不 同草藥上之生態因素並可用於品質控制,法庭的及海關部 門以管理國人所關心的草藥使用與誤用。1358540 V. INSTRUCTIONS (92) The polarity of the molecule. The characterization of an identical drug extracted at different p Η values helps to understand the release of the drug in the intestinal system at different pH values to promote the drug thermodynamics of the study drug. 2. The spectral band of all components can be provided in a single picture to assess the efficacy and nature of the drug, which is very easy. There is a sub-division of S. The sub-division of each sub-element is as follows: one has been singled out, one finger is in the form, and the permutation spectrum is analyzed. g-plasma-D-light 3 has} the extreme length of the sex 3 and the yoke of the yoke heart r& ηβ material to the public levy of the special administration of the medicine to the grass gate to the door to the sea and the national court One method. In the use of the use of more than misleading, and the use of the control of the quality of the 4 medicines in the grass help 5. The database also provides medical evaluation of various medicinal plant areas in the country (by efficacy classification) Information and the role of this ecological factor in the chemical composition of the same plants available in various tropical regions of the country. It may facilitate a medical expert or an herbalist to select a plant for the collection of herbs suitable for the treatment. 6. The use of this software for characterization can provide ecological considerations for different herbs available in the country and can be used for quality control. The courts and customs departments manage the use and misuse of herbs of concern to the country.

第96頁 1358540 五、發明說明(93) 7 ·該特徵分析有助於了解該藥物如古代文獻中所報導 之物理-化學性質的療效使用。 8. 該分析也提供關於該國家中各種藥用植物的藥用評 價資訊,以及該生態因素在可得自該國家的各種地區之相 同藥物在化學成分上的角色。 9. 該治療的特徵及其乙醇一植物性的特徵之分類有助 於帶來一些歸納,可幫助醫生和研究者藉以分析該特徵而 對該傳統藥物有全盤了解。 1 0.藉由製作該影像性質該藥物/植物萃出物/植物的 條碼以避免剽竊,因為使用該影像的設備經由一筆記本工 具創造一條碼。 11.該條碼可運用在現代企業資源計晝與客戶關係管 理應用的所有商業交易中。 本發明之申請功效 在國際上 本發明有助於任何國家對於該國家的傳統藥物之特徵 鑑定及專利權取得。因為一單一藥用植物的特徵由於其化 學概況中的差異不會與另一地方或國家之相同植物的一鑑Page 96 1358540 V. INSTRUCTIONS (93) 7 • This characterization helps to understand the efficacy of the drug as reported in the ancient literature for physico-chemical properties. 8. The analysis also provides information on the medicinal evaluation of various medicinal plants in the country and the chemical composition of the ecological factors in the various regions available in the country. 9. The characteristics of the treatment and its classification of ethanol-phytochemical characteristics help to bring about some generalizations that can help doctors and researchers analyze the characteristics and have a complete understanding of the traditional medicine. 10. By making the image of the drug/plant extract/plant barcode to avoid plagiarism, the device using the image creates a code via a notebook tool. 11. The barcode can be used in all commercial transactions of modern enterprise resource planning and customer relationship management applications. Efficacy of the Applicability of the Invention Internationally, the present invention facilitates the characterization and patenting of traditional medicines in the country in any country. Because the characteristics of a single medicinal plant will not be related to the same plant in another place or country due to differences in their chemical profiles.

第97頁 1358540 五、發明說明(94) 定特徵相似。該化學概況中的差異是由於該生態因素的影 響例如其熱帶地區的差異,土壤,水質與該植物群及動物 群在該植物的化學上的差異因素。 該方法有助於該國家執行由世界衛生組織所制定之規 章,以及針對該成員國將對於該藥物之效用與品質管理及 其規章的方法標準化。 在國家上 本發明有助於作為一工具藉由通過一 該藥用植物所 發展的鑑定特徵是國家的資產〃的法律以防止傳統藥物之 國際性的剽竊。若一藥物在世界的各個地方適用於任何類 型的專利,並且如果該鑑定特徵,符合該藥物的特徵鑑定 ,可得自該挑戰的國家,則該專利可被反對。 在策略上 該藥物的鑑定特徵之條碼製作有助於該藥用植物可靠 的管理及保護。 藉由將該特徵的條碼轉換成一機器可閱讀的語言,使 商業及管理的工作變得容易。 該藥物的特徵可幫助該食品與藥物管理人,海關及中 央貨物稅部門來管理並檢查該藥物在該國家之内的使用, 誤用和竊盜行為,以及當這類藥物同意進口的時候。 在產業上Page 97 1358540 V. INSTRUCTIONS (94) The characteristics are similar. The difference in this chemical profile is due to the influence of this ecological factor such as the difference in its tropics, the soil, the water quality and the chemical differences of the flora and fauna in the plant. This approach helps the country to implement the regulations developed by the World Health Organization and to standardize the methods for the utility and quality management of the drug and its regulations. In the country, the present invention contributes to the prevention of international plagiarism of traditional medicines by virtue of a law developed by a medicinal plant that is characterized by the state's assets. A patent may be objectionable if it applies to any type of patent in various parts of the world, and if the identification feature is in accordance with the characterization of the drug, which is available from the challenge country. In strategy, the barcode design of the identification characteristics of the drug contributes to the reliable management and protection of the medicinal plant. Business and management work is made easier by converting the bar code of the feature into a machine readable language. The drug is characterized by the food and drug manager, the Customs and Central Goods Tax Department, which manages and inspects the use, misuse and theft of the drug within the country, and when such drugs are approved for import. In the industry

第98頁 1358540 五、發明說明(95) 一為了一藥物或配方而發展的特徵鑑定可幫助該企業 藉由與其他品牌的相同藥物之特徵做比較來保護其製程技 術。所以,本發明有助於更有效率地執行其專利法規。 該特徵鑑定有助於監測該藥物在籌備一配方的製程之 不同階段中是如何藉由另一藥物的添加來改變其藥物性 質。 工業可使用該對於所有可得自該國家之原生植物而發 展的特徵資料庫,作為一藥物的採集地點之選擇。該資料 庫可幫助該工業,該國家的部分,以及當地的季節進行適 合該草藥的採集,當該生態因素改變該藥物療效的時候。 在科學上 該方法可幫助研究員們去了解傳統配方的配製。其也 有助於監控一配製中的新配方。 其有助於了解新分子如何在配製一複雜的傳統配方的 時候形成。 為了一相同藥物在不同pH值下萃取而發展的該特徵有 助於了解該藥物在一個體之不同pH值的腸道系統中之釋放 情形。 該藥物的輪廓層析譜變成該藥物之一特徵。因為該層 析譜包含具有該成分的濃度,伴隨著該分子的極性,之紫 外-可見光光譜帶。 所有成分的光譜帶已提供至一單一圖中,所以評估該 藥物的療效及本質變得非常容易。Page 98 1358540 V. INSTRUCTIONS (95) A characterization developed for a drug or formulation can help the company protect its process technology by comparing it to the characteristics of the same drug from other brands. Therefore, the present invention helps to enforce its patent regulations more efficiently. This characterization helps to monitor how the drug changes its drug properties by the addition of another drug at different stages of the process of preparing a formulation. The industry can use this library of signatures for all native plants available in the country as a selection of locations for a drug. The database can help the industry, part of the country, and the local season to be suitable for the collection of the herb when the ecological factors change the efficacy of the drug. Scientifically, this method helps researchers understand the formulation of traditional formulations. It also helps monitor new formulations in a formulation. It helps to understand how new molecules are formed when formulating a complex traditional recipe. This feature, developed for the extraction of the same drug at different pH values, helps to understand the release of the drug in the intestinal system at different pH values. The profile chromatogram of the drug becomes a feature of the drug. Because the spectrum contains a concentration with this component, along with the polarity of the molecule, the ultraviolet-visible spectral band. The spectral bands of all components have been provided in a single plot, so it is very easy to assess the efficacy and nature of the drug.

第99頁 1358540 五、發明說明(96) 該3— D層析譜變成在一單一圖片中每一成分的所有波 長之所有光譜的照片,可指出所沖提出的分子之化學(共 概與極性)性質。 該資料庫也提供關於該國家中各種藥用植物區域(依 療效分類)在醫療評估上的資訊,及該生態因素在可得自 該國家的各種熱帶地區之相同植物的化學成分上的角色。 其有助於一醫藥專家或一草藥商針對適用於該治療處理之 草藥的採集來選擇一植物。 該治療的特徵及乙醇一植物性的特徵之分類有助於帶 來一些歸納可幫助醫生和研究者藉由分析該特徵而對於該 傳統藥物有全盤的了解。 當前的方法可促進準備草藥及配方的層析特徵鑑定, 有助於許多品質控制及管理的用途。 當前的方法有助於上述藥物的化學標準化(定性及定 量的),藉由提供該藥物中個別分子的共輛和極性特質或 任何具有紫外-可見光吸收性質的有機或有機-金屬化合物 。這類的分析是屬於大部分用於單一及複方的草藥之色層 分析,在其中外標準品或内標準品的使用實際上是不可能 的。 本發明寸促進研究,了解及監控該上述研究中的藥物 之療效。本發明有助於了解該治療的作用及已報導於古代 文獻之傳統藥物的性質並以一可再現的分析數據形式來確 認相同部分。因此,本發明提供該研究藥物的治療標準化 。本發明表現出其極性區域如該樣品中的極性,中極性和Page 99 1358540 V. INSTRUCTIONS (96) The 3-D chromatogram becomes a photograph of all spectra of all wavelengths of each component in a single picture, indicating the chemistry of the proposed molecule (common and polar) )nature. The database also provides information on the medical assessment of various medicinal plant areas in the country (by efficacy) and the role of this ecological factor in the chemical composition of the same plants available in various tropical regions of the country. It helps a medical professional or an herbalist to select a plant for the collection of herbs suitable for the treatment. The characteristics of this treatment and the classification of ethanol-vegetable features help to bring some generalizations to help doctors and researchers have a holistic understanding of the traditional drug by analyzing the feature. Current methods facilitate the chromatographic characterization of prepared herbs and formulations, and are useful for many quality control and management purposes. Current methods facilitate the chemical standardization (qualitative and quantitative) of the above drugs by providing co- and polar traits of individual molecules in the drug or any organic or organic-metal compound having UV-visible absorption properties. This type of analysis is part of the analysis of most of the herbs used in single and compound herbs, where the use of external or internal standards is virtually impossible. The present invention facilitates research, understanding and monitoring the efficacy of the drugs in the above studies. The present invention helps to understand the role of this treatment and the nature of conventional drugs that have been reported in ancient literature and to identify the same portion in the form of a reproducible analytical data. Accordingly, the present invention provides therapeutic standardization of the study drug. The present invention exhibits polar regions such as polarity in the sample, medium polarity and

第100.頁 1358540 五、發明說明(97) 非極性分子,從而有助於了解該藥物就整體而言的功效。 本發明可促進重新標準化該已報導的藥物至現在的治 療需要。該方法有助於監控並研究新的有機及有機一金屬 分子的配方,具有紫外一可見光吸收性質,在配製一已報 導或一新配方的過程中。其也有助於標準化一已報導或一 新的配方之製程技術,藉由監控該成分及其化學的與治療 的性質之改變。 本發明有助於藉由一内建的條碼製作軟體產生一條碼 ,其中X為滯留時間,Y為波長,R是紅映像點,G是綠映像 點及B是藍映像點,藉由目前軟體所提供的座標。本發明 也可促進出現在該特徵中的成分之一或更多的條碼製作從 而促進該商業的交易變得容易,藉由企業資源計晝與客戶 關係管理的應用。一從而準備的資料庫可幫助管理當局來 監控該上述藥物在該國家内部或外部從生產到消費者的動 態。該從而準備的條碼資料庫,變成對於ERP販賣機或任 何這類的資源 <:該機器將顯示該藥物所有的細節如公司其 化學特徵及該上述藥物的療效。本發.明使該藥物的鑑定比 之前更可靠。 使用該方法從而產生之特徵資料庫有助於帶來一特殊 治療種類的植物在療效上的許多歸納。所以,可了解為何 將某一特定的植物歸至該種類。該原因已解釋於表格1 4中 〇 該已印在該藥物的標籤上的特徵可幫助醫生在使用之 前了解該藥物之療效並確認每一批該藥物的品質控制。Page 100. 1358540 V. INSTRUCTIONS (97) Non-polar molecules help to understand the overall efficacy of the drug. The present invention facilitates the re-standardization of the reported drug to current therapeutic needs. This method helps to monitor and study the formulation of new organic and organic-metal molecules with UV-visible absorption properties during the preparation of a reported or new formulation. It also helps to standardize the process technology of a reported or new formulation by monitoring changes in the composition and its chemical and therapeutic properties. The invention facilitates generating a code by a built-in barcode making software, wherein X is a residence time, Y is a wavelength, R is a red image point, G is a green image point, and B is a blue image point, by current software. The coordinates provided. The present invention can also facilitate the production of one or more of the components appearing in the feature to facilitate the transaction of the business, by enterprise resource accounting and customer relationship management applications. A prepared database can help management to monitor the dynamics of the above drugs from production to consumer inside or outside the country. The thus prepared barcode database becomes a resource for an ERP vending machine or any such <: the machine will display all details of the drug such as the company's chemical characteristics and the efficacy of the drug. The present invention makes the identification of the drug more reliable than before. The use of this method to generate a library of features helps to bring about a generalization of the efficacy of plants of a particular therapeutic class. So, find out why a particular plant is assigned to that species. This reason has been explained in Table 1 4 〇 The characteristics printed on the label of the drug can help the doctor understand the efficacy of the drug before use and confirm the quality control of each batch of the drug.

第101頁 1358540 五、發明說明(98) 析同 層不 之的 物用 藥應 fcBl hL·% 種其 各於 的助 )有 方析 複分 及像 一 影 單的 任何已發展的哲學 鑑定影像(輪廓層析譜 步驟之許多用途。 在社會上 本發明針對一消費者有助於其了解,單一或複合的藥 物在該標籤上已提出之要求的療效與確定其内含相同。 本發明可幫助消費者來監控該市場販售草藥的品質控 制並保護消費者利益。 在添加物上 任何已發展的哲學(單一及複方)的各種藥物之層析 特徵鑑定影像(輪廓層析譜)的影像分析,有助於該藥物 中任何添加物的债測。Page 101 1358540 V. Description of invention (98) Analysis of the same layer of the drug should be fcBl hL·% of its various help) There are decomposed complexes and any developed philosophical images like a single image (contour layer Many uses of the profiling step. In the society, the present invention is directed to a consumer to help him understand that the efficacy of a single or complex drug that has been proposed on the label is the same as determining its inclusion. The present invention can help consumers To monitor the quality control of the market-sold herbal medicines and to protect the interests of consumers. Image analysis of chromatographic characterization images (contoured tomography) of any developed philosophical (single and compound) drugs on the additive, Helps with the determination of any additives in the drug.

第102頁 1358540 五、發明說明(99) - •zc 却萆 应-35- --^- &取 E bsi: r's ^^"ί> h>ui: 3ss-- 0SS-?>;T二73 25>5·) ^-^--•.系今均 ϋ- "13·®; !::,asif is 4.ΛΙ.;# κ^^ΐ&-ίΛ-ι-ι-1..?-ι--νιν-'Jks) •-----gam,-") '-.mK^-Msnlhwi.si3 ^-(Ε--^ϊ ALs3s{NCSI-r£•jt^stMkhri'^^) 2.-^.^---1-^-=. ,M- •/"s--p-^.-*"- -¾ i· pr per -αΛ-ίί {£- 2,i 3·λ 4.? ys--二 >ri > rx$>;lr-£ •ίϊ-ε 一Iwwa. /¾) 3.s"--;mi* --Uiulvml-JL) l-u (s;·^-/;"-"(chu, y^, >1-'-(Mry-*- •r-7/iE-<lgr-a- 1. ;K 2. h •Λ昤 并 I.SM1. J- •^^(Nccr.^} 3-r(Thcc.^s"-->gl5' 4. -ii(vayu.?) 5. K-il(>kasa. ΰ --5 -5···5 一.-2.- -·- 1.·ϊ-ίΞ,Β;1π11. i-flssll·-) 3.ssr"(s-l.-.'") 4"农^r??u>uldi-ii) I·- 2.c'-3k -.tt 5.客 1 :s:--?i£ 2-y -Mri=5 3:3sir<nco—} "-s'--vipilkam) 1·ίκδ-;轵-6 -i--'-Jsi--l^J! 20 H-ts&i//5'2 i-T-s-_3 5..iHas^i'--·"一 ιΐϊ-31-5 -i^-l-1·2 ·ί1·ίϊ 1.^60 2---- 3.S -.-s -'s-s^:皆涔.-;.·3'·'-淳- ^-ssi:: 1.-1,¾^iMM2ilhs<Kml.^.Al.ri:-Ns) •^-^namya.-^'"--- ,-/®,Hr-surccha:&」ss'2=·- 4. •vuitiMMU ii V- iy-.'*sff'g/,v.s ) v^s^s^-···.-^- ^s-^Ji-^LcszunsBdull} l.^^^sisN.la.^8·*5^'-'^;.2 Khrg-'Jk^) S(I -&羿(Ts-.sa) 'Kvss·85^.*- 6.3^--:11--.-1= '/fcLiKhl-ia.it*-"^) rs^ 2. JkA* 3. 芦a 4.S 5-·- l.&wUKauam3一 m>3 '-^-sil-la-N-us--ίν^^^κο/-ιιρρυ--2";" ^--^^l-umbu-klllc) •^^^j^/l—vindhu. Karu, -淨,-屮) |;'>"-·^ 2.";.^ ,ϋι •ss '",i.s 7'-t?s "ϋ:, Γί-5-3 ^u^r^^--MHJUiJP^l·1-"-^^怠-ψπ-ι-έ^- ♦ I.^-'(I3C5 ^-^(Barai) 3.sAr3(-asccna) it^^'ri Ma> l.^s-yae 2-soci-l) 砝-一淤朵辛-* ι·&-2;1 一 am) a-s<2utram) •-ts'iiuvcrv-') 1-^.5.0==--1-2. ;M-£2utra) s-u-s\vcda) ^片^-老 Π-Μ>·Λ- lllllll 第103頁 1358540 五、發明說明(100) y N r z (a - O厂Page 102 1358540 V. Description of invention (99) - • zc but 萆-35- --^- & take E bsi: r's ^^"ί>h>ui: 3ss-- 0SS-?>; T二73 25>5·) ^-^--•.系均ϋ- "13·®; !::,asif is 4.ΛΙ.;# κ^^ΐ&-ίΛ-ι-ι- 1..?-ι--νιν-'Jks) •-----gam,-") '-.mK^-Msnlhwi.si3 ^-(Ε--^ϊ ALs3s{NCSI-r£•jt ^stMkhri'^^) 2.-^.^---1-^-=. ,M- •/"s--p-^.-*"- -3⁄4 i· pr per -αΛ-ίί {£- 2,i 3·λ 4.? ys--two>ri >rx$>;lr-£ •ίϊ-ε I Iwawa. /3⁄4) 3.s"--;mi* -- Uiulvml-JL) lu (s;·^-/;"-"(chu, y^, >1-'-(Mry-*- •r-7/iE-<lgr-a- 1. ;K 2. h •Λ昤 and I.SM1. J- •^^(Nccr.^} 3-r(Thcc.^s"-->gl5' 4. -ii(vayu.?) 5. K -il(>kasa. ΰ --5 -5···5 I.-2.- -·- 1.·ϊ-ίΞ,Β;1π11. i-flssll·-) 3.ssr"(sl. -.'") 4"Agricultural^r??u>uldi-ii) I·- 2.c'-3k -.tt 5. Guest 1: s:--?i£ 2-y -Mri=5 3:3sir<nco-} "-s'--vipilkam) 1·ίκδ-;轵-6 -i--'-Jsi--l^J! 20 H-ts&i//5'2 iTs- _3 5..iHas^i'--·"一ιΐϊ- 31-5 -i^-l-1·2 ·ί1·ίϊ 1.^60 2---- 3.S -.-s -'ss^: all 涔.-;.·3'·'-淳- ^-ssi:: 1.-1,3⁄4^iMM2ilhs<Kml.^.Al.ri:-Ns) •^-^namya.-^'"--- ,-/®,Hr-surccha:&amp ;"ss'2=·- 4. •vuitiMMU ii V- iy-.'*sff'g/,vs ) v^s^s^-···.-^- ^s-^Ji-^LcszunsBdull} L.^^^sisN.la.^8·*5^'-'^;.2 Khrg-'Jk^) S(I -&羿(Ts-.sa) 'Kvss·85^.*- 6.3 ^--:11--.-1= '/fcLiKhl-ia.it*-"^) rs^ 2. JkA* 3. Ai a 4.S 5-·- l.&wUKauam3-m>3 '-^-sil-la-N-us--ίν^^^κο/-ιιρρυ--2";" ^--^^l-umbu-klllc) •^^^j^/l—vindhu. Karu, -Net,-屮) |;'>"-·^ 2.";.^ ,ϋι •ss '",is 7'-t?s "ϋ:, Γί-5-3 ^u^r^^--MHJUiJP^l·1-"-^^怠-ψπ-ι-έ^- ♦ I.^-'(I3C5 ^-^(Barai) 3.sAr3(-asccna) it ^^'ri Ma> l.^s-yae 2-soci-l) 砝-一淤朵辛-* ι·&-2;1 a) a-s<2utram) •-ts'iiuvcrv-' ) 1-^.5.0==--1-2. ;M-£2utra) sus\vcda) ^片^-老Π-Μ>·Λ- lllllll Page 103 1358540 V. Invention Description (100) y N Rz (a - O factory

$^智坤-咔 ί3 S •.itb2. 、K3. ^4. "5k (芽蒔|±2$^智坤-咔 ί3 S •.itb2. , K3. ^4. "5k (buds|±2

r^0 2. nrjttr;3. st4. siis 5. ^5¾6. ^-5 i->juiL s- (s-adruch-s) akJr^s.JiL b.£p c.-lss d_-£ ZHJily: 2^-^-:^^^-^ ^3s l./uf鋅扣 (vaishcshik) •-^^{sanlanya) •^-^i&ns) :£·啦薄淬as^=: _ϋ(5) ^卟(^®) 纹聆泫(渰s) sAL#ii (抻舞艺,斿 2s,抻垚s)珐AIL (-s) ^ Is- 3(;-s) 3.-3铎-2 4 .-I*--•^-liL-^i'iuts a. ?+失 b. K-AL(>glli)+ ? c. ^^clala)十St- ALdk+舆fjtb+is. 圉茧ss- (ΜΑ—υτΛ RELATIONS WITH DHATUS) a. ^^-^实贫b. -农容- d.-t-^^^ c"--5"^^- ^ f &-itBsiyi琀均 a. '^i-iLb. ^4p c.^^3-13-*·,5^^^ckJ^A-iL d.+sc^J^^-i-'^s. c+函 「.刼农,卟扭-鈐扣均 Γ.+函 砮吟^SIS55 # --s+ (vipaka)s =--3-盎3淬) 画·· 第104頁 1358540 五、發明說明(101) -t- UJ to 一 SINo. 睁 h- 元素 -Η α β 感受器官 膀胱 大脱! ss ώη 膽汁 腹斯 (Pus) 腎臟 肺臟 脾臟 心臟 肝臟 臟 (Tsangs) 恐懼 c;w 高興 發怒 情感 骨骼 _μ__ 肌肉 血管 奸脈衣 、二* *«* -&* QH- 雜蒸 4 〇 坪ο·、 知萃4:^孩畀厗扣+函较-fe-e-st、*r唞玢尹黟艺网今 g萃£>ii!£t!Mt~sipl->飪 t-Λ UJ ίΟ 一 SI No. > 元索 Ή-Τ :ι·硝 ;ra | 颜色 % Ε» 味边 芩 乾旱 潮源 後續影f- ft老 成熟 -wt. Cy 成長I 出生 發展 第105頁 1358540 五、發明說明(102) 妻子 m的 離性 1 確定的 疾病 (3 混亂 虛邡的 缺點 醜陋 有害的 寒冷的 潮汲的 夜晚 光亮 暘 (山坡60陰暗面) 丈夫 | 好的 雄性 | 否定的 | 次序 歡樂 徤康的 p7 美麗 有益的 it> 乾燥的 © 黑暗 陰 (山坡的光明面) 馋萃6: iu&^it^-c-匦輮铝f菸靼1¾ S t-鉍 \〇 'j on UJ h· 卜 h· W 令 «Λ *Λ OU ίν i χ> ς> CS G^ 睁 h· 升 丨元素 〇 OC 〇\ to as> Cffr as> Crrr 1φ 1Φ •Λ «-Λ4 c> C> > 昤 m 元素 £=> £=> ffi^T π> π> Π> Π> 0> C^' Μ* 玲 Sm C: Ϊ Μ η P? ?? S3 > + a 知莩S:知举择iluL-6·函輮倍渰^'_53艺芸尜涔拉盆运芽R^0 2. nrjttr;3. st4. siis 5. ^53⁄46. ^-5 i->juiL s- (s-adruch-s) akJr^s.JiL b.£p c.-lss d_-£ ZHJily: 2^-^-:^^^-^ ^3s l./uf zinc buckle (vaishcshik) •-^^{sanlanya) •^-^i&ns) :£·啦薄淬 as^=: _ϋ (5) ^卟(^®) 纹听泫(渰s) sAL#ii (抻舞艺,斿2s,抻垚s)珐AIL (-s) ^ Is- 3(;-s) 3.-3铎-2 4 .-I*--•^-liL-^i'iuts a. ?+mis b. K-AL(>glli)+ ? c. ^^clala) 十St- ALdk+舆fjtb+is.圉茧ss- (ΜΑ—υτΛ RELATIONS WITH DHATUS) a. ^^-^实贫b. -农容- d.-t-^^^ c"--5"^^- ^ f &-itBsiyi琀a. '^i-iLb. ^4p c.^^3-13-*·,5^^^ckJ^A-iL d.+sc^J^^-i-'^s. c+ letter ".刼农,卟卟-钤扣均Γ.+函砮吟^SIS55 # --s+ (vipaka)s =--3-An 3 quenching) Painting·· 104th page 1358540 V. Invention description (101) -t - UJ to one SINo. 睁h- Element-Η α β Receptor bladder detachment! ss ώ 胆 腹 (Pus) Kidney lung spleen heart liver (Tsangs) fear c; w happy angry emotion skeleton _μ__ muscle vascular脉衣,二* *«* -&* QH- miscellaneous steam 4 〇 ping ο·知萃4:^孩畀厗扣+函比-fe-e-st,*r唞玢尹黟艺网今格萃£>ii!£t!Mt~sipl-> cooking t-Λ UJ Ο SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI SI ι ι ι ι ι ι ι ι ι ι ra ra ra ra ra ra ra ra ra ra ra ra ra ra ra ra ra ra ra ra ra 芩 芩 芩 芩 芩 芩 芩 芩 芩Description of the invention (102) Wife m's sexuality 1 Definite disease (3 Disorders of ugly ugliness, harmful cold, tidal night, bright 旸 (hillside 60 dark side) Husband | Good male | Negative | P7 beautiful and beneficial it> dry © dark yin (bright side of the hillside) 馋 6 6: iu&^it^-c-匦輮aluminous f 靼13⁄4 S t-铋\〇'j on UJ h· Bu h· W 令«Λ *Λ OU ίν i χ>ς> CS G^ 睁h· upgrade element 〇OC 〇\ to as> Cffr as> Crrr 1φ 1Φ •Λ «-Λ4 c>C>> 昤m Element £=>£=> ffi^T π>π>Π>Π>0> C^' Μ* Ling S m C: Ϊ Μ η P? ?? S3 > + a 知莩 S: Knowing the choice of iluL-6·輮輮倍渰^'_53艺芸尜涔拉盆芽芽

第106頁 1358540 五、發明說明(103) 枓嗥淞穿s&+>^诤1!0-耷私-+ 1 該掐物/材料 的名字 3¾ 在珊克利柏 屮的名字 (Name in Sancrit) 昶色 -1 蘇饮吩促納(SudhaCliuna,Lime) 卡克吃怕普利斯塔(Kaclihapa Prisla, 也殼) 旋客哈(Slumkha,海螺) 尚克提(Shukti,珍珠般) 瓦拉提卡(Varatika,小貝殼) 布魯须迅須^(13rushtashma,灰化的石 頭) 撒闽卡拉(^rkara,糖) *納甲坭根圆經山維狄亞納拉哈里 (Rajanighantu by Vaidya Narahari) lltf 从九拉發坳加· (Shukla Varga) 白色铯物 古森跋蒲彡M帕(KusimibaPuslipa} 佥蘇卡(布提亞莫諾斯伯瑪) (Kimshuka, Bulca monosperma) 哈里德拉(充庫瑪隆加) (Maridra, Curcuma longa) 帕攤加(凱索匹尼亞撒盆) (Patanga, Caesalpinia sappan) 梅達陽提卡(拉梭尼亞因納彌斯) (MaeJayantika, Lasonia Incrmis) *拉达納瓦 (Rasarnava) 丄ii m It 匹塔加 (Pccta Varga) 黃色锒物 達伙瑪(普妮卡納騰) (Dadima, Punica granatum) 丨 帕拉辽(布提亞莫諾斯伯瑪) (Palasha, Butca monosperma) 拉克夏(拉瑟斐拉拉卡) (Laksha, Laccifcra lacca) 邦德胡卡(Bandhuka) 哈里德位(克庫瑪隆加) (liaridra, Curcuma longa) (Kusumba Pushpa) tt思塔(盧比亞口伙怫里亞) (Manjista, Rubia cordifolia) *納甲媒根圆(Kajanighamu) GhiVCTtiv q$ 朮免塔發抑加 (Rakta varga) 紅色藥物 卡遠里姆撒帕拉狄希亞卡 (Kadali, Musa paradisiaca) 卡拉維里卡(莫諾狄亞恰藍提亞) (Karavcllika, Momordia charantia) 特里發拉(三個米里巴藍斯) (Triphala, Three myribalans) 擬里卡(m迪勾斐拉停克託里亞) (Ncclika, Indigofcra Tinctoria) 納拉(信玻怫剛斯苕西斯) (Nala, Cymbophogan species) 潘卡(蓮仏)(Panka,Lolus) 卡希撒(Kaseesa,Fc2Sj) 巴篮拉(印里彭芒果) (Balamra, Unripen Mango) *拉珊德拉周丹曼尼 (Rasendra Cluidamani) 綱 mi 免!IL 納發明加 (Krishna Varga) — Ο.-—-- 黑色娘物 11圓__11Page 106 1358540 V. INSTRUCTIONS (103) 枓嗥淞 s&+>^诤1!0-耷私-+ 1 The name of the animal/material 33⁄4 in the name of Sanctuary (Name in Sancrit ) -1色-1 Sueha Cliuna (Lime) Kak eats Priscilla (Kaclihapa Prisla, also shell) Cyclone Ha (Slumkha, Conch) Shankti (Shukti, pearl-like) Varati Card (Varatika, small shell) Bruce Xun ^ (13rushtashma, grayed stone) Satan Kara (^rkara, sugar) * Nagaki roots through the mountain Vijayantu by Vaidya Narahari Lltf From Shukla Varga White 铯物古森跋蒲彡 Mpa (KusimibaPuslipa) 佥 Suka (Bimca Monosperma) (Kimshuka, Bulca monosperma) Harry Della (Longdra) (Maridra, Curcuma longa) Patanga (Caesalpinia sappan) (MaeJayantika, Lasonia Incrmis) * Pull Rasarnava 丄ii m It Pccta Varga Yellow scorpion Dharma (Puni Karnateng) (Dadima, Punic a granatum) Palasha, Butca monosperma (Laksha, Laccifcra lacca) Bandhuka (Hardud) (Kiarumra, Curcuma longa) (Kusumba Pushpa) ttSita (Manbiasta, Rubia cordifolia) *Kajanighamu GhiVCTtiv q$ Rakta varga Red drug card Kadali, Musa paradisiaca (Karavcllika, Momordia charantia) Terry Fara ( (Triphala, Three myribalans) (Ncclika, Indigofcra Tinctoria) (Ncclika, Indigofcra Tinctoria) Nala (Nippon Bosphorus) Cymbophogan species) Panka, Lolus Kaseesa (Fc2Sj) Barrama (Unripen Mango) *Rasendra Cluidamani Guide mi free! IL 纳 invention (Krishna Varga) — Ο.-—-- black mother 11 round __11

第107頁 1358540 五、發明說明(104) 宝含丨和钎蚱(?-的艺薛芽苯奔3莩121-:;;1為&0>'诤。 MT^piHirisv^ 2. 裔癖11為- 3. 净莽-irri ·5. ΪΓΪ-6. ¾% - ooMiiL - 9.S2H1& - 0. sss^- 1. ^异铬- 2. 苺-«-|二11眾- 4.莽Φ -|>钤卜舶 f 1. -ri'ssse 2. ^is.3=vJk 陶3. ^-/1 ssg 4.3?-^ 5kutis势¢3 6.s^ l.-&sst.a% 4¾¾ 5.?H./S- 6.S 7.弇#垆荔 oo.lva^^- 1.¾•苕Fi? ^β -2.S 3.f»iA 4.1^2¾ 5.邮m 1 .E-N-Tsis' 2.&皂60势與· 3.萆孬60熱袅- 4.irr·'*. 5. Ί..Β - 6. 各丄〇-12-0辞公;袞 7. 甚障>斧6011^ 8.41MS - o.if/N-l-^f - 1. 身旖 6〇 iilHCT 爿π 2. 萆S-2-孬 Ilie 3. #、fu3rrJ 4. -&^4*ίφί' 1.玛資 2.S 3.降瘁 4a;il 5. ¾¾. 6. E-5 7.SSJ泠 8.Τ.ΒΨΪΨΪ [Β> 夺· ύ>'. η 耷 C5> 郎 择 -C ο* 茚 ο 貧 # _關 第108頁 1358540 五、發明說明(105) 枓亩 > 茶垚升畀it聆眾芽會汶聆洚溆s^ow街盂 澀(卡S亞) 苦(提克塔) 棟(卡固) 拉伐納) 酸(安拉) 糾(馬德明,Miidluii·) 1 + V·· + · + + $ + + 主要的元素 伐塔ΐ 皮塔與卡發4· 伐塔ΐ 皮塔與卡發丄 皮塔與伐塔t 卡發i 皮塔與卡發ΐ 1 伐塔丄 皮塔與卡發t _伐塔4> 卡發1s 伐塔與皮塔i 在都夏上的作用 W: 苦·的场蘆 艾索斐提達(Asoefctida),胡 椒,紅番椒,乾燥處理過的 金格(Zinger) 陲 跟望子,白脫牛奶,杖乳, 生芒果 荔爸t g奪 ^ίρ - 卡滿 J ^ S 9- 飲食的項目 | fa-r 何梨勒 (Temii丨ialia chcbula), 特米納里亞貝樂里卡 (Trcminalia Bcllcrica), 珍珠、 珊瑚 艾札德瑞克塔S迪卡1 (Azadiracta indica), 斯渥提亞其萊塔 (Svverlia cliiraita), 提諾斯坡拉扣狄佛里 亞 (Tinospora Cordifolin) 派坡 隆根 (Piper longum) 嫋 茵巴里卡歐菲欣納里 斯(Embalika oiTicinalis) 格里.¾海札拉伯拉 (Glyccrrhiza Glabra), 艾斯帕拉古斯拉总摩 希 斯 (Asparagus Raccmoscs),金 >赛ir^萃畀轵外彘头捽(扣3弈思奋it + sll«痒)客谇琦烊的33:谇均靼总涔Page 107 1358540 V. Description of invention (104) Treasures containing enamel and brazing (?-Art Xue bud Benz Ben 3莩121-:;; 1 for &0>'诤. MT^piHirisv^ 2. 癖11 is - 3. Net 莽 -irri · 5. ΪΓΪ-6. 3⁄4% - ooMiiL - 9.S2H1& - 0. sss^- 1. ^Isochrome - 2. Raspberry-«-|二十一众- 4.莽Φ -|> 钤 舶 f f 1. -ri'ssse 2. ^is.3=vJk 陶 3. ^-/1 ssg 4.3?-^ 5kutis ¢ 3 6.s^ l.-&sst .a% 43⁄43⁄4 5.?H./S- 6.S 7.弇#垆荔oo.lva^^- 1.3⁄4•苕Fi? ^β -2.S 3.f»iA 4.1^23⁄4 5. Mail m 1 .EN-Tsis' 2.& soap 60 potential and · 3.萆孬60 hot 袅 - 4.irr·'*. 5. Ί..Β - 6. 丄〇-12-0 ;衮7. Very difficult> Axe 6011^ 8.41MS - o.if/Nl-^f - 1. Body 6〇iilHCT 爿π 2. 萆S-2-孬Ilie 3. #,fu3rrJ 4. -&amp ;^4*ίφί' 1. Ma Zi 2.S 3. 瘁 4a; il 5. 3⁄43⁄4. 6. E-5 7.SSJ泠8.Τ.ΒΨΪΨΪ [Β>夺·ύ>'. η 耷C5&gt Lang choose-C ο* 茚ο Poor # _关第108页1358540 V. Invention description (105) 枓亩> Tea 垚 畀 聆 聆 聆 聆 聆 会 会 洚溆 洚溆 洚溆 ow ow ow ow ow ow ow ow ow 卡 卡 卡 卡 卡Asia) Bitter (Ticka) Building (Calgu) Lavalna) Acid (Allah) Correction (Ma Deming, Miidluii·) 1 + V·· + · + + $ + + The main element of the 伐塔ΐ Pita and Kafa 4· 伐塔ΐ Pita and Kafa 丄Pita with 塔塔t 卡发i Pita and Kafa ΐ 1 丄 丄 丄 与 与 卡 卡 卡 卡 4 卡 卡 卡 卡 卡 卡 卡 卡 卡 卡 卡 卡 卡 卡 卡 卡 卡 卡 卡 在 在 在 在 在 在 在 在 在 在 在 在 在 在 在 在 在 在 在 A A A A A A A A A ), pepper, red bell pepper, dried Ginger (Zinger) 陲 望 ,, 脱 脱 milk, squid milk, raw mango 荔 dad tg win ^ ίρ - card full J ^ S 9- diet items | fa- r Temii丨ialia chcbula, Trcminalia Bcllcrica, pearl, coral Azadiracta indica, Stytia yaleta Svverlia cliiraita), Tinospora Cordifolin Piper longum Embalika oiTicinalis Gry.3⁄4海扎拉拉拉 (Glyccrrhiza Glabra), Asparagus Raccmoscs, gold > 赛 ^ 畀轵 畀轵 畀轵 捽 捽 捽 捽 捽 捽 弈 弈 弈 弈 弈 弈 弈 弈 弈 弈 弈 弈 弈 弈 弈 弈) Off the insult Qi smelt 33: offend all dressed leather total cen

_1_画 第109頁 1358540 五、發明說明(106) 茲妇韋译眾芽;|2|;1备12-^60笤@苒因私^^3~-1:.^丨$莽笤|!1&0洚芹^知-%&&0苕^。 >780 650-780 595-650 580-595 560-580 500-560 490-560 | 480-490 435-480 380-435 <380 波長 nm 近紅外線 紅色 椏色 黃色 黃綠色 綠色 藍綠色 綠藍色 篮色 紫色 紫外光 顏色 (吸收自白色光) 藍綠色 綠藍色 藍色 紫色 紫紅色 紅色 位色 责色 黃綠色 被趾察的顏色(被傳送)或 互補的色彩* s s.. IBii_1_画第109页1358540 V. Invention description (106) Zifuwei translation of the bud;|2|;1 preparation 12-^60笤@苒因私^^3~-1:.^丨$莽笤| !1&0洚芹^知-%&&0苕^. >780 650-780 595-650 580-595 560-580 500-560 490-560 | 480-490 435-480 380-435 <380 Wavelength nm Near Infrared Red Twilight Yellow Yellow Green Green Blue Green Green Blue Basket color purple UV color (absorbed from white light) Blue green green blue blue purple purple red red color color yellow green toe color (transmitted) or complementary color * s s.. IBii

第110頁 1358540 五、發明說明(107) 淨" 稀釋 緩衝 (:02排泄 H4的吸收 CPS丰k -^Its"- Λ -"cps-^ -=1"--〇60洚- --UILS-沪 酸屮毒 正常 鹼+毒 死亡 第111頁 1358540Page 110 1358540 V. Description of invention (107) Net " Dilution buffer (: 02 excretion H4 absorption CPS abk -^It"- Λ -"cps-^ -=1"--〇60洚- -- UILS-Hua acid scorpion venom normal base + poison death page 111 1358540

五、發明說明([TMT 5备 Jss^s-^iu-saiL^iHrro-PLC) ^s-n^^^-r 射萍择 ^iuap^^s-lpLC) atBiuifL^^-ri.淬、β) p-^s-5 l"ss-iilh>--E-涔詗. 2. ^3^^^^--^ 茲-'-衮埘妄昤fe--vr7-s 今-r 3. -;n3-D^ar--> l-t—-^^^s^^r- ^ββ 4-ϋκίΓ, ~·ρ l.lsfs^铤 ϋ-^^-ί/;-si-buxit 筘氐 弘笛菡.Ηι-Β60··'>+ •33". ;*哞8^,7-^^窟 200,800 1^ES^--iuuo 洚-·^^;?; 呤赶一^帘孟斧落绔软洚^3-^5^ +。 •^^^sl®"1--'5*3芘芽 ^^^^''''"so-iJUSJirNtuwHO5 ^-· 5. s^T^^ill-s 洛 $t-&-a 笨&""珀* •^-:-丨-异-洛铱荽忘铒-Θ 糸 ii ("ta弈s^^s — jmils 粦薛弈3琴筘朵猝£岧-· l.ii-sa>铎 2-"涔涔茲绞 4n s宇"a if 筘 ai> ^^ti-gls^—f -.¾ · •-3--.^^. •-衾卜--坊汸芦 -.s却· 2,-3;-£we----Jls-tHi" ~别刼5菸邰?:功 (荈卡笨丨.^ iut^^^'-'-if^ifM2 •^^s---ii 菸片-^保三呙81-?,/,- -iui vh-rl-:lw 1 .s^3-tss 4^--3¾和斗--£/i^s忠/rp^Ar -3 •-泛条-汶-冷益泠3丨饮-奔薛妗阵坌-呦交琪呤今驽 -S袋鲜炉^因今窆^乂涔Y宮_L · •今笨菸5饮-s:0奔-^-^^^-g-/iKSJPEG-^--"^^-^^t-/A^^sid-f&ls。 4.鉍-冶汶-琛啉踣;宫--X1=Y2 -落葜功。 浼旮^34α-&Λυ Ait> S 拌敌-^孑萁-译。 ~科相拉"»刼功-今笨床甜宫泠古诔51--- s^岛片-菸决s-JU£"^4u/M5-?,)^ •^^όο^ϋ-功 3.射^5#;--功 •--呂-^年冷竺》^ 3 .^4鈐00-菸薛-抑&筇^冷耷-"士-'和斿>汶榷 •妗相私芪 s^fN-v^^^iiua^^tr^--fe^-^ 5.刼^60夯雜-功 ut-p-iilL^^'i-^ •爿^岭5^备识溶筘-异^艺今镖 3. 爿 4ws-iilB-^& 棼免'·'-"--'-'^^卜迕45 4. 矜相拉芪效^坤芑令笨穿甜^斧-鉍玄-'-·-"^-^^ -涔&'^孕菸齐SS >--^lu舟益-?';r-s。 si 第112頁 1358540 五、發明說明(109) 表格13:使用於藥物的特徵發展之參數 圖 编號 該植物的植物學名稱 植物的俗名 使用的部分 3-D參數* 正視圊 度數 旋轉 度數 29 麝香黃葵 (ABEL MOSCHUS MOSCHATUS MEDICUM) 卡斯圖里班達 (KASTURJ BENDA) 整株植物 20 15 30 刺槐 (ACACIA SUMA) 斯維申卡迪拉 (SWETHAKHADIRA) 樹皮 15 65 31 印度戗筧 (ACALYPHA INDICA) 庫坪塔 (KUPPINTA) 嫩葉 10 60 32 艾達托達瓦撒卡 (ADHATODA VASAKA) 瓦沙 (VASA) 葉子 25 45 33 鞭葉鐵線蕨 (ADIANTUM CAUDATUM) 馬由拉須凯 (MAYURASHIKHI) 葉子 20 40 34 臭樁細ί包花 (AILANTHUS EXCELSA) 艾拉盧 (ARALU) 莖 樹皮 10 65 35 菖蒲 (ACORUS CALAMUS) 瓦恰 (VACHA) 地下莖 10 130 36 韭蔥 (ALLIUM PORUM) 馬哈拉蘇納 (MAHALASUNA) 拉森 (LASS ΑΝ). Λ 的單獨鱗莖 20 130 37 大蒜 (ALLIUM SATIVAM) 拉蘇納 (LASUNA) ‘拉森, 小鱗莖 20 130 38 南薑 (ALPINIA GALANGA) 較大的薑科植物 (GREATER GALANGA) 地下莖 20 75 39 南良薑 (ALPINIA OFFIdNARUM) 較小的薑科植物 (LESSER GALANGA) 地下莖 15 75 40 月桃 (ALPrNIA SPECIOSA) 較輕的薑科植物 (LIGHTER GALANGA) 地下莖 10 60 41 檳榔 (ARECA CATECHU) 荖葉果 (BEETLE NUT) 未加工的果 實, 堅果 15 40 42 枝榔 荖葉果 已加工的 15 40 43 艾瑞卡卡提 (ARECA KATEEH) 拉克沙卡迪拉 (RAKTHA KHADIRA) 果實堅果 莖皮 15 65 Η 第113頁 1358540 44 山金車 (ARNICA) 山金車 整株植物 10 55 45 假馬齒莧 (BACOPA MONNIERI) 布拉彌 (BRAHMI) 整株草本植 物 15 45 46 針緣葉小薜 (BERBERIS ARISTATA) 達蘆哈里德拉 (DARUHARIDRA) 根皮 15 170 47 柏爾海維亞迪富撒 (BORRHIEVIA DIFFUSA) 普納爾納瓦 (PLTNARNAVA) 整株植物 15 55 48 蕃椒 (CAPSCICUM ANNUM L) 莫奇 (MIRCH) 大的,.剝開 的果實. 10 70 49 蕃椒 莫奇 大的,未剝 開的果實 10 70 50 蕃椒 莫奇 小的*未剝 開的果實 10 70 51 扣西妮恩芬尼斯特拉提恩 (COSCINIUM FENESTRATIUM) 拉塔達爾維 (LATA DARVI) I皮 15 125 52 扣西妮恩葛蘭迪斯 (COCCINIDIUM GRANDIS) 東達 (DONDA) 根及葉子 25 30 53 竹目草(直立的) DACTLYLACTINIUM AEGYPTIUM(ERECT) 葛拉斯 (GRASS) 葉子 25 40 54 竹目草(匐匐的) (PROSTRATE) 葛拉斯 葉子 25 40 55 德里斯塔其斯吸納拉里亞 (DIRISTACHIS CINERARIA) 圖瑞 (TUMMA) 葉子及樹皮 20 15 56 茵巴里卡歐菲欣納里 斯 艾馬拉其 (AMALAKI) 果實外果皮 5 50 57 美容潔膚膏 (FACE PACK) 商標1 配方 20 25 58 美容潔膚膏 商標2 配方 20 25 59 格里瑟欣亞格拉伯拉 (GLYCERRHZIA GLABRA) 亞須提馬德胡 (YASHTI MADHU) 根皮 15 130 60 格里瑟欣亞格拉伯拉 亞須提馬德胡 粉末 15 130 61 金納瑪西佑維斯特拉 (GYMNEMA SYLVESTRAE) 波達帕特里 (PODAPATRI) 整株植物 25 15 62 侯勒羅納安提迪森特里卡 (HOLLERONA ANTIDYSENTRICA) 庫塔加 (KUTAJA) 莖皮 10 60 圖_隱1 第114頁 1358540 63 Μ奴拉瑞西莫撒 (INNULA RECEMOSA) 普卡喇姆拉 (PUSHKARAMUL A) 根 5 45 64 黃玉蘭 (MICHELLIA CHAMPAKA) 瑪奴綺潘加 (MANU SAMPENGA) a*· 化 20 40 65 辣木 (MORINGA OLIFERA) 姆那加 (MUNAGA) 葉子 25 40 66 蠟香桃木 (MYRICA CEREFERA) 月桂樹漿果 (BAY BERRY) 果實及種子 20 35 67. 納海艾克希拉 CNAHI AXILLAE) 納海 (NAHI) 整株植物 10 130 68 木蝴蝶 (OROXYLUM INDICUM) 息歐納卡 (SYONAKA) 莖皮 10 170 69 聖羅勒 (OCIMUM SANCTUM) 拉瑪圖拉希 (RAMA TULASI) 葉子 15 130 70 普蘆恰藍西歐拉塔 (PLUCHEA LANCEOLATA) 帕特拉拉斯納 (PATRA RASNA) 葉子 10 65 71 胡黃連 (PICRORRHIZA KURROH) 卡圖其蘿海妮 (KATUKI ROHINI) 莖皮 15 125 72 筠醬 (PIPER BEETLE) 荖葉 (BEETLE) 葉子 25 160 73 索拉里亞扣里黎佛黎 亞 (PSORALIA CORILIFOLIA) 巴庫其 (BAKUCHI) 種子 25 60 74 大菜 (RAPHANUS SATIVUS) 木蘭吉,白色 (MULLANGI,WHITE) 葉子 15 25 75 ϋ麻 (RICINUS CUMMUNIS) 伊藍達木拉 (ERANDA MULA) 根 10 135 76 ' 茜草 (RUBIA CORDIFOLIA) 曼吉斯塔 (MANJISTA) 莖,根 10 40 77 雲香木 (SAUSSREA LAPPA) 苦須塔 (KUSHTA) 根 5 80 78 斯芬蘭瑟斯茵迪庫斯 (SPHERANTHUS INDICUS) 夢迪 (MUNDI) 整株草本植物 15 70 111 第115頁 1358540 五、發明說明(112) 79 信普罹庫斯拉希莫瑟斯 (SYMPLOCUS RACEMOSUS) 龍德拉 (LODHRA) 莖皮 15 65 80 訶梨勒 (TERMiNALIA CHEBULA) 哈里塔其 (HARITAKI) 果實 10 40 81 川楝 (TERMiNALIA BELLERICA) 維海塔其 (VIBHITAKI) 果實 20 35 82 葫蘆巴 (TRIGONELLA FAENUM G.) 曼席 (MENTHI) 整株植物 15 160 83 蒺祭 (TRIBULUS TERRESTRIAS) 鉤徐拉 (GOSHURA) 莖與根 25 45 84 泰洛否拉艾斯馬提卡 (TYLOPHORA ASTHMATICA) 葉子 10 65 85 莢迷 (VIBURNUM) 染料來源 相似的藥物 20 15 86 維欣尼亞聳妮菲拉 (WITHINIA SOMNIFERA) 艾斯瓦干達 (ASWAGANDHA) 根 5 50 87 金極柏爾歐菲欣納里斯 (ZINZIBER OFFIONAUS) 孫提 (SHUNTI) 加工後的金 格,地下莖 15 130 88 艾墨帕塔卡拉雀爾那 阿祐®惟達 配方 粉末 25 60 89 卡瑪讀各 (KAMADUGA) 席德哈 配方 粉末 10 25 90 庫馬拉雅撒發 經過發酵過程的 阿祐爾惟達藥物 液體 10 35 91 馬哈拉克須米維拉斯 瑞斯 席德哈 配方 粉末 20 35 92 蘇瓦爾納悠格拉加 古咕盧 席德哈 配方 粉末 10 40 波長範圍,吸收值大小及滯留時間的所有其他參數顯示於個別的圊中。 画_1關 第116頁 1358540 五、發明說明(113) 0^ 雜 ^ fr 辟抅 a» m S S =t私 铲A §1*3 ^ 1W $ ^ < a» > 7S > . 门淤 >泠 2S σ η > 庫馬拉雅撒發 (KUMARAYASAVA) 卡瑪讀各 3 r~ ^ > HS % ^ > κ 穴老1 o S Ο ς«* 2寐 =爸 安南德伯海拉維 (ANANDABHAIRAVI) 印度鐵莧 1 艾墨帕塔卡拉雀爾那 該植物的植物學名稱 草本的破物 艾修卡 (ASHOICA) 發酵過程 Έ3Λ 斐藍这斯憂里納 里亞 (PHYLLANTHUS URINARIA) 草本的破物 草本的礦物 (HIZRBOMINERAL) 哈里塔曼佳里 (HARITA MANJARI) 阿祐Μ惟達的 1 配方 植物的俗名 % 婦科疾病 婦科疾病, 黃殖病 消化性潰瘍 黃-应病 肝臟疾病, 皮廣病 3. ^- 通便的, 消化性潰瘍, 痔疥 4- <- <r- <r~ <- <- <- 都夏赫拉 (平定在其上的混亂) cF> 薛 4 整株草本植物 ρ 邾 屮 使用的部分 ♦V. Description of the invention ([TMT 5 preparation Jss^s-^iu-saiL^iHrro-PLC) ^sn^^^-r 射萍择^iuap^^s-lpLC) atBiuifL^^-ri. quenching, β) P-^s-5 l"ss-iilh>--E-涔詗. 2. ^3^^^^--^ 兹-'-衮埘妄昤fe--vr7-s 今-r 3. - ;n3-D^ar--> lt--^^^s^^r- ^ββ 4-ϋκίΓ, ~·ρ l.lsfs^铤ϋ-^^-ί/;-si-buxit笛菡.Ηι-Β60··'>+ •33". ;*哞8^,7-^^ Cave 200,800 1^ES^--iuuo 洚-·^^;?; 呤 一一^帘孟斧绔 绔 soft 洚 ^ 3- ^ 5 ^ +. •^^^sl®"1--'5*3芘芽^^^^^'''"so-iJUSJirNtuwHO5 ^-· 5. s^T^^ill-s Luo $t-&- a stupid &""" 珀* •^-:-丨- 异-洛铱荽忘铒-Θ 糸ii ("塔弈s^^^s — jmils 粦薛弈3琴筘朵猝£岧- · l.ii-sa>铎2-"涔涔兹绞4n s宇"a if 筘ai> ^^ti-gls^-f -.3⁄4 · •-3--.^^. •-衾卜-坊汸芦-.s but · 2,-3;-£we----Jls-tHi" ~Do not 刼5烟邰?:功(荈卡丨丨.^ iut^^^'-'- If^ifM2 •^^s---ii 烟片-^保三呙81-?,/,- -iui vh-rl-:lw 1 .s^3-tss 4^--33⁄4 and bucket--£ /i^s忠/rp^Ar -3 •-Fan-Wen-Lengyi泠3丨饮-奔薛妗妗-呦交琪呤今驽-S bag fresh furnace^因今窆^乂涔Y宫_L · • This stupid smoke 5 drink-s: 0 奔-^-^^^-g-/iKSJPEG-^--"^^-^^t-/A^^sid-f&ls. 4 .铋- 冶汶-琛琛踣; Palace--X1=Y2 - 葜 葜. 浼旮^34α-&Λυ Ait> S mixed with enemy-^孑萁-translation. ~科相拉"»刼功- Today's bed sweet palace 泠古诔51--- s^ island film - smoke s-JU£"^4u/M5-?,)^ •^^όο^ϋ-gong3.射^5#; --功•--吕-^年冷竺》^ 3 .^4钤00-烟薛-抑&筇^冷-"士-'和斿>汶榷•妗相私芪s^fN-v^^^iiua^^tr^--fe^-^ 5.刼^60夯-- ut-p-iilL ^^'i-^ •爿^岭5^ Ready to dissolve 异-Different ^Art Today Dart 3. 爿4ws-iilB-^&棼免'·'-"--'-'^^卜迕45 4. 矜相拉芪效^坤芑令笨穿甜^斧-铋玄-'-·-"^-^^ -涔&'^孕烟齐 SS >--^lu Zhou Yi-? ';rs. si Page 112 1358540 V. Description of the invention (109) Table 13: Parameter drawing for the development of the characteristics of the drug. Number of the plant's botanical name. Part of the 3-D parameter used by the common name of the plant. Rotation degree 29 ABEL MOSCHUS MOSCHATUS MEDICUM KASTURJ BENDA Whole plant 20 15 30 Hedgehog (ACACIA SUMA) SWETHAKHADIRA Bark 15 65 31 Indian 戗笕 ( ACALYPHA INDICA) Kuppinta (KUPPINTA) Young leaves 10 60 32 ADHATODA VASAKA Vasa (VASA) Leaves 25 45 33 ADIANTUM CAUDATUM MAYURASHIKHI Leaves 20 40 34 Smelly Pile Fine 包 包 (AILANTHUS EXCELSA) 艾拉卢 (ARALU) Stem Bark 10 65 35 ACORUS CALAMUS VACHA Underground stem 10 130 36 Allium PORUM MAHALASUNA Larsen (LASS ΑΝ). 单独 Individual bulbs 20 130 37 Garlic (ALLIUM SATIVAM) LASUNA 'Lasen, small bulb 20 130 38 South Ginger (ALPINIA GALANGA) Large Ginger plant (GREATER GALANGA) Underground stem 20 75 39 South Ginger (ALPINIA OFFIdNARUM) Smaller Zingiberaceae (LESSER GALANGA) Underground stem 15 75 40 Apricot (ALPrNIA SPECIOSA) Lighter Ginger plant (LIGHTER GALANGA) Underground stem 10 60 41 Areca (ARECA CATECHU) BEETLE NUT Unprocessed fruit, nut 15 40 42 Leaf fruit processed 15 40 43 ARECA KATEEH RAKTHA KHADIRA Fruit nut bark 15 65 Η Page 113 1358540 44 Arnica Arnica whole plant 10 55 45 BACOPA MONNIERI BRAHMI Whole plant 15 45 46 BERBERIS ARISTATA DARUHARIDRA Root bark 15 170 47 Berhaivi Yadi Fusa (BO RRHIEVIA DIFFUSA) PRNANARNAVA Whole plant 15 55 48 CAPSCICUM ANNUM L Mohi (MIRCH) Large, peeling fruit. 10 70 49 Fan Moqi big, unpeeled Open fruit 10 70 50 Bell pepper Mochi small * Unstripped fruit 10 70 51 Cousin Nirvana FENESTRATIUM LATA DARVI I skin 15 125 52 buckle West COCCINIDIUM GRANDIS DONDA Roots and Leaves 25 30 53 Bamboo Grass (Upright) DACTLYLACTINIUM AEGYPTIUM (ERECT) GRASS Leaves 25 40 54 Bamboo Grass (匐匐的(PROSTRATE) Glas leaves 25 40 55 Dristachis CINERARIA TUMMA Leaves and bark 20 15 56 Inbarrica Ou Fahinaris Amarama (AMALAKI) Fruit Exocarp 5 50 57 Beauty Cleansing Cream (FACE PACK) Trademark 1 Formula 20 25 58 Beauty Cleansing Cream Trademark 2 Formulation 20 25 59 Glycyr HZRA GLABRA Yasiti Madhu (YASHTI MADHU) Roots 15 130 60 Grischenya Graber Yasiti Madhu powder 15 130 61 GYMNEMA SYLVESTRAE PODAPATRI Whole plant 25 15 62 HOLLERONA ANTIDYSENTRICA ) KUTAJA Stem skin 10 60 Figure _ hidden 1 Page 114 1358540 63 INNULA RECEMOSA PUSHKARAMUL A Root 5 45 64 MICHELLIA CHAMPAKA MANU SAMPENGA a*·化20 40 65 MORINGA OLIFERA MUNAGA leaves 25 40 66 MYRICA CEREFERA Laurel berry (BAY BERRY) Fruits and seeds 20 35 67. NAHAI All-in-one (NAHI) Whole plant 10 130 68 Wood butterfly (OROXYLUM INDICUM) SYONAKA Stem skin 10 170 69 OCIMUM SANCTUM Ramatuura (RAMA TULASI) Leaves 15 130 70 PLUCHEA LANCEOLATA PATRA RASNA Leaves 10 65 71 PICRORRHIZA KURROH KATUKI ROHINI Stem 15 125 72 PER ( (PIPER BEETLE) 荖 leaf (BEETLE) Leaf 25 160 73 PSORALIA CORILIFOLIA BAKUCHI Seed 25 60 74 Large dish (RAPHANUS SATIVUS) Mulanji, white (MULLANGI, WHITE) Leaves 15 25 75 ϋ RICINUS CUMMUNIS ERANDA MULA Root 10 135 76 'RUBIA CORDIFOLIA MANJISTA Stem, root 10 40 77 SAUSSREA LAPPA Bitter Tree Tower (KUSHTA) Root 5 80 78 SPHERANTHUS INDICUS MUNDI Whole plant 15 70 111 Page 115 1358540 V. INSTRUCTIONS (112) 79 信普罹库斯拉希莫瑟斯SYMPLOCUS RACEMOSUS) LODHRA Bark 15 65 80 TERMiNALIA CHEBULA HARITAKI Fruit 10 40 81 TERMiNALIA BELLERICA VIBHITAKI Fruit 20 35 82 Fenugreek (TRIGONELLA FAENUM G.) 曼HI (MENTHI) whole plant 15 160 83 蒺 ( (TRIBULUS TERRESTRIAS) 钩 徐拉 (GOSHURA) stem and root 25 45 84 Tylophhora ASTHMATICA leaves 10 65 85 pod fans (VIBURN UM) Drugs with similar sources of dyes 20 15 86 WITHINIA SOMNIFERA ASWAGANDHA Root 5 50 87 ZINZIBER OFFIONAUS Sun Ti ( SHUNTI) Processed Ginger, underground stem 15 130 88 Emerpata Karajerna Ayou® Weida Formula Powder 25 60 89 KamaduGA Sidha Formula Powder 10 25 90 Kumaraasa Ajurda Pharmaceutical Liquid 10 35 91 Maharac Mustavilis Sidha Formula Powder 20 35 92 Suvarna Ugraga Gulu Lusedha Formula Powder 10 40 wavelength range, All other parameters of the magnitude of the absorption and the residence time are shown in the individual enthalpy. Painting_1关第116页1358540 V. Invention description (113) 0^ Miscellaneous ^ fr 抅 a» m SS =t private shovel A §1*3 ^ 1W $ ^ < a» > 7S >.淤>泠2S σ η > KUMARAYASAVA Kama reading each 3 r~ ^ > HS % ^ > κ hole old 1 o S Ο ς«* 2寐= dad Annander ANANDABHAIRAVI Indian shovel 1 Ai Mopata Karajal The botanical name of the plant Herbaceous ruptures Ashioka (ASHOICA) Fermentation process Έ 3Λ Philippine Blue PHYLLANTHUS URINARIA Herb HIZRBOMINERAL HARITA MANJARI A common name for a formula plant of Ayou Μ 达 % gynecological diseases gynecological diseases, yellow sputum peptic ulcer yellow - should be sick liver disease, skin wide Disease 3. ^- laxative, peptic ulcer, 痔疥4- <- <r- <r~ <- <- <- Ducha Hera (confidence on it) cF&gt ; Xue 4 whole plant herb ρ 邾屮 part of the use ♦

II1I11I 第117頁 1358540 五、發明說明(114) --^^^^- ^si (Hmlsnus AIBIEr MOS.1US) -1¾ (CHOPACH1NYAD1 OHURMAM) =&".&^恝疟耷 脖·够 (>D1OD> v>SIn>)II1I11I Page 117 1358540 V. Invention description (114) --^^^^- ^si (Hmlsnus AIBIEr MOS.1US) -13⁄4 (CHOPACH1NYAD1 OHURMAM) =&".&^恝 malaria neck enough >D1OD>v>SIn>)

Stsrt04i,i—A*fs>s (ASPARAGUS ADlmSOElzDlE'zTUM) Α·--υ-- (LATA ICASTi) .^s J,i>s 6¾ 士丨画-钵 (KATUVEER.A) 专-^斗^食 ^^钵弈澄 s (SAFE) MUSArl) si蝌溢為钥y;5 略贫^^ {-hcsllma roga, pricha), &^癖=,時"^澄 (panduroga, _Rasayalla) "负, -"- ---熱袅 ^Jfp #r^i1t (swwsa)Stsrt04i,i-A*fs>s (ASPARAGUS ADlmSOElzDlE'zTUM) Α·--υ-- (LATA ICASTi) .^s J,i>s 63⁄4 士丨画-钵(KATUVEER.A) 专-^斗^ Food ^^钵弈澄s (SAFE) MUSArl) si蝌 is the key y; 5 slightly poor ^^ {-hcsllma roga, pricha), &^癖=, when"^澄(panduroga, _Rasayalla) " Negative, -"- ---热袅^Jfp #r^i1t (swwsa)

4^s#urJ -,-60^¾ -"备屮 -1-^ s^rss 、M4^ - ,t4^s#urJ -, -60^3⁄4 -"Ready -1-^ s^rss, M4^ - ,t

圓··I 第118頁 1358540 明 說 明 發 、 五 *R £3} 柏里哈特瓦塔勤塔馬尼+ 斯瓦爾納馬克須坎 (URIIIATVATACHINTAMAN] + SWAUNAMAKSHKAM) 7^ 銶 (VDI1V1A1VH1SV VnOHdOlAl) 〇 •Χΐ. •ψν 特 > 7P P- S & 普納爾納瓦 (PUNARNAVA) £ 芽 fr S 芽 η έ 銶 % > c> 艾f德衛徐 (AJADWBSHI) c> I a> s 、、、 莫卡,白色的 (MULKA, WHITE) Μ > a> I m ·§ί =¾ 與 Γώ % S知 孬寄 s韌 揉激 ίΜ * 洚 S 糖尿病,咳嗽、政府宣 導的疾病(g.i.tract disorders),纽特拉修 提扣斯(ncut-racculicals) Φ成 4AA. + 产1 耔耷 >«. v?-l r» — <- <— <- <- <— <r~ <- — <- <- <r- 莽 M jet Ά lei w. ~A vi^k r,r 屮 餡 sj* a> 3Ε(* 屮 \lAk 屮 %圆··I Page 118 1358540 Explain the hair, five *R £3} Berri Hatvata Talmani + Svarnamark Skankan (URIIIATVATACHINTAMAN) + SWAUNAMAKSHKAM) 7^ 銶 (VDI1V1A1VH1SV VnOHdOlAl) 〇• Χΐ. •ψν特> 7P P-S &Punnarnava (PUNARNAVA) £ buds fr S η έ 銶 &% >c> Ai Wei Dewei Xu (AJADWBSHI) c> I a> s , , Mocha, white (MULKA, WHITE) Μ >a> I m ·§ί =3⁄4 with Γώ % S 孬 s 揉 揉 揉 Μ Μ Disorders), ncut-racculicals Φ into 4AA. + production 1 耔耷>«. v?-lr» — <- <- <- <- <- &lt ;r~ <- — <- <- <r- 莽M jet Ά lei w. ~A vi^kr,r 屮Stuffing sj* a> 3Ε(* 屮\lAk 屮 %

1丨麗__匪 第119頁 1358540 五、發明說明(116) (C1TRULLUSnolbsYNTms) ^猝端、 mp^^s (AZAR1D1CTA IND1CA) ¾¾ ίπ&·£ίί1σ> s (ΛΟΛ01Λ OATECHU) (V>T> GAJANKUSA RAS) ^JLS^ii-isri-ii-a-i—ct· 、一 1^|0!弟鋅§ (SHISi) ^ΙιΗ1ϊίϊ42!ρ·ΛΟ α& ^♦与耷^霉扣驽 (R1QNUS 0OMMUZ1S) 硌辟^热&殍锌^. {i.l>Y〇G>RAJ> GUGGUlr-u) 圣章痒与 euthasaza)1丨丽__匪第119页1358540 V. Invention description (116) (C1TRULLUSnolbsYNTms) ^猝, mp^^s (AZAR1D1CTA IND1CA) 3⁄43⁄4 ίπ&·£ίί1σ> s (ΛΟΛ01Λ OATECHU) (V>T> GAJANKUSA RAS) ^JLS^ii-isri-ii-ai-ct· , 1^||0! 锌 § (SHISi) ^ΙιΗ1ϊίϊ42!ρ·ΛΟ α& ^♦ and 耷^ mold buckle 驽 (R1QNUS 0OMMUZ1S) ^热&殍Zn^. {i.l>Y〇G>RAJ> GUGGUlr-u) St. Zhang itching and euthasaza)

Bi^itK.^离 .(INDRAVApoi) {N1MB> ^^>4丨 (KRAMUKA) ΘΕΑ 料^^^^隹 (RA— Kl.lll> Μ·£ί ^^•ss# ^ί si^ ulRiii>钵 (ER>ZD> MCrA) s4$^i一耷垄 8&单ερ &.ISP, 薪^p, 1¾.¾¾Bi^itK.^从.(INDRAVApoi) {N1MB>^^>4丨(KRAMUKA) ^料^^^^隹(RA- Kl.lll> Μ·£ί ^^•ss# ^ί si^ ulRiii&gt ;钵(ER>ZD> MCrA) s4$^i 耷 88&single ερ &.ISP, salary^p, 13⁄4.3⁄43⁄4

sn=ssiv#J ^•ssy^^^m s $Sn=ssiv#J ^•ssy^^^m s $

Japsv 4 <- <- *s-ssi44^·^ β^, 陴所,^¾)¾ se.^ s K.NI/ K..VI/ 第120頁Japsv 4 <- <- *s-ssi44^·^ β^, 陴所,^3⁄4)3⁄4 se.^ s K.NI/ K..VI/ Page 120

J 1358540 五、發明說明(117) 索拉里亞扣里黎佛黎亞| 侯勒羅納 安提辿森特里卡 I 侯勒羅納 安提辿森特里卡 蒲桃 | (EUGENIA JAMBOLONA 1 SIZYG1UMCUMINI) 竹目草(匍匐與直立的) 桫金 扣西规恩芬尼斯特拉提恩 设金 锻金 (CURCUMA LONGA) 巴庠其 受古斯塔 庫路加 庫塔加 將布 (JAMBU) 禾本科植物 (GRASS) j 哈里德拉 ! (HARIDRA) 1 拉塔達爾維 .啉 ..淖 薑黃 白病, 皮膚病 皮膚病 白J&L病 血液淨化器 腹裘, 所有政府宣導的疾病i 腹温, 搏 喂吐,糖尿病, 痢疾 利尿劑, 改善膚色 S (¾ 5 ^ ^ 糖尿病, 肥胖, 皮膚病 - ±浒 i浐 (J 2¾ 4- <r- <- <- <- <— <- <- <- <- <- — <- — <- 種+,揸子油 莖,根· ρ诗 ;ί>血 S # 取自安it拉.普拉 得須(ANDHItA PREADESH)的莖 -皮· 果實丨 整株植物 葉子·· 生的地下莖 1_:_:_ :S. -^ UJ 商業的粉末-2 商業的粉末-1 _繼匯1 第121頁 1358540 五、發明說明(118) 卡發伐塔赫拉 睇 辣木 黃玉iVi 艾格妮也迪納 (AGNITUNDINA) 蘆薈 (ALOEVERA) £ii 斯芬關迖斯茁迪庫斯 灰木 (SYMPLOCOS RACEMOSA) 胡黃速 納加瓦里 (NAGA VALLI) 辛甚苽 (SIGRU) 全帕卡 (CHAMPAKA) 配方 庫瑪里 (KUMAR1) 瓦恰 夢迪 隆德拉 (LODHRA) 曼席卡 (METHIKA) 卡圆其敌海妮 卡撒,斯瓦撒, 消化系統的疾病 膿瘡,水肢 化妝品, 皮廣病 消化不良, 皮膚病 婦科疾病, 肝癌(hepatomegaly), 脾臟癌(splccno megalyX 燒傷,子宮的疾病 氣1 s>| 答 Η CB &衣弈 I |· 私《3* 3·· 乒 | 出‘的疾病,股满, 痢疾 糖展病,急腹痛 瀉藥 肝臟疾病 -> —> <- 4- <- <- <- — <- <- <— <- <- <- <- <- <Γ- 4- 來自海庠的安德 拉 普拉得須之葉子 葉子 配方 葉子,葉子的汁 地下莖 整株草本杭物 樹皮 整株草本也物 .筠 1_画1111 第.122頁 1358540 五、發明說明(119) 肯恰納拉 咕古盧 (KANCHANARA GUGGULU) 茵妮扣斯坦妮瑪 艾克希拉 (ENICOSTEMMA AXILLAE) 迪充羅斯塔其斯辛那拉 (DICROSTACI-IYS CINERA) ψ 安南德伯海拉維 艾卡希亞速瑪 草本的 配方 1 1 納海 維拉塔蘆,固瑪 (VE12RATARU, TUMMA) 布拉彌 草本的礦物 斯維巾卡迪拉 炎症性的疾病 瘧疾 何里迪亞(Hiidya), 肥胖 梅德海亞,皮膚病 普拉馬哈 <— — <r~ <— <— —> <- <r~ <r- <- 配方 整株草本植物 m子及樹皮 整株草本植物 配方 两·J 1358540 V. INSTRUCTIONS INSTRUCTIONS (117) Solaria de Liferia | Houlerona Antiche Sentrika I Houlerona Antiche Sentrika Rose | (EUGENIA JAMBOLONA 1 SIZYG1UMCUMINI) Bamboo grass (匍匐 and erect) 桫金扣西规恩芬尼斯特拉蒂恩金金锻金(CURCUMA LONGA) 巴庠其由古斯塔库路加库塔加布 (JAMBU) 禾Undergraduate Plant (GRASS) j Harry Della! (HARIDRA) 1 Latadarvi.. 淖 姜黄白病, Dermatological skin disease White J&L disease blood purifier abdominal cramps, all government-sponsored diseases i Abdominal temperature, vomiting, diabetes, dysentery and diuresis Agent, improve skin tone S (3⁄4 5 ^ ^ diabetes, obesity, skin disease - ±浒i浐(J 23⁄4 4- <r- <- <- <- <- <- <- < - <- <- — <- — <- species +, scorpion oil stem, root · ρ poetry; ί> blood S # taken from the stem of ANDHItA PREADESH Peel fruit 丨 whole plant leaves · raw underground stem 1_:_:_ :S. -^ UJ Commercial powder-2 Commercial powder-1 _ 继汇1 Page 121 1358540 V. Invention description (118) Card发 塔 塔 赫 i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA ) SIGRU (CHAMPAKA) Formula Kumali (KUMAR1) Vacha Dream Dillondra (LODHRA) Mansika (METHIKA) card round its enemy Henika Kas, Vassar, digestive system diseases, abscesses, water and limb cosmetics, skin diseases, indigestion, skin diseases, gynecological diseases, liver cancer (hepatomegaly), spleen cancer (splccno megalyX burns, uterus disease gas 1 s)| answer A CB & Yi Yi I |· Private "3* 3·· Ping Pong | Out of the disease, stocks full, dysentery sugar disease, acute abdominal pain laxative liver disease -> -> <- 4- <- <- &lt ;-- <- <- <- <- <- <- <- <- <Γ- 4- From the leaves of Anda Pradesh The juice of the leaves, the whole stem, the whole plant, the herb, the bark, the whole plant, and the herb. 筠 1_画1111 第.122 页1358540 V. Invention description (119) KANCHANARA GUGGULU 茵妮扣斯坦妮玛ENICOSTEMMA AXILLAE DICROSTACI-IYS CINERA ψ Annan De Bohai Lavi Acacia Syma Herb Formula 1 1 Nahai Villatalu, Guma ( VE12RATARU, TUMMA) Brami Herb Minerals Swede Cadillac Inflammatory Disease Malaria Heli Hiidya, Obesity Medhaia, Skin Disease Pramaha<-<r~<- <--><-<r~<r-<- Formulation Herbaceous plant m and bark whole plant herb formula

^ S 1 桊洛否拉艾斯馬提卡 特里卡圓秋納GH-3 (TRIKATU CIIUKNA GH-3) 特里卡圓秋納SP-2 (TRIKATU CHURNA SP-2) 特里卡圃秋納-1 (TRIKATU CHURNA-1) 艾甲德紐 鉤徐拉 单木的 配方 萆木的 配方 萆本的 配方 納加瓦里 糖旅病,哮喘 泌床系統的痕痛, 水腫 消化不良 消化不良 • 1 消化不良 卡撒,斯瓦撒, 消化系統的疾病 —> <— <- <— 4r- — <— — — <— — I» Γ4 5J肆 屮 $ llllill 第123頁 1358540 五、發明說明(120) 、J';®.(0N10NSM>F) >»-«·-£3;.οΝ10Ν BIG) -ι:—®φ^ϋ 拉鸯 (KARPURAD1 RAS)^ S 1 桊洛拉拉艾斯马提卡特里卡圆秋纳GH-3 (TRIKATU CIIUKNA GH-3) 特里卡圆秋纳 SP-2 (TRIKATU CHURNA SP-2) Trika 圃chuna - 1 (TRIKATU CHURNA-1) Formulation of Acacia de Nubola Xula single wood formula of eucalyptus 萆 的 纳 纳 纳 纳 纳 纳 纳 纳 纳 , , , , , , , , , , , , , , , • • • • • • • • • • • • Bad Caesar, Swassa, Digestive Diseases -> <- <- <- 4r- — <- — — <- — I» Γ4 5J肆屮$ llllill Page 123 1358540 V. DESCRIPTION OF THE INVENTION (120), J';®.(0N10NSM>F) >»-«·-£3;.οΝ10Ν BIG) -ι:—®φ^ϋ 拉鸯 (KARPURAD1 RAS)

Ets:^^殍 JM^^SS (E2BLo> OFF】CINALls) (ocnnUUGo ORnHlolDES) es:^呤&耷 (ASPARAGUS ABSOENDEZSPS) 爸;#衣拉 -s-hs农拉 3:卸谇 ®ϋ/5. (PALANDU) 姑>60各芽 嘀鉍命专萚sr (HAEMORRHOID_^_ (ΑΜΑΓ-ΛΚ1) KALI 2CSAL1 妝冷筘ίιΜρ·(icl.l, KATIVEERA) sstv.-'>痒阵 (SWETHA MUSAU) ±5S, ^.掛茄, 蛘^1¾¾ % β,Μ a-airfrw, 蛑^防签 ^4-22:-|-雜40鸯Ets:^^殍JM^^SS (E2BLo> OFF) CINALls) (ocnnUUGo ORnHlolDES) es:^呤&耷(ASPARAGUS ABSOENDEZSPS) Dad;#衣拉-s-hsNongla 3: Unloading®ϋ/5 (PALANDU) 姑>60 buds dedicated to sr (HAEMORRHOID_^_ (ΑΜΑΓ-ΛΚ1) KALI 2CSAL1 makeup cold 筘ίιΜρ·(icl.l, KATIVEERA) sstv.-'> itch array (SWETHA MUSAU ) ±5S, ^. Hanging eggplant, 蛘^13⁄43⁄4 % β, Μ a-airfrw, 蛑^防签^4-22:-|-杂40鸯

Ji$rK-i,ss^-3rr 木蝴蝶 ,ϋ欧納卡 水腫 消化系統的疾病 4- 4-Ji$rK-i,ss^-3rr Wood Butterfly, ϋOnaka edema Digestive diseases 4- 4-

S 8¾ se.^· 亩 圓_ϋ 第124頁 1358540 五、發明說明(121) 相似的藥物 添加物 蠟香桃木. 蠟香桃木 山金車 苹本洗頭粉(13) 萃本洗頭粉(G) 美容潔膚骨〇3) 美容潆膚膏(G) 維欣尼亞 (WITHINIAPUB.) 染料來源 月桂乾果仁 月桂乾果仁 艾斯瓦干達紅色植 子植物的根 (ASWAGANDHA RED SEEDS PLANT ROOT) 婦科的疾病 肝臟的保護 肝臟的保護 在傷害的影響之後解 除痛苦 役雜以發沿劑 沒有發现發泡劑 缺乏一些重要的成分如琢 须峪(收塞里亞拉帕) (kushta) (sausscrea lappa)及 交古斯嗒(如比亞扣狄邠 里亞)(manjista) (rubia cordifolia),造成该66方的, 效用較差 功效充分的 一般的袞弱,回春 <- 相似的藥物 相似的顏料來源商 標-2 相似的顏料來源 商標-1 相似的顏料來源 S己方 配方 配方 配方 7=S 83⁄4 se.^· 亩圆_ϋ Page 124 1358540 V. Description of invention (121) Similar drug additives waxy mahogany. Wax scented mahogany jinjinping this shampoo powder (13) extract shampoo powder ( G) Beauty Cleansing Bones 3) Beauty Skin Cream (G) WITHINIAPUB. Dye Source Laurel Dried Nuts Laurel Dried Nuts Aesva Ganda Red Plant Roots (ASWAGANDHA RED SEEDS PLANT ROOT) Gynecological diseases The protection of the liver The protection of the liver after the effects of the injury relieves the pain of the miscellaneous to the hair agent. No foaming agent is found to lack some important ingredients such as the scorpion scorpion (sedria) (kushta) (sausscrea) Lappa) and the genus genus (such as jibia) (rubia cordifolia), causing the 66-party, the utility of the poor general effect, rejuvenation <- similar drugs similar Pigment Source Trademark-2 Similar Pigment Source Trademark-1 Similar Pigment Sources S own Formula Formulations 7=

第125頁 1358540 五、發明說明(122) 分離的化合物 針緣锥小薜 糖尿病的草本猞物 1 艾札瑪里辛 (AZAMALYCIN) 牡袖 (VITEXNEGUNDO) 1 .. 里 被單獨分離的標準 化合物 [ 單一的化合物 單一的化合物 i 普拉馬哈 1 肝臟的保護 1_ 小薜鹼標準物(福 洛卡) BERBARIN STD (Γ1ΛΙΚΛ) 挽雜以一利尿的 對抗療法的4&化 合物 (ALLOPATHIC AMIDE)成分 被單獨分離的化 合物 類黃_素 (Λ FLAV0N01D) mh (7-HYDR0XY QUERCETIN) 11111 第126頁 1358540 五、發明說明(123) 表格15:藥物的名稱以特徵鑑定的略圊來表示 樣品的名稱 使用的部位 對抗療法的藥物 圊109 維生素-B群 商業的商標 安乃近(Analgin) 商業的商標 氨洗心安(Atenolol) 商業的商標 漠夫拉辛(Bromoflexin) 商業的商標 希特里辛(Citerizine) 商業的商標 芙南佳阴(Furazoli^ine) 商業的商標 異丁笨丙酸-捕熱息痛(Ibuprofeti-Paracetamol) 商業的商標 捕熱息痛(Paracetamol) 商業的商標 草本化妝品的樣品 圖110 美容潔膚膏(功效貧乏的) 商業的商標 美容潔膚膏(功效先分的) 商業的商標 洗髮粉(功效貧乏的) 商業的商標 洗髮粉(功效充分的) 商業的商標 草本配方 圊111 艾格妮唐迪納 商業的商標 安南德伯海拉維 商業的商標 艾羅吉亞瓦哈媒(Arogyavardhani) 商業的商標 柏里哈特瓦塔勤塔馬尼 +斯瓦爾納馬克須坎 商業的商標 秋帕欽亞迪卻南 商業的商標 商業的薑黃商標1 商業的商標 商業的基黃商標2 商業的商標 商業的a黃商標3 商業的商標 湖砑撒那 商業的商標 相似的藥物 圖112 山金車酊 染料來源 金盞花 染料來源 卡羅幸瑟斯(Colosynthis) 染抖來源 分離的藥物 @ 113 櫟精 分鎊自牡荊 類黃酮素 分趋自牡荊 艾札瑪里辛 i票準 地塞美松(Dexamethasone) 偉準 mm 第127頁 1358540 五、發明說明(124) 單一藥物 圊114 蘆薈 葉子 印度纸莧 葉子 茵巴里卡歐菲欣納里斯 果實 艾拉蘆 樹皮 檳榔 種子 艾斯瓦干達紅色果實 根 艾斯瓦干達白色果實 根 荖葉之安德拉普拉得須 葉子 著葉之扣庫塔(Culcutta) 葉子 扣希妮恩(Coscinium) 莖皮 竹目草(直立的) 葉子 竹目草(匍匐的) 葉子 達蘆哈里德拉 莖皮 哈里德拉 生的地下莖 卡拉加木(Kalajamun) 果實 洋蔥 球莖 i 庫塔加 莖皮 丨 拉克运哈迪拉(Raktakhadira) 心材 許拉集特 加工的恶青來源1 許拉集特 加工的S青來源2 許拉集特 葉子 ΦPage 125 1358540 V. INSTRUCTIONS (122) Isolated compound needle cone cone 薜 Diabetic herbaceous material 1 AZAMALYCIN oyster sleeve (VITEXNEGUNDO) 1 .. separated standard compound [single Compound single compound i Pramanha 1 Liver protection 1_ Berberine standard (Froca) BERBARIN STD (Γ1ΛΙΚΛ) The 4& compound (ALLOPATHIC AMIDE) component of a diuretic anti-therapeutic therapy is isolated separately The compound is yellow-like (Λ FLAV0N01D) mh (7-HYDR0XY QUERCETIN) 11111 Page 126 1358540 V. Description of invention (123) Table 15: The name of the drug is indicated by the characterization of the sample. Therapeutic Drugs 圊109 Vitamin-B Group Commercial Trademark Analgin Commercial Trademark Atenolol Commercial Trademark Bromoflexin Commercial Trademark Citerizine Commercial Trademark Furazoli^ine commercial trademark Isoprofen-Paracetamol Logo for Paracetamol Commercial Samples for Herbal Cosmetics Figure 110 Beauty Cleansing Cream (Effective) Commercial Trademark Beauty Cleansing Cream (Efficacy) Commercial Trademark Shampoo (Lack of efficacy) ) Commercial trademark shampoo (full-featured) Commercial trademark herbal formula 圊 111 Agnie Dondina commercial trademark Anandre Bohai Lava commercial trademark Arogyavardhani Commercial trademark cypress Rihart Watatar Tamani Mani + Svarnamark Sukkan Commercial Trademark Qiu Pachin Yadi butan commercial trademark commercial turmeric trademark 1 commercial trademark commercial base yellow trademark 2 commercial trademark commercial a yellow Trademark 3 Commercial Trademark Lake Lucerne Commercial Trademark Similar Drugs Figure 112 Arnica Dye Source Calendula Dyes Source Carolusus (Colosynthis) Diffuse Source Separation Drugs @ 113 栎 精分分磅 from Vitex flavonoids Dixamethasone, Weimeng Ai Mamarisin, Weimei mm, page 127, 1358540 V. Invention Description (124) Single Drug 圊114 Aloe Vera Leaf Indian Paper 苋 Leaves Inbarrica Ou Fahinaris Fruit Aila Luk Bark Betel Seeds Esva Ganda Red Fruit Roots Eswa Ganda White Fruit Roots 之 之 安Laplacian leaves with clasps (Culcutta) leaves clasped with heathine (Coscinium) stems of bamboo grass (erect) leaves of bamboo grass (匍匐) leaves up to Luhari de la stalk Harid Laguna's underground stems, Kalagamun, fruit onion bulbs, kutaga, bark, scorpion, scorpion, sauerkraut, Raktakhadira, heartwood, Xu Laji, special processing of evil green source 1 Xu Laji special processing S Qing source 2 Lajit leaves Φ

第128頁 1358540 五、發明說明(125) 升泠&蚱孕-^护拃洚芹艺凇赏·!一坞。岭茲、、> 屮s^赏.f±琦泠狯畀^举洚异办冷射60耔咖(8〇〇 1)。0芦和奋£码谇+苏许今莩>鋅 會涅^邙-& .6-IS-s»/^P 菸 +¾萍佘^12>-艺每泠。槔嗒洚今 S 3ΜΠ·弈托旮ίιε·淬 s#rvsiv/ia> S 烊 I-it 兹洚 tCT±c-o 蚱岑-爿扣决洚·Itis 5?。 »τ ^--Jls^^'s-"^-) -"-菡详~择系泞/f. 20 40 60 S 一1^^^ ί —MrHILP $ir· -二:5i-ip 1 ! 皮塔-伐塔 皮塔-卡發 皮塔 〇>, 1 -V ^'r k 欠00 nm ^or-p 600 i -t-p --) um S0 200 i ☆ - 碎 till 第129頁 1358540 圖式簡單說明 下列的範例是藉由說明的方式來提供且這些範例不應 解釋為限定本發明的申請專利範圍。 I.表格 1. 表格陳述在不同醫學中所使用之不同的哲學及各 種的專門用語 2. 表格陳述體液性質及人體不同部位間的關係 --阿祐爾惟達的方法 3. 表格陳述在中國醫學中就大宇宙而論的區分 4. 表格陳述在中國醫學中就小宇宙而論的區分 5. 表格陳述五種自然元素間的關係及其相關物 .表格陳述在中國醫學中陰與陽的意義 7. 表格陳述醫學的療效分類之顏色根據 8. 表格陳述不同顏色在不同疾病上的影響 9. 表格陳述六種味道(在阿祐爾惟達中的蕊撒)的 性質及它們的性質與功效 1 0.表格陳述顏色與波長的相關性 1 1 .表格陳述酸性與鹼性在人體内的角色 1 2.表格陳述用於特徵鑑定及化學標準化之不同分析 技術的比較 1 3.表格陳述使用於藥物的特徵發展之參數 1 4.表格陳述在已提出的發明中之藥物療效分類 1 5 .以短文展示藥物之表格 1 6.表格陳述該特徵根據共軛與極性區分至療效區Page 128 1358540 V. Inventions (125) 泠 泠 & Pregnancy - ^ 拃洚 拃洚 拃洚 凇 凇 !! A dock.岭兹,, > 屮s^赏.f±琦泠狯畀^ 洚 办 办 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷 冷0 芦和奋£码谇+苏许今莩> Zinc will be Nie-邙-& .6-IS-s»/^P 烟+3⁄4萍佘^12>-Art every 泠.槔嗒洚今 S 3ΜΠ·弈托旮ίιε·Quenching s#rvsiv/ia> S 烊 I-it 洚 tCT±c-o 蚱岑-爿扣洚·Itis 5?. »τ ^--Jls^^'s-"^-) -"-菡详~择系泞/f. 20 40 60 S 1^^^ ί —MrHILP $ir· - 2: 5i-ip 1 ! Pita-Vata Pitta-Cafapita〇>, 1 -V ^'rk owed 00 nm ^or-p 600 i -tp --) um S0 200 i ☆ - Broken till Page 129 1358540 BRIEF DESCRIPTION OF THE DRAWINGS The following examples are provided by way of illustration and should not be construed as limiting the scope of the invention. I. Form 1. The table states the different philosophies and various specific terms used in different medicines. 2. The table states the relationship between body fluid properties and different parts of the human body. - Ajal's method 3. Table stated in Chinese medicine The distinction between the big universe and the universe 4. The table states the distinction between small universes in Chinese medicine. 5. The table states the relationship between five natural elements and their related objects. The table states the meaning of yin and yang in Chinese medicine. The table states the color of the medical efficacy classification according to the table 8. The effect of different colors on different diseases is stated in the table. 9. The table states the nature of the six flavors (the ruthenium in Ajal, and their properties and effects). The table states the correlation between color and wavelength. 1 1. The table states the role of acidity and alkalinity in the human body. 1. 2. Table states the comparison of different analytical techniques used for characterization and chemical standardization. 1. Table statement for the characteristics of the drug. Parameters for development 1 4. The table states the classification of the efficacy of the drug in the proposed invention. 15. The table showing the drug in short text 1 6. The table states that the feature is based on the conjugate Polarity differentiation

第130頁 1358540 圖式簡單說明 I I .圖 圖1 A與B陳述中國醫學中五種基本元素及其間的關係 。任何一元素的不平衡(過量或缺乏)會造成擾亂其他元 素並變成一疾病的根本原因。人體健康是藉由管理及控制 上述在中國醫學令的元素而實現。 圖2陳述顏色在基本體液上的影響根據選用相同顏色 的藥物為了損害該相關的體液。一藥物的顏色是由於其中 成分的化學性質所引起,也因此該化學性質間接地用在治 療的標準化。 圖3陳述兩種不同商標的許拉集特的特徵。該特徵中 的化學概況顯示出該療效是由於更多具有充分共軛性質的 分子之存在。該化學概況隨著該樣品的年齡而異,其被耗 費在土裡面,並且該樣品若愈老則其愈具有療效而且可能 會根據其採集地點及純化過程而異。 圖4陳述在一標籤上特徵層析化的現存用途 圖5陳述商業的薑黃 (turmeric,食物)之色彩層析 譜 圖6陳述芙南佳酮 (Furazolidine,對抗療法)之色 彩層析譜 圖7陳述克里米庫特拉瑞斯 (Krimikutara Ras,配 方)之色彩層析譜 圖8陳述許拉集特(在功效方面良好的)之色彩層析 譜Page 130 1358540 Brief description of the diagram I I . Figure 1 A and B illustrate the five basic elements of Chinese medicine and their relationship. Any imbalance of one element (excess or lack) can cause the other elements to be disturbed and become the root cause of a disease. Human health is achieved by managing and controlling the above-mentioned elements of medical order in China. Figure 2 illustrates the effect of color on the basic body fluids in order to damage the associated body fluids by selecting the same color of the drug. The color of a drug is caused by the chemical nature of the ingredients therein, and thus the chemical nature is indirectly used in the standardization of treatment. Figure 3 illustrates the characteristics of the two different trademarks. The chemical profile in this feature shows that the efficacy is due to the presence of more molecules with sufficient conjugation properties. The chemical profile varies with the age of the sample, which is consumed in the soil, and the older the sample, the more effective it may be and may vary depending on where it is collected and the purification process. Figure 4 illustrates the existing use of feature chromatography on a label. Figure 5 illustrates the commercial color chromatogram of turmeric (food). Figure 6 illustrates the color chromatogram of Furazolidine. A color chromatogram of the Krimikutara Ras (formula) is presented in Figure 8 to illustrate the color chromatogram of Xu Lai Te (good in terms of efficacy)

第131頁 1358540 圖式簡單說明 圖9陳述許拉集特(在功效方面粗劣的)之色彩層析 譜 圖10陳述瑟里亞發爾提 (Suryavarti,配方)之色彩 層析譜 圖1 1陳述茶(食物)之色彩層析譜 圖12陳述特里卡圖 (Trikatu,配方)之色彩層析譜 圖13陳述所有黃色藥物的特徵。在此珊迪各達 (Sandigdha Dravyas,一有爭議的藥物)陳述一明顯的不 同,使得該鑑定更容易。 圖14陳述在本質上皮塔赫拉的所有藥物之特徵。在 第一區出現的成分指出該藥物的功效。 圖15陳述在本質上卡發赫拉的所有藥物之特徵。在 第二區出現的成分指出該藥物的功效。 圖16陳述在本質上伐塔赫拉的所有藥物之特徵。在 第三區出現的成为指出該藥物的功效。 徵 圖17陳述在本質上皮塔卡發赫拉的所有藥物之特 。在第一區及第二區出現的成分指出該藥物的功效。 徵 圖18陳述在本質上卡發伐塔赫拉的所有藥物之特 。在第二區及第三區出現的成分指出該藥物的功效。 徵 圖19陳述在本質上皮塔伐塔赫拉的所有藥物之特 。在第一區及第三區出現的成分指出該藥物的功效。 圖20陳述在本質上促伊都夏赫拉的所有藥物之特徵 在所有二個區域出現的成分指出該藥物的功效。 圖2 1陳述被當作促伊-都夏赫拉藥物使用的卡里慕Page 131 1358540 Schematic description of the figure Figure 9 illustrates the color chromatogram of Xu Lai Te (inferior in terms of efficacy) Figure 10 shows the color chromatogram of Suryavarti (recipe) 1 1 statement Color Chromatogram of Tea (Food) Figure 12 states that the color chromatogram of Trikatu (Formula) states the characteristics of all yellow drugs. In this case, Sandiddha Dravyas (a controversial drug) stated a distinct difference, making the identification easier. Figure 14 illustrates the characteristics of all drugs in Pittala in nature. The ingredients appearing in the first zone indicate the efficacy of the drug. Figure 15 illustrates the characteristics of all drugs in nature of Kapela. The ingredients appearing in the second zone indicate the efficacy of the drug. Figure 16 illustrates the characteristics of all drugs in nature of katahla. The appearance in the third zone indicates the efficacy of the drug. Figure 17 illustrates the nature of all the drugs in Pitakafa Hera. The ingredients appearing in the first zone and the second zone indicate the efficacy of the drug. Figure 18 illustrates the nature of all drugs in the card. The ingredients appearing in the second and third zones indicate the efficacy of the drug. Figure 19 illustrates the nature of all drugs in Pittavatahra in nature. The ingredients appearing in the first and third zones indicate the efficacy of the drug. Figure 20 illustrates the characteristics of all drugs that promote Idishahira in nature. The ingredients appearing in all two regions indicate the efficacy of the drug. Figure 2 1 states that Carrima is used as a drug for the Iraqi-Ducha

第132頁 1358540 圖式簡單說明 撒里(Kali musali)及撒非德慕撒里(safed musali)之 特徵。 圖22陳述西挫勒斯卡羅幸瑟斯(Citrallus C〇1〇Synthis)的不同樣品之特徵。該特徵表示一些成分 的缺乏是由於被用在來自植物相同的顏色來源之萃取過程 的標準化。 圖23陳述採集自該國家的不同地點之侯拉黎納( Holarrena Antidyssentric)的不同樣品之特徵。該特徵 表示出在該植物材料的化學成分上的生態學因素之影響。 圖24陳述來自不同地點的兩種荖葉樣品之特徵。在 30— 40分鐘的時間範圍内出現的類黃酮表現出在該植物材 料的化學成分上之遺傳的,顯型的差異及生態學因素之影 響。 圖2 5陳述印度的人造衛星照片。這些人造衛星照片 指出印度有不同熱帶的氣候帶。 圖2 6陳述兩種用於化妝品的配方如草本洗髮粉之特 徵。 圖27陳述兩種不同商標的特里卡圖(TRIKATU)之特 徵。在其s式驗中的差別可月b疋由於在特里卡圖(TRIKATU) 的組成成分中的差異。 圖28陳述該薑黃及其三個不同商業產品的特徵。一 常見的吸收峰在所有這些特徵中出現在2〇分鐘處。 (圖2 9至9 2顯不出所有在表格丨3中所報導藥物的特徵 鑑定)Page 132 1358540 Schematic description of the characteristics of Kali musali and safed musali. Figure 22 illustrates the characteristics of different samples of Citrallus C〇1〇 Synthis. This feature indicates that the lack of some components is due to the standardization of the extraction process used for the same color source from the plant. Figure 23 illustrates the characteristics of different samples collected from different locations in the country, Holarrena Antidyssentric. This feature shows the effect of ecological factors on the chemical composition of the plant material. Figure 24 illustrates the characteristics of two temporal lobe samples from different locations. Flavonoids that occur over a 30-40 minute time period exhibit genetic, phenotypic differences and ecological factors in the chemical composition of the plant material. Figure 2 5 shows a photograph of an artificial satellite in India. These satellite photos indicate that India has different tropical climate zones. Figure 2 6 illustrates the characteristics of two formulations for cosmetics such as herbal shampoo. Figure 27 illustrates the characteristics of two different trademarks, TRIKATU. The difference in its s-test can be due to the difference in the composition of the TRIKATU. Figure 28 illustrates the characteristics of the turmeric and its three different commercial products. A common absorption peak appears in 2 of these features in all of these features. (Figures 2-9 to 9 show no characterization of all the drugs reported in Table 丨3)

第133頁 1358540 圖式簡單說明 圖 29 陳述麝香(Abel moschus),黃葵(Moschatus medium)兩者的整株植物的特徵。 圖30陳述刺槐 (Acacia suma)的樹皮之兩種特徵。 圖31陳述印度鐵莧 (Acaltpha indica)的嫩葉之兩 種特徵。 圖32陳述艾德哈圖達發撒卡(Adhatoda vasaka)的 葉子之兩種特徵。 圖33陳述鞭葉鐵線蕨 (Adiantum caudatum)葉子之 兩種特徵。 圖34陳述臭樁細鉋花 (Ailanthus excelsa)的莖皮 之兩種特徵。 4 圖35陳述菖蒲(Acorus calamus)的地下莖之兩種特 徵。 圖36陳述並蔥(Allium porum)的大的單一小鱗莖之 兩種特徵。 圖37陳述大蒜(Allium sativam)的小鱗莖之兩種特 徵。 圖38陳述南薑(Alpinia galanga)的地下莖之兩種特 徵。 圖39陳述1^良薑 (Alpinia officinarum)的地下莖 之兩種特徵。 〇 圖40陳述月桃 (Alpinia speciosa)的地下莖之兩 種特徵。 圖41陳述檳榔 (Areca catechu)的未加工的堅果果Page 133 1358540 Brief description of the diagram Figure 29 illustrates the characteristics of the whole plant of both Abel moschus and Moschatus medium. Figure 30 illustrates two characteristics of the bark of the Acacia suma. Figure 31 illustrates the two characteristics of the young leaves of the Indian scorpion (Acaltpha indica). Figure 32 illustrates the two characteristics of the leaves of Adhatoda vasaka. Figure 33 illustrates two characteristics of the leaves of Adiantum caudatum. Figure 34 illustrates two characteristics of the stem bark of Ailanthus excelsa. 4 Figure 35 illustrates the two characteristics of the underground stem of Acorus calamus. Figure 36 illustrates two characteristics of a large single small bulb of Allium porum. Figure 37 illustrates two characteristics of small bulbs of garlic (Allium sativam). Figure 38 illustrates two characteristics of the underground stem of Alpinia galanga. Figure 39 illustrates two characteristics of the underground stem of 1^Alpinia officinarum. 〇 Figure 40 illustrates the two characteristics of the underground stem of Alpinia speciosa. Figure 41 illustrates the raw nut fruit of Areca catechu

第134頁 1358540 圖式簡單說明 -— 實之兩種特徵。 圖4 2陳述樓榔的乳液加工堅果之兩種特徵。 圖43陳述乂瑞卡卡提 reca kateeh)的莖皮之兩 種特徵。 又心网 圖44陳述山金車(Arnica)相同來源的染料之兩種 特徵。 圖45陳述假馬齒莧(Bacopa monneri)的整棵植物 之兩種特徵。 圖4 6陳述針緣葉小薜的莖皮之兩種特徵。 圖47陳述柏爾海維亞迪富撒(Borrhievia diffusa) 的整棵植物之兩種特徵。 圖48陳述蕃椒(Capscicium Annum linn)之大的, 被剝開的果實之兩種特徵。 圖4 9陳述蕃椒之大的’未剝開的果實之兩種特徵。 圖5 0陳述蕃椒的小的,未剝開的果實之兩種特徵。 圖51陳述扣希妮恩菲妮斯特拉唐(Coscinium fenestratum)的莖皮之兩種特徵。 圖52陳述扣希妮恩葛蘭迪斯 (Coccinidium gr*aridis)的根及葉子之兩種特徵。 圖 53 陳述竹目草(Dactlylactinium Aegyptium,直 立的)的葉子之兩種特徵。 圖5 4陳述竹目草(俯臥的)的葉子之兩種特徵。 圖55陳述瓜葉菊(Diristachis cineraria)的葉子 及樹皮之雨種特徵。Page 134 1358540 Schematic description - two characteristics. Figure 4 2 illustrates two characteristics of emulsion processing nuts in the floor. Figure 43 illustrates the two characteristics of the stem bark of 乂瑞卡卡提 reca kateeh). Heart Network Figure 44 illustrates the two characteristics of the same source of dye from Arnica. Figure 45 illustrates two features of the whole plant of the Bacopa monneri. Figure 4 6 illustrates two characteristics of the bark of the needle stalk. Figure 47 illustrates two characteristics of the entire plant of Borrhievia diffusa. Figure 48 illustrates the two characteristics of the large, peeled fruit of Capscicium Annum linn. Figure 49 illustrates the two characteristics of the 'unstripped fruit' of the large pepper. Figure 50 illustrates two characteristics of small, unstripped fruits of bell pepper. Figure 51 illustrates the two characteristics of the stem bark of the Coscinium fenestratum. Figure 52 illustrates the two characteristics of the roots and leaves of the Coccinidium gr*aridis. Figure 53 illustrates the two characteristics of the leaves of Dactlylactinium Aegyptium (erect). Figure 5 4 illustrates two characteristics of the leaves of the bamboo grass (prone). Figure 55 illustrates the characteristics of the leaves and bark of the genus Diristachis cineraria.

第135頁 1358540 圖式簡單說明 圖5 6陳述茵柏利卡歐菲欣场里 斯(Emb 1 i ca officinalis)之果實的外果皮之 圖57陳述一美容潔膚膏的配士 圖58陳述一美容潔膚膏的配之兩種特徵 圖59陳述格里瑟欣亞格之兩種特徵 . 议伯妆 glabra)的根皮之兩種特徵。 圖6 0陳述格里瑟欣亞 兩種特徵。 圖61陳述金納瑪西佑維斯特妆 sylvestrae)的整棵植物之兩種特徵 圖62陳述侯勒羅納安提帶森 A . t 林将里卡(Hollerona Antidysentrica)的莖皮之兩種特徵。 圖63陳述茵奴拉瑞西莫撒r ' m v Innula recemosa)的 根之兩種特徵。 圖6 4陳述黃玉蘭 種特徵。 圖65陳述辣木(Moringa 〇lifera)的葉子之兩種特 徵。 兩種特徵 (G1ycerrhz i a o 伯扭之整棵植物的粉末之 (GymnemaPage 135 1358540 Brief description of the diagram Figure 5 6 Statement of the exocarp of the fruit of Emb 1 i ca officinalis Figure 57 presents a dedication of a beauty cleansing cream Figure 58 states a beauty The two characteristics of the cleansing cream are shown in Fig. 59, which describes the two characteristics of Grissingiag. The two characteristics of the root bark of glabra. Figure 60 shows the two characteristics of Grischenya. Figure 61 illustrates the two characteristics of the whole plant of Jinnamasi vista (Sylvestrae). Figure 62 shows the two characteristics of the stems of Hollerona Antidysentrica. . Figure 63 illustrates the two characteristics of the roots of Innu Resimos r 'm v Innula recemosa. Figure 6 4 illustrates the characteristics of the Magnolia. Figure 65 illustrates the two characteristics of the leaves of Moringa 〇lifera. Two characteristics (G1ycerrhz i a o The whole plant's powder (Gymnema)

Michellia champaka)的花之兩 圖66陳述蟻香桃木(MyriCa cerefera)的相同來源 的染料之兩種特徵。 圖67陳述納喜艾克席拉(Nahi axi 1 lae)的整棵植 物之兩種特徵。 圖68陳述木蝴蝶 (〇r〇xylum indicum)的莖皮之兩 種特徵。Two flowers of Michelia champaka) Figure 66 illustrates two characteristics of the same source of dye from MyriCa cerefera. Figure 67 illustrates two characteristics of the whole plant of Nahi axi 1 lae. Figure 68 illustrates the two characteristics of the bark of the wood butterfly (〇r〇xylum indicum).

第136頁 1358540 圖式簡單說明 圖69陳述聖羅勒(Ocimum sanctum)的葉子之兩種 特徵》 圖70陳述普魯恰藍西歐拉塔(Pluchea lanceolata)的葉子之兩種特徵。 圖71陳述胡黃連 (Picrorrhiza kurroh)的莖皮之 兩種特徵。 圖72陳述辑醬 (Piper beetle)的葉子之兩種特 徵。 圖73陳述索拉里亞扣勒里佛里亞(Ps〇ralia cori 1 i fol ia)的種子之兩種特徵。 圖74陳述大菜(Raphanus sativus)的葉子之兩種 特徵。 圖75陳述蓖麻 (Ricinus cummunis)的根之兩種特 徵。 圖76陳述_@草(Rubia cordifolia)的莖與根之兩 種特徵。 圖77陳述雲香木(Saussrea lappa)的根之兩種特 徵。 圖78陳述斯菲藍瑟斯茵迪扣斯(Spheranthus indicus)的整棵植物之兩種特徵。 圖7 9陳述辛普羅扣斯拉瑟摩瑟斯(s y m p 1 〇 c u s racemosus)的莖皮之兩種特徵。 圖80陳述_梨勒(Terminalia chebula)的果實之 兩種特徵。Page 136 1358540 Brief description of the diagram Figure 69 illustrates the two characteristics of the leaves of Ocimum sanctum. Figure 70 illustrates the two characteristics of the leaves of the Pluchea lanceolata. Figure 71 illustrates two characteristics of the stem bark of Picrorrhiza kurroh. Figure 72 illustrates the two characteristics of the leaves of the Piper beetle. Figure 73 illustrates two characteristics of the seeds of Ps〇ralia cori 1 i fol ia. Figure 74 illustrates two characteristics of the leaves of the large dish (Raphanus sativus). Figure 75 illustrates two characteristics of the root of Ricinus cummunis. Figure 76 illustrates the two characteristics of stem and root of _@草(Rubia cordifolia). Figure 77 illustrates the two characteristics of the root of Saussrea lappa. Figure 78 illustrates two characteristics of the entire plant of Spheranthus indicus. Figure 7 9 illustrates two characteristics of the stem bark of s y m p 1 〇 c u s racemosus. Figure 80 illustrates two characteristics of the fruit of Terminalia chebula.

第137頁 1358540 圖式簡單說明 圖81陳述川棟(Terminal ia bel lerica)的果實之 兩種特徵。 圖82陳述箱蘆巴(Trigonella faenumg)的整棵植 物之兩種特徵。 圖83陳述㈢杂(Tribulus terrestrias)的莖與根 之兩種特徵。 圖84陳述泰羅佛拉艾兹邁提卡(Tyloph ora asthmatica)的葉子之兩種特徵。 圖85陳述相同的藥物莢迷(Viburnum)的來源染料 之兩種特徵。 圖86陳述維欣尼亞聳妮菲拉 (Withinia somnifera)的根之兩種特徵。 圖8 7陳述加工過的金極柏爾歐菲欣納里斯 ( Zinziber 〇fficinalis)的地下莖之兩種特徵。 圖88陳述又維帕塔卡拉充納(Avipattakara churna)的粉末之兩種特徵。 圖89陳述卡瑪5賣各瑞斯(Kamaduga Ras)的.一草本 配方之兩種特徵。 圖90陳述 庫馬拉雅撒發 (Kumarayasava) —草藥 的兩種特徵經由發酵的過程 圖91陳述馬哈拉克須米維拉斯瑞斯(Mahalakshmi vilas ras)的一草本配方之兩種特徵。 圖92陳述蘇瓦爾納悠格拉加古咕盧 (Suvarna yoga raj a Guggulu)的一草本的配方之兩種特徵。Page 137 1358540 Brief description of the diagram Figure 81 illustrates the two characteristics of the fruit of Terminal ia bel lerica. Figure 82 illustrates two features of the entire plant of Trigonella faenumg. Figure 83 illustrates the two characteristics of the stem and root of the (Tri) (Tribulus terrestrias). Figure 84 illustrates the two characteristics of the leaves of Tyloph ora asthmatica. Figure 85 illustrates two characteristics of the same source dye of the drug pod (Viburnum). Figure 86 illustrates the two characteristics of the roots of Withinia somnifera. Figure 8 7 illustrates the two characteristics of the underground stem of the processed Zinziber 〇fficinalis. Figure 88 illustrates two features of the powder of Avipattakara churna. Figure 89 illustrates the two characteristics of a herbal formula for Kamauga Ras. Figure 90 illustrates Kumarayasava—the two characteristics of the herb through the fermentation process. Figure 91 illustrates two characteristics of a herbal formula of Mahalakshmi vilas ras. Figure 92 illustrates two characteristics of a herb formulation of Suvarna yoga raj a Guggulu.

第138頁Page 138

1OJ0D4U 圖式簡單說明 圖9 3陳述安南德伯海拉維 Ras>的特徵。在任一特定吸收垃(AnandabhairaVi 軟體將顯示出該吸收峰的x ” 上接滑鼠右鍵,該影像 於條碼製作上。這些座標顯示於^ 8座標軸,已使用 並出現在工具列令。 框内(接近該吸收峰 圖94陳述克里米庫特拉瑞 顯示出一特定吸收峰的條碼值。 ·徵。该影像軟體將 圖9 5陳述由安南德伯海拉維 圖96陳述由克里米庫特拉瑞斯f生的條碼。 圖97陳述安南德伯海拉維瑞斯的顯碼。 圖98陳述克里米庫特拉瑞斯的顯示二固 圖9 9陳述電腦網絡如何將本發明之 料庫應用在企業資源計畫及客戶關係管理=法所製作的資 圖100陳述一在二月採集的印度楝枯’上。 indica)之柔軟的葉子在彩色長條圖方' (Azadiracta 圖1 0 1陳述一草藥配方,安南德伯海拉維、=色彩f析譜 彩色長條圖方面的新色彩層析譜 、瑞斯的藥物在 圖1 0 2陳述一草藥配方,克里米庫特 ^ 在彩色長條圖方面的新色彩層析譜 瑞斯的藥物 圖 103 陳 述 克 里 米 庫 特 拉 瑞斯 的 圖 圖 104 陳 述 安 南 德 伯 海 拉 維 瑞 斯 形圖 圖 105 陳 述 克 里 米 庫 特 拉 瑞斯 的1OJ0D4U Schematic description of the figure Figure 9 3 shows the characteristics of Anandreha Hirawi Ras>. Right click on any particular absorption (AnandabhairaVi software will show the x of the absorption peak), the image is on the bar code production. These coordinates are displayed on the ^ 8 coordinate axis, have been used and appear in the tool list. Approaching the absorption peak Figure 94 states that Crimy Coutarei displays a bar code value for a particular absorption peak. • The image software is presented in Figure 9.5 by Anand Bob Lavitu 96 stated by Crimicu The barcode of Tracy's f. Figure 97 shows the code of Annan Deborah Lavis. Figure 98 shows the display of Crimique Coutures. The two solid diagrams 9 show how the computer network will make the invention The database is applied in the enterprise resource planning and customer relationship management = the legal map produced by the law 100 stated in a collection of Indian smashed 'indica' in February. The soft leaves in the color strip diagram ' (Azadiracta Figure 1 0 1 Stated a herbal formula, Annan Deborah Ravi, = color f spectrum color bar graph of the new color chromatogram, Rees's drug in Figure 1 0 2 stated a herbal formula, Crimicut ^ New color chromatograms in color bar graphs Adams pharmaceutical FIG Chen said Kerry 103 meters Tela Reese library 104 of FIG. Annan Chen said primary de Swiss-dimensional Gaussian-shaped sea pull FIG Chen said Kerry 105 meters library Tela Reese

I 彩層析譜之餅I color chromatographic cake

第139頁 1358540 圖式簡單說明 圖 圖1 0 6陳 圖1 0 7陳 圖108陳 圖1 0 9陳 述該量 述該量 述該量 述該特 供於一資料庫且已用 化的損害失調(都夏)之餅形圖 化的損害失調(都夏)之餅形圖 化的損害失調(都夏)之餅形圖 徵以數種草藥的3_ D及輪廓影像,提 於各種的企業資源計畫及客戶關係管 理之應用。 徵以數種草藥的3— D及輪廓影像,提 於各種的企業資源計畫及客戶關係管 圖1 1 0陳述該特 供於一資料庫且已用 理之應用。 圖1 1 1陳述該已攙雜的化妝品樣品的特徵以3— D及輪 廓影像。 圖1 1 2陳述一母顏料的特徵如3— D及輪廓影像可用來 找出該母顏料的稀釋。 圖1 1 3陳述一已分離藥物的特徵及其以3— D及輪廓影 像表示的紫外光圖譜。 抗療法的藥物成3-D及輪廓影像。 有好幾個功能的軟體的操作順序之圖 圖1 1 4陳述一對 圖115陳述一具 表。Page 139 1358540 Schematic description of the figure Figure 1 0 6 Chen Figure 1 0 7 Chen Figure 108 Chen Figure 1 0 9 statement the amount of the quantity that describes the amount of the damage that is used in a database and has been used (Du Xia)'s pie-shaped damage disorder (Du Xia)'s pie-shaped damage disorder (Du Xia)'s pie-shaped map with several kinds of herbal 3_D and contour images, for various corporate resources Project and customer relationship management applications. The 3D and outline images of several herbs are presented for various corporate resource plans and customer relationship management. Figure 1 1 0 states that this application is specifically for use in a database. Figure 1 1 1 illustrates the characteristics of the noisy cosmetic sample in 3-D and profile images. Figure 1 1 2 states that features of a parent pigment such as 3-D and contour images can be used to find the dilution of the master pigment. Figure 1 1 3 illustrates the characteristics of an isolated drug and its UV spectrum as represented by 3-D and contour images. Anti-therapeutic drugs are 3-D and contour images. Figure of the operation sequence of a software with several functions Figure 1 1 4 a pair of statements Figure 115 shows a table.

第140頁Page 140

Claims (1)

13585401358540 •(更)正各 修正 六、申請專---- 1. 一種用於來自植物或動物的萃出物 天然 的來源之構造的偵測與鑑定識別的方法,使用層析 鑑定技術,上述的方法至少包含以下步驟: i )使用一適當溶劑來萃取有機或有機金屬分子 i i )在步驟(i )中所得之萃取物經過一分離分 用高壓液相色層分析技術; 、 i i i )所沖提出的組成部分根據其p Η值與極性來 廓及3 - D層析譜; iv) 將所得之3-D及輪廓層析譜藉由一内建軟體 彩色的影像,從上述影像中個別顏色所使用的座標 該影像之所有3-D性質以分析該彩色影像; v) 以時間來表示各種已沖提出的組成部分之濃 v i ) 根據該分析顏色產生一層析譜,隨著該分 軛成分而有出現在不同滯留時間的峰; ’ v i i )以該影像中各成分的紫外-可見光吸收性 認在上述組成部分中的化合物; ’ v i i i )將該已沖提出的化合物根據其極\生與共 加以確認,判定並分類成極性,中極佳及低或非極 i X ) 針對一選定的峰使用X軸為滯留時間,Y軸 長,R是紅映像點,G是綠映像點及B藍映像點來產 碼;與 X)產生一特徵與條碼的資料庫並確認該樣品中 化合物。. 或人造 的特徵 析,使 產生輪 轉成一 來表示 度; 子的共 質來確 軛性質 性; 為波 生一條 個別的• (more) Correction VI. Application---- 1. A method for the detection and identification of structures derived from the natural source of extracts from plants or animals, using chromatographic identification techniques, The method comprises at least the steps of: i) extracting an organic or organometallic molecule using a suitable solvent; ii) extracting the extract obtained in step (i) by a separation using high pressure liquid chromatography; (iii) The components are based on the p Η value and polarity to understand the 3 - D chromatogram; iv) the resulting 3-D and contour chromatograms are imaged by a built-in soft color, from the individual colors of the above images The coordinates used are all the 3-D properties of the image to analyze the color image; v) the concentration of the various components that have been flushed out in time. vi) a chromatogram is generated from the analyzed color, along with the conjugate component There are peaks that appear at different residence times; 'vii) compounds that are recognized in the above components by the UV-visible absorption of the components in the image; ' viii ) according to their polar compounds A total of confirmation, classification and classification into polarity, excellent and low or non-polar i X) for a selected peak using the X-axis for the retention time, Y-axis length, R is the red image point, G is the green image point and B The blue image is used to generate the code; and X) generates a database of features and barcodes and confirms the compound in the sample. Or man-made eigenanalysis, such that the rotation is expressed in one to represent the degree; the symmetry of the sub is used to confirm the yoke property; 第141頁 1358540 _案號 90100326 _年月日__ 六、申請專利範圍 2. 如申請專利範圍第1項之方法,其中上述溶劑具有 不同的極性是根據該研究樣品的親水性及疏水性來選擇 ,乙醇可用於藥物的標準化。 3. 如申請專利範圍第1項之方法,其中上述特徵可發 展成為在不同pH範圍下萃取相同藥物。 4. 如申請專利範圍第1項之方法,其中上述高壓液相 色層分析設備是選自任何可買得到的高壓液相色層分析設 備,具有一光學偶極陣列偵測器,最好是具有一梯度的或 三元系統的幫浦。 5. 如申請專利範圍第1項之方法,其中上述動相的pH 與極性是藉由改變一含水溶劑,水或一在所需p Η值藉由使 用一鹽類(如磷酸鉀或磷酸氫二鉀與磷酸維持所需的ρ Η 值)的缓衝液,與一非含水溶劑的混合比例從0到1 0 0%莱控 制。 6. 如申請專利範圍第1項之方法,其中上述非含水 的,有機和含水的,水或在一已知pH值的緩衝液是用於步 驟1 (i i i ) 並且是根據其極性範圍所做的選擇。 7. 如申請專利範圍第1項之方法,更包含將上述的輪 廓層析譜轉成一包含該研究藥物的共軛與極性性質之彩色Page 141 1358540 _ Case No. 90100326 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Alternatively, ethanol can be used for the standardization of drugs. 3. The method of claim 1, wherein the above features are developed to extract the same drug at different pH ranges. 4. The method of claim 1, wherein the high pressure liquid chromatography apparatus is selected from any commercially available high pressure liquid chromatography apparatus having an optical dipole array detector, preferably A pump with a gradient or ternary system. 5. The method of claim 1, wherein the pH and polarity of the mobile phase are changed by using an aqueous solvent, water or a desired p Η value by using a salt such as potassium phosphate or hydrogen phosphate. The buffer ratio of di-potassium and phosphoric acid to maintain the desired ρ Η value, and a non-aqueous solvent, is controlled from 0 to 100%. 6. The method of claim 1, wherein the non-aqueous, organic and aqueous, water or buffer at a known pH is used in step 1 (iii) and is based on its polarity range s Choice. 7. The method of claim 1, further comprising converting the above-described profile chromatogram into a color comprising a conjugated and polar nature of the study drug 第142頁 1358540 _•案號 90100326_年月日__ 六、申請專利範圍 影像。 8. 如申請專利範圍第1項之方法,一藥物(單一或複 方)是利用該成分存在於一特殊極性與紫外一可見光吸收 區域的數量來評估。 ·· 9. 如申請專利範圍第1項之方法,該軟體針對所選定 之一峰或多組峰或影像產生一條碼,使用X.軸為滯留時 間,Y軸為波長,R是紅映像點,G是綠映像點及B藍映像點 作為座標,由該軟體所提供,使該產物性質走向企業。. 10. 如申請專利範圍第1項之方法,其中上述所使用 的軟體稱為”彩虹",至少具有以下特徵: (a ) —軟體具有開啟來自該檔案夾以不同格式(範圍) 如BMP、JPEG、TIF、GIF的層析特徵影像之能力,並以出 現在該影像中具單一映相點靈敏度的不同顏色來分析; (b ) —軟體具有顯示該映相點資訊的能力以形式1 . 一 具有X (0- (min. 時間單位)和Y (200—800 nm) 座標的 圖表及2. —具有每一峰自動.或手動的個別數值在該圖·旁的 兩單獨欄中的餅形圖; (c ) 一軟體具有列印所有分析後所產生的數據的能力 藉由使用一列印圖像; (d ) —軟體具有改變列印的頁面設定的能力藉由使用 一頁面設定圖像;Page 142 1358540 _• Case No. 90100326_年月日日__ VI. Application for patent coverage Image. 8. As in the method of claim 1, a drug (single or compound) is evaluated by the amount of the component present in a particular polarity and ultraviolet-visible absorption region. ·· 9. If applying the method of item 1 of the patent scope, the software generates a code for one or more sets of peaks or images selected, using the X. axis as the retention time, the Y axis as the wavelength, and R as the red image point. G is the green image point and the B blue image point as coordinates, which are provided by the software to make the product property go to the enterprise. 10. The method of claim 1, wherein the software used above is called "rainbow" and has at least the following characteristics: (a) - the software has an opening from the folder in a different format (range) such as BMP , JPEG, TIF, GIF tomographic image capabilities, and analyzed in different colors appearing in the image with a single point sensitivity; (b) - the software has the ability to display the information of the image point in form 1 A chart with X (0- (min. time unit) and Y (200-800 nm) coordinates and 2. - a cake with two peaks in each of the separate columns with automatic or manual individual values (c) The ability of a software to print data generated by all analyses by using a printed image; (d) - the ability of the software to change the page settings of the print by using a page to set the image ; 第143頁 1358540 案號 90100326 月 曰 修正 六、申請專利範圍 (e ) —軟體具有選擇部分影像並分析之的能力藉由使 用一重新估量圖像; (f ) 一軟體具有為不同影像而開啟任何數量的影像分 析視窗及狀態顯示於視窗圖像的能力; (g) —軟體具有將該影像區分成三個區域在2〇分鐘的 庫έ圍的能力*精由使用區域圖像; (h ) —軟體具有使所選影像倒轉的能力藉由使用倒轉 圖像; (Ο 軟體具有將β亥影像轉換成Notepad 'Word pad及 MS Word的能力,藉由使用編輯圖像; (j ) 一軟體具有關於該軟體操作上各種操作資訊的特 徵之能力,藉由使用輔助圖像;及 、 (k) 一軟體具有儲存該產生的數據’使用另存新檔圖 像’成.JPEG檔案格式的能力。 11. 一軟體被用於一 層析譜之數據處理之方法 括: 組成部分的彩色輪廓影像及3 _ D ,上述的數據處理之方法至少包 根據不同顏色(具有在發表的註釋 a 考 ·,生命週期,加 ,中被提及的標準)的選擇來分析(摘錄顏色)該彩 ίΐί影像,並表示各種隨著時間而沖提出之成分的滚度 次根·據滯留時間的極性; ^制所有該藥物在該影像中的三次元性質來分析 4 *物之3 —D層析譜;Page 143 1358540 Case No. 90100326 Issue Amendment VI. Patent Application (e)—The ability of the software to select a portion of the image and analyze it by using a re-evaluation image; (f) A software has any means for opening different images The number of image analysis windows and the ability of the status to be displayed in the window image; (g) - the software has the ability to distinguish the image into three regions in a 2 minute library * fine by the use area image; (h) - The software has the ability to reverse the selected image by using an inverted image; (Ο The software has the ability to convert the β-Hui image into Notepad 'Word pad and MS Word, by using the edit image; (j) a software with The ability to manipulate the features of the various operational information of the software by using the auxiliary image; and, (k) a software having the ability to store the generated data 'using the saved new image' into the .JPEG file format. A method in which a software is used for data processing of a chromatogram includes: a color contour image of a component and 3 _ D , and the above data processing method is at least packaged according to different Color (with the standard mentioned in the published notes a, · life cycle, plus, mentioned in the standard) to analyze (extract color) the color ίΐί image, and indicate the rolling of various ingredients that are rushed over time Secondary roots according to the polarity of the residence time; ^ the three-dimensional nature of all the drugs in the image to analyze the 3-D chromatogram of the 4*; 13585401358540 柰號 90100326 六、申請專利範圍 c. 產生一具有許多伴隨以一明讀 時間沖提出之分子的共軛性質而出現/ π的極性順序隨 的層析譜; 出現在不同滞留時間之峰 d. 藉由在該影像t不同成分的誓 來確認在上述分子_的化合物; ’、τ &光* °及收性質 e. 根據該分子的極性與共軛性質將鑑定及 軸上劃分成療效區域來使該研究藥物中 在X及Y 生物的,治療的性質相關聯; 中各種成分已報導之 f. 使用該影像的座標,即X軸為滯 長,R是紅映像點,G是綠映像點及B · s Y軸為波 薦軟體提供,對於所選定的峰羞+ 孤映像點,由所推 τ從玍~條碼. g. 對於該樣品產生一特徵與條碼的資 種資料庫的效用如企業資源計晝盥 庫棱昇各 h. 對於所有已用於商業應 關係官理應用;及 關係管理型式的樣品產生—1 :,3的企業資源計晝和客戶 /、有顯示窗’的資料庫。 1 2 ·如申請專利範圍第丨丨.項 名為,彩虹,的新軟體來作31)及鈐夂方法,其中上述使用一 提供一在X及γ軸上有滯留時盥廓層析谱的分析,該軟體 B /、波長的層析譜。 13.如申請專利範圍第u項 提供一可用百分比方式指出都之=法,其中上述使用一 3 D及輪廓層析譜的分析。 的知害程度之新軟體來作 1358540 _案號 90100326_年月日__ 六、申請專利範圍 14.如申請專利範圍第1 1項之方法,其中上述所使用 之名為’彩虹’的軟體至少具有下列特徵: i · 一軟體具有開啟層析特徵影像以不同格式(範圍) 的能力如BMP、JPEG、TIF、GIF 來自該檔案夾,並以出現 在該影像中具單一映相點靈敏度的不同顏色來分析該影像 i i . 一軟體具有顯示該映相點資訊的能力,以形式1. 一具有X (0- (min.時間單位)和Y ( 2 0 0 — 8 0 0 nm )座標 的圖表及2. —餅形圖具有每一峰自動或手動的個別數值在 該圖旁的兩單獨的欄.中; i i i. 一軟體具有列印所有分析後所產生的數據的能 力藉由使用一列印圖像; i v. —軟體具有改變列印的頁面設定的能力藉由使用 一頁面設定圖像; v. 一軟體具有選擇部分影像並分析之的能力藉由使 用一重新估量圖像; vi . 一軟體具有為不同影像而開啟任何數量的影像分 析視窗及狀態顯示於視窗圖像的能力; vi i. 一軟體具有將該影像區分成三個區域在20分鐘 的範圍的能力,藉由使用區域圖像; v i i i · —軟體具有使所選影像倒轉的能力使用倒轉圖 像; ix. —軟體具有將該影像轉換成Notepad、Word pad 及MS Word的能力,藉由使用編輯圖像;Nickname 90100326 VI. Scope of Application C. Produce a chromatogram with a number of polar sequences with / π occurring with the conjugate nature of the molecule presented at a read time; peaks appearing at different residence times d. Confirm the compound in the above molecule by the oath of the different components of the image; ', τ & light* ° and the property e. According to the polarity and conjugate properties of the molecule, the identification and the axis are divided into therapeutic regions. To correlate the therapeutic properties of the X and Y organisms in the study drug; the various components have been reported f. Use the coordinates of the image, ie the X axis is stagnation, R is the red image point, and G is the green image The point and B · s Y-axis are provided for the wave recommendation software, for the selected peak shame + orphan image point, by pushing τ from 玍 ~ bar code. g. The utility of generating a feature and bar code resource database for the sample For example, the enterprise resource plan library is arbitrarily h. For all the applications that have been used for commercial applications; and the relationship management type of sample generation -1, 3 enterprise resource planning and customer /, with display window' database. 1 2 · If the patent application scope is 丨丨. Item name, Rainbow, the new software is used for 31) and the 钤夂 method, wherein the above-mentioned use one provides a relief profile when there are retention on the X and γ axes. Analysis of the chromatogram of the software B /, wavelength. 13. As set forth in the U.S. Patent Application Serial No. U provides a percentage method for indicating the =, wherein the above analysis uses a 3D and contour chromatogram. The new software of the degree of knowledge is 1358540 _ case number 90100326_年月日日__ VI. Patent application scope 14. The method of claim 1 of the patent scope, wherein the above-mentioned software called 'Rainbow' At least the following features: i. A software having the ability to open tomographic features in different formats (ranges) such as BMP, JPEG, TIF, GIF from the folder, and having a single point of view sensitivity in the image Different colors to analyze the image ii. A software has the ability to display the information of the image point, in the form of 1. One having X (0- (min. time unit) and Y (200-800 nm) coordinates Chart and 2. - Pie chart with individual values for each peak automatically or manually in two separate columns next to the graph; ii i. The ability of a software to print data generated by all analyses by using a column Print image; i v. - the ability of the software to change the page settings of the print by using a page to set the image; v. a software having the ability to select a portion of the image and analyze it by using a re-evaluation image; a soft The ability to open any number of image analysis windows and states for viewing on a window image for different images; vi i. A software has the ability to distinguish the image into three regions over a 20 minute range, using the region image ; viii · The software has the ability to reverse the selected image using the inverted image; ix. - the software has the ability to convert the image into Notepad, Word pad and MS Word, by using the edit image; 第.146頁 1358540 案號 90100326 Β 修正 六、申請專利範圍 X. —軟體具有關於該軟體操作上各種操作資訊的特 徵之能力,藉由使用輔助圖像;及 xi . 一軟體具有儲存該產生的數據,藉由使用另存新 檔圖像,成.JPEG檔案格式的能力。 15. 來自一植物、動物或一天然可得或人工製造可作 為藥物的材料之層析特徵鑑定、化學及治療的標準化與有 機或有機金屬分子之條碼製作的計算機方法,該上述方法 至少包含: a) .藥物的選擇及成分的萃取; b) 將該成分分離成個別的成分,以產生個別成分的 紫外-可見光光譜,接著,由個別成分的紫外-可見光光譜 產生個別成分的3-D及輪廓圖,並轉換該3-D及輪廓圖成鑑 定特徵; c) 以一發展出的軟體來分析該特徵,其中該發展出 的軟體具有下列特徵: i. 一軟體具有開啟層析特徵影像以不同格式(範圍) 的能力如BMP、JPEG、TIF、GIF來自該標案夾,並以出現 在該影像中具單一映相點靈敏度的不同顏色來分析該影 像; i i . 一軟體具有顯示該映相點資訊的能力,以形式1. 一具有X (0- (min. 時間單位)和Y (200-800 nm) 座標 的圖表及2. —餅形圖具有每一峰自動或手動的個別數值在 該圖旁的兩單獨的攔中;Page 146 1358540 Case No. 90100326 修正 Amendment 6. Patent Application X. — The ability of the software to have features relating to various operational information on the operation of the software, by using auxiliary images; and xi. A software has the effect of storing the generated Data, the ability to create a .JPEG file format by using a new file. 15. A computer method for the standardization of chromatographic characterization, chemistry and therapy, and bar code fabrication of organic or organometallic molecules from a plant, animal or a naturally available or artificially achievable material, the method comprising at least: a) selection of the drug and extraction of the component; b) separation of the component into individual components to produce an ultraviolet-visible spectrum of the individual component, followed by the 3-D of the individual component from the ultraviolet-visible spectrum of the individual component Contour map, and convert the 3-D and contour map into identification features; c) analyze the feature with a developed software, wherein the developed software has the following characteristics: i. A soft body has an open tomographic feature image to Different formats (range) capabilities such as BMP, JPEG, TIF, GIF are from the folder and are analyzed in different colors appearing in the image with a single point sensitivity; ii. A software has the display The ability of phase information to be in the form 1. A graph with X (0- (min. time unit) and Y (200-800 nm) coordinates and a pie chart with each peak Automatically or manually separate the two individual number next to the bar graph in; 第147頁 1358540 ._案號 901Q0326_年月日__ 六、申請專利範圍 i i i. 一軟體具有列印所有分析後所產生的數據的能 力藉由使用一列印圖像; i v. —軟體具有改變列印的頁面設定的能力藉由使用 一頁面設定圖像; v. —軟體具有選擇部分影像並分析之的能力藉由使 用一重新估量圖像; v i . —軟體具有為不同影像而開啟任何數量的影像分 析視窗及狀態顯示於視窗圖像的能力; v i i. —軟體具有將該影像區分成三個區域在2 0分鐘 的範圍的能力,藉由使用區域圖像; vi ii. 一軟體具有使所選影像倒轉的能力使用倒轉圖 像; ix. —軟體具有將該影像轉換成Notepad、Word pad 及MS Word的能力,藉由使用編輯圖像; X. 一軟體具有關於該軟體操作上各種操作資訊的特 徵之能力,藉由使用輔助圖像;及 xi. —軟體具有儲存該產生的數據,藉由使用另存新 檔圖像,成.JPEG檔案格式的能力;及 d ) 詮釋所得之數據。 16.如申請專利範圍第1 5項之方法,其中上述藉由使 用該發展出的新軟體,來提供該研究藥物中的成分之化學 分析,及該藥物·的共耗與極性性質。Page 147 1358540 ._Case No. 901Q0326_年月日日__ VI. Patent Application ii i. A software has the ability to print data generated after all analyses by using a printed image; i v. —Software The ability to change the page settings of the print by using a page to set the image; v. - the software has the ability to select a portion of the image and analyze it by using a re-evaluation image; vi. - the software has been turned on for different images The ability of any number of image analysis windows and states to be displayed in a window image; vi i. - the ability of the software to distinguish the image into three regions in the range of 20 minutes, by using the region image; vi ii. The software has the ability to reverse the selected image using the inverted image; ix. - the software has the ability to convert the image into Notepad, Word pad and MS Word by using the edit image; X. A software has operations on the software The ability to apply various features of the information by using the auxiliary image; and xi. - the software has the data stored, and by using the saved new image, the .JPEG The ability of the file format; and d) the interpretation of the data obtained. 16. The method of claim 15, wherein the chemical analysis of the components of the study drug, and the co-consumption and polarity properties of the drug are provided by using the developed new software. 第148頁 1358540 _案號 90100326_年月日_修正 _ 六、申請專利範圍 17. 如申請專利範圍第15項之方法,其中上述提供草 藥之層析鑑定方法的新概念,有助於迅速確認該正在使用 中藥物的化合物之實際概況。 18. 如申請專利範圍第1 5項之方法,其中上述使用.所 提議該草藥及配方的輪廓及3 — D層析譜,其層析譜發展自 一高壓液相色層分析儀的光學偶極陣列偵測器,來提供該 草藥及配方之一新的層析鑑定方法,描述該草藥中的成分 之特殊性質的數據,在相似實驗的分析條件下以一特定次 序的極性沖提出。 19. 如申請專利範圍第1 5項之方法,其中上述方法所 提供的該化合物之紫外一可見光光譜已顯示出該分子的共’ . 軛與極性性質及伴隨著這些分子極性的分子個別濃度。 2 0.如申請專利範圍第1 5項之方法,其中上述方法所 提供所有成分之紫外-可見光光譜顯示於一單一影像"層析 鑑定特徵",上述特徵變成在一草藥或配方中的成分之藍 圖可作為該研究藥物的試驗與迅速確認。 21.如申請專利範圍第2 0項之方法,其中上述以相同 的標準分析參數,諸如以同樣的溶劑乙醇來萃取,同樣的 實驗時間0 — 6 0分鐘,同樣的動相乙晴伴隨著一 pH範圍5. 5 -7. 5之磷酸鹽緩衝液及一同樣的紫外-可見光範圍200-800Page 148 1358540 _ Case No. 90100326_年月日日_Amendment _ VI. Patent application scope 17. The method of claim 15, wherein the above-mentioned new concept of providing a chromatographic identification method for herbal medicine helps to quickly confirm The actual profile of the compound being used in the drug. 18. The method of claim 15, wherein the above-mentioned use of the herbal and formula outline and 3-D chromatogram, the chromatogram developed from a high pressure liquid chromatography analyzer optical couple A polar array detector provides a new chromatographic method for identifying one of the herbs and formulations, describing data describing the specific properties of the ingredients in the herb, and rushing in a particular order of polarity under similar experimental conditions. 19. The method of claim 15, wherein the ultraviolet-visible spectrum of the compound provided by the above method has been shown to have a conjugate and polar nature of the molecule and an individual concentration of the molecule accompanying the polarity of the molecule. The method of claim 15, wherein the ultraviolet-visible spectrum of all the components provided by the above method is displayed in a single image "chromatographic identification feature", the above characteristics are changed into an herb or a formulation The blueprint of the ingredients can be used as a test and rapid confirmation of the study drug. 21. The method of claim 20, wherein the above parameters are analyzed by the same standard, such as extraction with the same solvent ethanol, the same experimental time 0-6 minutes, the same phase is accompanied by a pH range of 5. 5 -7. 5 phosphate buffer and a similar UV-Vis range 200-800 第149頁 1358540 _案號90100326_年月曰 修正_ 六、申請專利範圍 nm來進行特徵鑑定及化學與治療的標準化。 22. 如申請專利範圍第20項之方法,其中上述特徵鑑 定可用於攙雜的、代替的、契約的及商業的食物與藥物樣 品之研究並確認其純度與不純物。 : 23. 如申請專利範圍第20項之方法,其中上述之特徵 鑑定方法已用以確認其中的成分之目的是對於過程標準化 、品質管理行為及對抗療法的、阿祐爾惟達的、同種療法 的、席得哈、悠納尼、中國的、西藏的、坎坡(日本的) 藥物之治療的標準化。 24 如申請專利範圍第20項之方法,其中上述特徵鑑 定方法可用在研究化學成分由於生態學的因素,地賀學的 因素,遺傳型及顯型變化所造成在自然出現的樣品中的差 異(在植物中),及確認並標準化其中的化學成分。 25.如申請專利範圍第2 0項之方法,其中上述特徵鑑 定已用於研究人工合成的樣品中之化學成分及確認並標準 化其中的化學成分對於曾經合適的化學與治療的標準化 2 6. 如申請專利範圍第2 0項之方法,其中上述特徵鑑 定已用於研究在單一藥物樣品之草本產物中的化學成分及 對其中的化學成分作化學與治療的標準化方面的確認。Page 149 1358540 _ Case No. 90100326_Yearly 曰 Amendment _ VI. Application for patent range nm for characterization and standardization of chemistry and treatment. 22. The method of claim 20, wherein the feature identification described above can be used for the study of noisy, alternative, contractual, and commercial food and drug samples and to confirm their purity and impurities. : 23. The method of claim 20, wherein the above-described characterization method has been used to confirm that the ingredients are for process standardization, quality management behavior and anti-therapeutic, Ajal, homeopathic Standardization of the treatment of drugs in Shedha, Younani, China, Tibet, and Kanpo (Japan). 24 For example, in the method of claim 20, wherein the above-mentioned characterization method can be used to study the difference in chemical composition due to ecological factors, factors of euphoria, genotype and phenotypic changes caused by naturally occurring samples ( In plants), and to confirm and standardize the chemical components therein. 25. The method of claim 20, wherein the characterization is used to study the chemical composition of the synthetic sample and to standardize and normalize the chemical composition therein for the appropriate chemistry and treatment. The method of claim 20, wherein the above characterization has been used to study the chemical composition of the herbal product of a single drug sample and to confirm the chemical composition of the chemical components therein. 第150頁 1358540 _案號 90100326_年月曰_ί±ί._ 六、申請專利範圍 27.如申請專利範圍第2 0項之方法,其中上述特徵鑑 定已用於研究在複方藥物樣品之草本產物中的化學成分及 對其中的化學成分作化學與治療的標準化方面的確認。 2 8.如申請專利範圍第2 0項之方法,其中上述特徵鑑 定方法已被用於研究化學成分在生物樣品中的差異及確認 並標準化其中的化學成分。 29.如申請專利範圍第2 0項之方法,其中特徵鑑定方 法已用於研究化學成分在商標產品的單一及複方食物與藥 物樣品中的差異及確認並標準化其中的化學成分。 3 〇 .如申請專利範圍第2 0項之方法,其中一大量樣品 資料庫的準備可提供許多關於一特定植物族群之歸納,因 為一特定疾病或治療的分類而分在同一族群。 31.如申請專利範圍第2 0項之方法,其中上述藥物的 特徵,鑑定有助於將一藥物的組成成分分類,以及根據來 自3 - D與輪廓層析譜的極性和共軛將該成分量化並評估該 藥物在體液上的作用(損害)。 32.如申請專利範圍第20項之方法,其中上述特徵鑑 定可了,解並標準化該藥物的物理一化學性質如顏色對於Page 150 1358540 _ Case No. 90100326_年月曰_ί±ί._ VI. Patent Application Area 27. The method of claim 20, wherein the above identification has been used to study the herb in the compound drug sample. The chemical composition of the product and the chemical standardization of the chemical components in it are confirmed. 2 8. The method of claim 20, wherein the feature identification method has been used to study the difference in chemical composition in a biological sample and to confirm and normalize the chemical composition therein. 29. The method of claim 20, wherein the characterization method has been used to study the difference in chemical composition between single and compound food and drug samples of the trademark product and to confirm and standardize the chemical composition therein. 3 如 As in the method of claim 20, one of the large sample database preparations provides a number of generalizations for a particular plant group, which are grouped together by a particular disease or treatment classification. 31. The method of claim 20, wherein the characterization of the drug aids in classifying a component of a drug and the component is based on polarity and conjugation from a 3-D and contour chromatogram Quantify and evaluate the effect (damage) of the drug on body fluids. 32. The method of claim 20, wherein the characterizing is identifiable, and the physical chemistry of the drug, such as color, is resolved and normalized. 第151頁 1358540 _+ 案號90100326_年月曰 修正_ 六、申請專利範圍 藥物體液之治療的標準化的使用,利用在該層析特徵中所 提供之共軛與極性性質。 33.如申請專利範圍第20項之方法,其中上述特徵鑑 定可了解,並標準化該藥物的物理一化學性質·,如味道( .蕊撒)即酸、鹹、辣、苦、及澀(如在阿祐爾惟達中分別 提及的安拉、拉伐納、卡圖、提克塔及卡夏亞)用於治療 的標準化,利用在該層析特徵中所顯示之共扼與極性性質 34. 如申請專利範圍第20項之方法,其中上述特徵鑑 定可以了解,並標準化該藥物的物理一化學性質如屬性、 效力、代謝物、特殊性能如該分子的光學活性(古納、維 爾亞、維帕卡、普拉伯哈伐)用於該治療的標準化利用該 個別成分的共軛與極性性質在該層析特徵中所顯示的整個 藥物。 35. 如申請專利範圍第2 0項之方法,其中上述特徵鑑 定可了解,並標準化該藥物的物理-化學性質(古納斯)如 冷的、熱的、作用緩慢的、作用強烈的、重的、輕的、軟 的、滑潤的、柔順的、乾的(古納的諸如席塔、悠虛納、 曼達、提克虛納、古盧、拉古、斯尼戈達、及盧克夏如在 阿祐爾惟達中所述)用於該治療的標準化,利用在該層析 特徵中所顯示之該藥物的共軛與極性性質。Page 151 1358540 _+ Case No. 90100326_Yearly 曰 Amendment _ VI. Scope of Patent Application The standardized use of the treatment of bodily fluids utilizes the conjugate and polar properties provided in the chromatographic features. 33. The method of claim 20, wherein the above characterization identifies and normalizes the physical chemistry of the drug, such as the taste, acid, salt, spicy, bitter, and sputum (eg, Standardization of treatment for Allah, Lavala, Kathu, Ticeta, and Caxia, respectively referred to in Ajal, using the symmetry and polarity properties shown in the chromatographic features 34 The method of claim 20, wherein the above characterization can understand and standardize physical chemistry of the drug such as properties, potencies, metabolites, specific properties such as optical activity of the molecule (Guna, Vera, Verapaka, Prabhavar) Standardization for this treatment utilizes the entire drug exhibited by the conjugate and polar properties of the individual components in the chromatographic features. 35. The method of claim 20, wherein the above characterization can be used to understand and standardize the physico-chemical properties of the drug (Gunas) such as cold, hot, slow-acting, intense, heavy Light, soft, smooth, supple, dry (Guna's such as Xita, Youxun, Manda, Tikena, Gulu, Lagu, Snigoda, and Luksharu Standardization for this treatment, as described in Ajalta, utilizes the conjugate and polar properties of the drug as shown in the chromatographic features. 第152頁 1358540 _案號 90100326_年月曰 修正_ 六、申請專利範圍 36. 一軟體已用於一組成部分的彩色輪廓影像及3 — D 層析譜之數據處理器,上述的處理器至少包含計算工具及 以下的能力: i ) 一分析器(摘錄顏色)對於分析該彩色輪廓影像 根據不同顏色(具有在發表的註釋,生命週期,加工處理 中被提及的標準)的選擇表示各種隨著時間而沖提出之成 分的濃度及根據滯留時間的極性; i i ) 一分析器關於使用該影像所有的三次元性質來分 析該藥物的3-D層析譜; i i i ) 一工具關於產生一具有許多伴隨以一明確說明 的極性順序,隨時間沖提出之分子的共軛性質而出現在不 同滯留時間之峰的層析譜; i v ) —識別器關於藉由該影像中不同成分的紫外一可 見光吸收性質來確認在該上述分子中的化合物; . v) —工具根據該分子的極性與共軛性質將特徵在X及 Y軸上劃分成療效區域來使該研究藥物中各種成分已報導 4生物的,治療的性質相關聯; v i ) —工具使用該影像的座標,即X軸為滯留時間,Y 軸為波長,R是紅映像點,G是綠映像點及B 是藍映像點, 由所推薦軟體提供,針對所選定的峰產生一條碼; v i i) 對於該樣品產生一特徵與條碼的資料庫,以提 昇各種資料庫的效用如企業資源計晝與客戶關係管理應用 ;及Page 152 1358540 _ Case No. 90100326_Yearly revision _ Six, the scope of application for patents 36. A software has been used for a part of the color contour image and 3-D chromatographic data processor, the above processor at least Includes calculation tools and the following capabilities: i) an analyzer (extracted color) for the analysis of the color contour image according to the choice of different colors (with the mentioned standards in the published notes, life cycle, processing) The concentration of the component that is rushed over time and the polarity according to the residence time; ii) an analyzer analyzing the 3-D chromatogram of the drug using all of the three-dimensional properties of the image; iii) a tool with respect to generating one Many chromatograms appearing at peaks of different residence times with a conjugated nature of the molecules oscillated over time in a well-defined polarity sequence; iv) - the identifier for ultraviolet-visible light with different components in the image Absorbing properties to identify compounds in the above molecules; v) - the tool will characterize X according to the polarity and conjugate properties of the molecule And the Y-axis is divided into therapeutic regions to make the various components of the study drug have been reported to be related to the nature of the treatment; vi) - the tool uses the coordinates of the image, ie the X-axis is the retention time and the Y-axis is the wavelength. R is a red image point, G is a green image point, and B is a blue image point, provided by the recommended software, generating a code for the selected peak; vii) generating a database of features and barcodes for the sample to enhance various Database utilities such as enterprise resource planning and customer relationship management applications; and 第153頁 1358540 案號 90100326 年 月 a 修正 六、申請專利範圍 v i i i ) 對於所有已用於商業應用的企業資源計畫和客 戶關係管理型式的樣品產生一具有’顯示窗’的資料庫。 37. 如申請專利範圍第36項之數據處理器,其中上述 用來萃取的溶劑選取是根據其極性,該成分,樣品及其研 究成分,的親水性與疏水性。Page 153 1358540 Case No. 90100326 Year Month a Amendment VI. Patent Application v i i i ) Generate a database with 'display windows' for all samples of enterprise resource planning and customer relationship management that have been used for commercial applications. 37. The data processor of claim 36, wherein the solvent used for the extraction is selected based on its polarity, the hydrophilicity and hydrophobicity of the component, the sample and its components. 38. 如申請專利範圍第36項之數據處理器,其中上述 所使用的高壓液相色層分析設備是選自任何可買得到的高 壓液相色層分析設備,具有一光學偶極陣列偵測器,更好 地是具有一梯度的或三元系統的幫浦。. 3 9.如申請專利範圍第3 6項之數據處理器,其中一非 含水溶劑及一特定p Η值之含水溶劑的動相之極性是藉由改 變一含水溶劑,如水或一已知ρ Η值的緩衝液,與一非含水 溶劑的混合比例從0到1 0 0 %來控制。38. The data processor of claim 36, wherein the high pressure liquid chromatography apparatus used above is selected from any commercially available high pressure liquid chromatography apparatus having an optical dipole array detection. Preferably, it is a pump with a gradient or ternary system. 3. The data processor of claim 36, wherein the polarity of the mobile phase of a non-aqueous solvent and a specific p-valued aqueous solvent is changed by changing an aqueous solvent such as water or a known ρ The ratio of the devaluation buffer to a non-aqueous solvent is controlled from 0 to 100%. 40. 如申請專利範圍第3 6項之數據處理器,其中上述 使用一名為’彩虹’的新軟體來作3D及輪廓層析譜的分析, 該軟體提供一在X及Υ軸上有滯留時間與波長的層析譜。 41. 如申請專利範圍第36項之數據處理器,其中上述 使用一提供一可以百分比方式指出都夏的損害程度之新軟 體來進行3D.及輪廓層析譜的分析。40. For the data processor of patent application No. 36, wherein the above uses a new software for 'Rainbow' for 3D and contour tomography analysis, the software provides a retention on the X and the Υ axis. Chromatography of time and wavelength. 41. The data processor of claim 36, wherein the use of the above provides a 3D. and contour chromatogram analysis by providing a new software that can indicate the degree of damage in summer. 第154頁 1358540 _案號 90100326_年月日__ 六、申請專利範圍 42. 如申請專利範圍第36項之數據處理器,其中一單 一溶劑乙醇可用來萃取該成分;相同的分析條件與儀器參 數已用於所有樣品以提出治療的標準化。從而達到該治療 的標準化。 43. 如申請專利範圍第36項之數據處理器,其中上述 所使用名為彩虹的軟體至少具有下列特徵: (a) 該軟體名為’彩虹. (b) —軟體具有以不同格式(範圍)如BMP、JPEG、 T IF、G I F,開啟來自該檔案夾的層析特徵影像之能力,並 以出現在該影像中具單一映相點靈敏度的不同顏色來分析 該影像; (c ) 一軟體具有顯示該映相點資訊的能力以形式1 . 一 具有X (0- (min. 時間單位)和Y ( 2 0 0 — 8 0 0 n m)座標的 圖表及2. —餅形圖具有每一峰自動或手動的個別數值在該 圖旁的兩單獨的欄中; (d ) —軟體具有列印所有分析後所產生的數據之能力 藉由使用一列印爵像; (e ) —軟體具有改變列印的頁面設定的能力藉由使用 一頁面設定圖像; (f ) 一軟體具有選擇部分影像並分析之的能力藉由使 用一重新估量圖像; (g ) —軟體具有為不同影像而開啟任何數量的影像分Page 154 1358540 _ Case No. 90100326_Year of the month __ VI. Patent application scope 42. For the data processor of claim 36, a single solvent ethanol can be used to extract the component; the same analytical conditions and instruments Parameters have been used for all samples to standardize the proposed treatment. Thereby achieving standardization of the treatment. 43. The data processor of claim 36, wherein the software described above using the rainbow has at least the following characteristics: (a) the software is named 'Rainbow. (b) - the software has a different format (range) Such as BMP, JPEG, T IF, GIF, the ability to open a tomographic image from the folder, and analyze the image with different colors appearing in the image with a single point sensitivity; (c) a software with The ability to display the information of the image point is in the form of 1. A chart with X (0- (min. time unit) and Y (200-800 nm) coordinates and a pie chart with each peak automatically Or manual individual values in two separate columns next to the figure; (d) - the ability of the software to print the data produced by all analyses by using a list of prints; (e) - the software has a change print The ability to set a page by using a page to set the image; (f) a software having the ability to select a portion of the image and analyze it by using a re-evaluation image; (g) - the software has any number of images open for different images Image score 第155頁 1358540Page 155 1358540 案號 90100326 六 、申請專利範圍 析視窗及狀態顯示於視窗圖像; (h) —軟體具有將該影像區分成三個區域在2〇分鐘的 距離之能力,藉由使用區域圖像; (1 ) 一軟體具有使所選影像倒轉的能力使用倒轉圖像 (j) 一軟體具有將該影像轉換成N〇tepad、word pad 及MS Word的能力,使用編輯圖像; (k) 一軟體具有關於該軟體操作上各種操作資訊的特 徵之能力,使用輔助圖像;及 (l) 一軟體具有儲存該產生的數據,使用另存新檔圖 像’成.JPEG棺案格式的能力。 44.如申請專利範圍第36項之數據處理器,其中上 述化學樂品的輪靡及3 ~~ D層析譜的特徵之使用是.對於化學 成分的確認之基礎。Case No. 90100326 6. The application scope analysis window and status are displayed in the window image; (h) - the software has the ability to distinguish the image into three regions at a distance of 2 minutes, by using the area image; A software has the ability to reverse the selected image using the inverted image (j). The software has the ability to convert the image into N〇tepad, word pad and MS Word, using the edit image; (k) a software with The ability of the software to operate various features of the operational information, using auxiliary images; and (l) a software having the ability to store the generated data, using the saved new image 'in a .JPEG file format. 44. The data processor of claim 36, wherein the use of the rim of the above chemical music and the characteristics of the 3~~D chromatogram is the basis for confirmation of the chemical composition. 第156頁Page 156
TW90100326A 2001-01-08 2001-01-08 A novel method for chromatographic finger printing TWI358540B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW90100326A TWI358540B (en) 2001-01-08 2001-01-08 A novel method for chromatographic finger printing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW90100326A TWI358540B (en) 2001-01-08 2001-01-08 A novel method for chromatographic finger printing

Publications (1)

Publication Number Publication Date
TWI358540B true TWI358540B (en) 2012-02-21

Family

ID=46728188

Family Applications (1)

Application Number Title Priority Date Filing Date
TW90100326A TWI358540B (en) 2001-01-08 2001-01-08 A novel method for chromatographic finger printing

Country Status (1)

Country Link
TW (1) TWI358540B (en)

Similar Documents

Publication Publication Date Title
CN1938586B (en) A method for standardization of chemical and therapeutic values of foods & medicines using animated chromatographic fingerprinting
US7144740B2 (en) Method for chromatographic finger printing and standardization of single medicines and formulations
US20090232706A1 (en) Novel method for chromatographic finger printing and standardization of single medicines and formulations
Gewali et al. Aspects of traditional medicine in Nepal
Sumarni et al. Indigenous knowledge of Indonesian traditional medicines in science teaching and learning using a science–technology–engineering–mathematics (STEM) approach
JP4886933B2 (en) A novel method for standardization of chromatographic fingerprints and single medicines and formulations
Etkin Edible medicines: an ethnopharmacology of food
Haddad et al. Comparative study on the medicinal plants most recommended by traditional practitioners in Morocco and Canada
CN100356380C (en) Method of chromatogram fingerprint atlas, single medicine and preparation standardization
Alamgir et al. Origin, definition, scope and area, subject matter, importance, and history of development of pharmacognosy
Bisht et al. Ethnobotanical study of traditional medicinal plants used by Banraji Community in Uttarakhand, West Himalaya
TWI358540B (en) A novel method for chromatographic finger printing
Mishra Essentials of Herbal Drug Technology: A Guide of Standardization Quality Control
Kahkeshani et al. Quality control of Nepeta menthoides Boiss & Buhse using micromorphological analysis and phytochemical screening
Egbuna et al. Pharmacognosy and prehistoric uses of medicinal plants
AU7238700A (en) A novel method for chromatographic finger printing and standardization of single medicines and formulations
Chaudhari et al. Importance of herbal drug for new drug development
Phengmala et al. Ethnobotany of Hmong ethnic groups in Bolikhamxay province, central Laos PDR
Oladeji et al. Capturing indigenous knowledge on medicinal plants use: Case study of selected communities in Old Oyo National Park, Nigeria
Menghani et al. Antidiabetic potentials of various ethno-medicinal plants of Rajasthan
Junaid et al. The concept of Ayurveda in medical science, an Indian traditional medicine: A review
Khare Evidence-based Ayurveda: Defining a new scientific path
Addae-Mensah Plant biodiversity, herbal medicine, intellectual property rights and industrially developing countries: socio-economic, ethical and legal implications
Bore et al. A Comparative Study of Alcohol Estimation in Different Samples of Draksharishta
Fadila et al. Oral herbs based on Serawai Seluma medicinal plants

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees